memantine profile

Memantine is a medication used to treat moderate to severe Alzheimer's disease. It is a non-competitive NMDA receptor antagonist, which means it blocks the activity of the NMDA receptor. The NMDA receptor is a type of glutamate receptor that is involved in learning, memory, and synaptic plasticity. By blocking the NMDA receptor, memantine is thought to reduce the excessive stimulation of neurons that can occur in Alzheimer's disease. Memantine was first synthesized in the 1960s by researchers at the pharmaceutical company Boehringer Ingelheim. It was originally investigated as a potential treatment for epilepsy, but it was found to be more effective in treating Alzheimer's disease. Memantine is typically taken orally, and it is generally well-tolerated. The most common side effects are dizziness, headache, and constipation. Memantine is not a cure for Alzheimer's disease, but it can help to improve cognitive function and slow the progression of the disease. Research into the mechanism of action of memantine is ongoing, and there is a great deal of interest in developing new drugs that target the NMDA receptor. Memantine is a valuable tool for treating Alzheimer's disease, and it is likely to continue to be used for many years to come.'

ID Source	ID
PubMed CID	4054
CHEMBL ID	807
CHEBI ID	64312
SCHEMBL ID	2688
SCHEMBL ID	13213676
MeSH ID	M0013333

Synonym
EU-0053634
CBMICRO_020348
BB 0216388
DIVK1C_000068
KBIO1_000068
SPECTRUM_000607
IDI1_000068
BSPBIO_001015
BPBIO1_001117
LOPAC0_000861
PRESTWICK2_000978
PRESTWICK3_000978
OPREA1_480562
BIOMOL-NT_000209
BPBIO1_001270
1-amino-3,5-dimethyladamantane
memantine ,
19982-08-2
3,5-dimethyladamantan-1-amine
AB00053600
3,5-dimethyl-1-adamantanamine
3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyl-1-aminoadamantane
1,3-dimethyl-5-adamantanamine
DB01043
NCGC00024782-03
tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-
tricyclo(3.3.1.13,7)decan-1-amine, 3,5-dimethyl-
memantina [inn-spanish]
memantine [inn:ban]
3,5-dimethyl-1-adamantylamine
memantinum [inn-latin]
memantin
hsdb 7327
KBIO2_006223
KBIO2_003655
KBIOGR_001543
KBIOSS_001087
KBIO2_001087
KBIO3_001926
SPECTRUM2_001408
SPECTRUM3_000923
NINDS_000068
SPBIO_002926
PRESTWICK0_000978
SPBIO_001456
PRESTWICK1_000978
SPECTRUM4_001022
SPECTRUM5_001355
NCGC00024782-02
1,3-dimethyl-5-aminoadamantane
NCGC00015705-05
drg-0267
chebi:64312 ,
nsc-757843
CHEMBL807 ,
AKOS000113995
D08174
exiba (tn)
memantine (inn)
HMS500D10
3,5-dimethyl-adamantan-1-ylamine
bdbm50062599
NCGC00015705-04
BBL000737
3,5-dimethyladamantanylamine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
STK520682
A814131
dtxcid3025174
tox21_110199
dtxsid5045174 ,
cas-19982-08-2
CCG-204092
AKOS015953276
NCGC00015705-03
alzantin
nsc 757843
w8o17sjf3t ,
memantina
drg 0267
unii-w8o17sjf3t
memantinum
dmaa [antiparkinson agent]
memantine [inn]
FT-0649142
nemdatine
memantine [hsdb]
tricyclo(3.3.1.1(sup 3,7))decan-1-amine, 3,5-dimethyl-
memantine [vandf]
memantine [mi]
memantine [who-dd]
3,5-dimethyltricyclo(3.3.1.1(sup 3,7))decan-1-amine
AKOS016340748
gtpl4253
1-amino-3,5-dimethyl-adamantane
1-amino-3,5-dimethyladamantan
1-amino-3,5-dimethyl adamantane
AB00053600-13
SCHEMBL2688
NCGC00015705-07
tox21_110199_1
SCHEMBL13213676
DS-3152
AB00053600_15
AB00053600_14
3,5-dimethyl-1-aminoadamantane hcl
tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl-
SBI-0020417.P004
Q412189
BCP29702
d145 pound>>d 145 pound>>d-145
SDCCGSBI-0020417.P005
NCGC00015705-16
D94592
NCGC00015705-09
retyliumtosylate
EN300-103626
dmaa (antiparkinson agent)
memantina (inn-spanish)
memantinum (inn-latin)
exiba
3,5-dimethyltricyclo-

Excerpt	Reference	Relevance
"Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that was initially indicated for the treatment of moderate to severe Alzheimer's disease. "	( Memantine and its benefits for cancer, cardiovascular and neurological disorders. Abbaszadeh, S; Janssen, PML; Shafiei-Irannejad, V; Soraya, H, 2021)	3.51
"Memantine is an orally administrative N-methyl-d-aspartate glutamate receptor antagonist used to slow the progression of moderate-to-severe Alzheimer's disease (AD) and dementia."	( Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer's drugs. Al Abdulmonem, W; Alhumaydhi, FA; Aljasir, MA; Alsagaby, SA; Alwashmi, ASS; Hassan, MI; Islam, A; Shahwan, M; Shamsi, A, 2021)	1.57
"Memantine is a drug for the management of Alzheimer's Disease (AD) due to its promising neuroprotective properties."	( Memantine ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection. Jiang, B; Luo, W; Wang, Y, 2022)	2.89
"Memantine is a non-competitive antagonist with a moderate affinity to the N-methyl-d-Aspartate (NMDA) receptor. "	( Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult. Eterovic, VA; Ferchmin, PA; Ferrer-Acosta, Y; Martins, AH; Pérez, D; Rodriguez-Massó, S, 2022)	3.61
"Memantine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which has shown a neuroprotective action in neurodegenerative diseases."	( Memantine associated with ventricular-subcutaneous shunt promotes behavioral improvement, reduces reactive astrogliosis and cell death in juvenile hydrocephalic rats. Almeida, TAL; Beggiora, PDS; da Silva, SC; Lopes, LDS; Machado, HR; Rodrigues, KP; Sampaio, GB; Silva, GAPM, 2022)	2.89
"Memantine is an N-methyl-D-aspartate receptor antagonist, approved for dementia treatment. "	( Randomized placebo-controlled crossover trial of memantine in children with epileptic encephalopathy. Ayash, TA; Berrahmoune, S; Corriveau, I; Dassi, C; Myers, KA; Osterman, B; Poulin, C; Schiller, K; Sébire, G; Shevell, MI; Simard-Tremblay, E, 2023)	2.61
"Memantine is an important addition to the psychopharmacological armamentarium. "	( Clinical Indications of Memantine in Psychiatry-Science or Art? Alayadhi, N; Aljuwaiser, M; Naguy, A; Ozidu, V; Rushdy, R; Shafik Zakhari, SA, 2023)	2.66
"Memantine is an anti-Alzheimer drug that antagonizes the activity of glutamate at N-methyl-D-aspartate (NMDA) receptors."	( Memantine mitigates ROS/TXNIP/NLRP3 signaling and protects against mouse diabetic retinopathy: Histopathologic, ultrastructural and bioinformatic studies. Attia, MA; El-Sherbeeny, NA; Eladl, MA; Elaskary, A; Elbayoumi, KS; ElSayed, MH; Enan, ET; Hegazy, A; Hisham, FA; Mohamed, AAK; Morsi, K; Mustsafa, AMA; Saleh, MAK; Zaitone, SA, 2023)	3.07
"Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease (AD). "	( Unfavorable effects of memantine on the skeletal system in female rats. Cegieła, U; Czuba, ZP; Folwarczna, J; Londzin, P; Trawczyński, M, 2023)	2.66
"Memantine is an FDA-approved, non-competitive NMDA-receptor antagonist that has been shown to have mitochondrial protective effects, improve cell viability and enhance clearance of Aβ"	( The Highs and Lows of Memantine-An Autophagy and Mitophagy Inducing Agent That Protects Mitochondria. Batt, R; de Wet, S; Kriel, J; Loos, B; Mangali, A; Niehaus, D; Theart, R; Vahrmeijer, N, 2023)	2.67
"Memantine functions as a beneficial agent in the management of diabetic neuropathy, which would significantly improve the quality of life in diabetic patients."	( Management of diabetic neuropathy with memantine: A randomized clinical trial. Aghamohammadzadeh, N; Beheshtirouy, S; Ghaffary, S; Jafarzadeh, E; Sarbakhsh, P; Shaseb, E, )	1.84
"Memantine is an NMDA glutamate antagonist used to improve cognitive function in people with Alzheimer's disease."	( Chronic memantine decreases nicotine self-administration in rats. Guo, W; Hawkey, AB; Howard, S; Levin, ED; Nangia, A; Pippen, E; Rezvani, AH; Rose, JE; Wells, C; Yao, L, 2019)	1.67
"Memantine is a glutamate receptor antagonist in the central nervous system of mammals that has been used for the treatment of Alzheimer's disease."	( The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi. Damasceno, FS; Marinho, CRF; Pral, EMF; Rapado, LN; Rocha, SC; Santos Souza, HF; Silber, AM, 2019)	1.6
"Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for the treatment of mild to moderate Alzheimer's disease (AD)."	( The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia. Cotroneo, AM; Gareri, P; Orsitto, G; Putignano, S, )	0.85
"Memantine which is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist is one such agent among these."	( Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019)	1.49
"Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist currently used for moderate-to-severe Alzheimer's disease. "	( Memantine misuse and social networks: A content analysis of Internet self-reports. Michel, B; Natter, J, 2020)	3.44
"Memantine misuse seems to be a growing phenomenon. "	( Memantine misuse and social networks: A content analysis of Internet self-reports. Michel, B; Natter, J, 2020)	3.44
"Memantine is a cognitive enhancer used to treat AD."	( Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression. Ercoli, L; Kilpatrick, L; Krause-Sorio, B; Laird, KT; Lavretsky, H; Milillo, MM; Narr, KL; Siddarth, P, 2020)	1.55
"Memantine is a non-competitive antagonist of glutamatergic NMDA receptor that is mainly used in the treatment of Alzheimer's disease. "	( Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. Ge, RL; Ji, W; Liu, J; Luo, J; Wan, Y; Zhang, Y, 2021)	3.51
"Memantine is an N-methyl-D-aspartate receptor (NMDA-R) antagonist, approved for dementia, but also studied in pediatric autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD)."	( A retrospective analysis of memantine use in a pediatric neurology clinic. Berrahmoune, S; Bouhadoun, S; Myers, KA; Poulin, C, 2021)	2.36
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease. "	( [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021)	2.33
"Memantine is a unique glutamatergic medication with proven ability to attenuate drug addiction in preclinical models."	( Mechanistic insights into the efficacy of memantine in treating certain drug addictions. Abulseoud, OA; Angebrandt, A; Montemitro, C; Pettorruso, M; Wang, TY, 2021)	1.61
"Memantine is an N-methyl-d-aspartate receptor antagonist used in dementia treatment that may have potential benefit for migraine prophylaxis."	( Role of memantine in the prophylactic treatment of episodic migraine: A systematic review. Brown, JN; Bryan, WE; Mistry, VM; Morizio, PL; Pepin, MJ, 2021)	1.78
"Memantine is a clinically licensed drug used for the treatment of moderate and severe Alzheimer's disease."	( Memantine inhibits degradation of the articular cartilage extracellular matrix induced by advanced glycation end products (AGEs). Li, W; Wang, L; Wu, Z; Yu, Y; Zhao, J, 2017)	2.62
"Memantine is a drug approved for the treatment of moderate-to-severe Alzheimer's disease (AD), and there is ongoing research on the potential expansion of its clinical applicability. "	( Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome. Bederman, IR; Costa, ACS; Victorino, DB, 2017)	2.19
"Memantine is an NMDA receptor antagonist with anti-inflammatory effects."	( Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. Chang, HH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, SY; Lu, RB; Wang, TY; Yang, YK, 2017)	1.58
"Memantine (MEM) is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist that has been demonstrated to increase the proliferation of hippocampal progenitor cells."	( Postnatal administration of memantine rescues TNF-α-induced decreased hippocampal precursor proliferation. Fan, X; He, X; Wang, Z, 2018)	1.5
"Memantine is an effective and well-tolerated augmentation in severe OCD patients refractory to SRI monotherapy."	( Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial. Eslami, K; Javadi, M; Kouti, L; Modarresi, A; Razooghi, S; Sayyah, M, 2018)	3.37
"Memantine is an N-methyl-d-aspartate (NMDA) antagonist approved for Alzheimer's disease treatment."	( Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. Calpena, AC; Camins, A; Cordeiro, MF; Davis, BM; Egea, MA; Espina, M; Ettcheto, M; García, ML; Guo, L; Ravindran, N; Sánchez-López, E; Silva, AM; Souto, EMB, 2018)	2.64
"Memantine is an FDA-approved Alzheimer's drug."	( Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells. Albayrak, G; Bilen, CY; Dikmen, AU; Konac, E, 2018)	2.64
"Memantine is an NMDA receptor antagonist clinically used for the treatment of moderate to severe Alzheimer's disease. "	( Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review. Jemiola-Rzeminska, M; Strzalka, K; Suwalsky, M; Zambrano, P, 2018)	2.17
"Memantine is a viable treatment option for patients with AD presenting not only with cognitive impairment, but also with a broader range of symptoms, including the behavioral and psychological symptoms of dementia."	( Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses. Fukuchi, Y; Kamata, T; Matsui, D; Matsumoto, T; Okuizumi, K; Saito, K, 2018)	3.37
"Memantine is a licensed drug providing clinically relevant efficacy in patients with Alzheimer's disease."	( Memantine protects against ischemia/reperfusion-induced brain endothelial permeability. Huang, Y; Liu, Y; Qu, P; Wang, M; Xu, Y, 2018)	2.64
"Memantine-HCl is a voltage-dependent N-methyl-D-aspartate (NMDA) receptor 'channel blocker' that selectively blocks pathological glutamate overactivity."	( Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial. Arnold, A; Cheng, J; Gavrilidis, E; Grigg, J; Gurvich, C; Hudaib, AR; Kulkarni, J; Tan, R; Thomas, N, 2018)	1.46
"Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects."	( The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. Amidfar, M; Kim, YK; Quevedo, J; Réus, GZ, 2018)	1.58
"Memantine is a noncompetitive NMDA receptor antagonist."	( Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. Koola, MM, 2018)	1.58
"Memantine is a selective, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that has previously been shown to have neuroprotective qualities in some animal models of neurologic disease. "	( Memantine treatment of juvenile rats with kaolin-induced hydrocephalus. Del Bigio, MR; Di Curzio, DL; Mao, X; Nagra, G, 2018)	3.37
"Memantine is a non-competitive N-methyl-d-aspartate receptor antagonist currently used for the treatment of Alzheimer's disease as an approved indication. "	( The use of memantine in neuropsychiatric disorders: An overview. Lu, S; Nasrallah, HA, 2018)	2.31
"Memantine is a US Food and Drug Administration approved drug for the treatment of Alzheimer's disease."	( Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies. F Kallmes, D; Seyedsaadat, SM, 2019)	2.68
"Memantine is a commonly used drug in treating Alzheimer disease. "	( Gastroprotective effect of memantine in indomethacin-induced peptic ulcer in rats, a possible role for potassium channels. Gaber, SS; Rofaeil, RR, 2019)	2.25
"Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. "	( Memantine for dementia. Debarros, J; Farrimond, LE; Maayan, N; McShane, R; Minakaran, N; Roberts, E; Schneider, L; Ware, J; Westby, MJ, 2019)	3.4
"Memantine is a non-competitive low-affinity antagonist of the NMDA receptor with a t(1/2) of 70 h."	( Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Eap, CB; Noetzli, M, 2013)	1.11
"Memantine is a noncompetitive NMDA receptor antagonist. "	( Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. Chang, YH; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, YS; Yang, YK; Yeh, TL, 2013)	2.29
"Memantine is a non-competitive NMDA-receptor antagonist."	( [Neuroprotective potential of akatinol-memantine in ischemic stroke]. Levin, OS; Makotrova, TA; Shrader, NI; Trusova, NA, 2013)	1.38
"Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD). "	( Memantine hydrochloride in the treatment of dementia subtypes. Peng, D; Yuan, X; Zhu, R, 2013)	3.28
"Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist with a mood-stabilizing effect. "	( Genotype variant associated with add-on memantine in bipolar II disorder. Chang, YH; Chen, SH; Chen, SL; Chu, CH; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, CL; Wang, LJ; Yang, YK; Yeh, TL, 2014)	2.11
"Memantine is an N-methyl-D-aspartate receptor antagonist used to treat AD in > 80 countries worldwide, and studies in the USA and Europe have shown it to be effective in improving language deficits; however, there are currently no data on language improvements in Japanese patients treated with memantine."	( Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Homma, A; Kitamura, S; Matsui, D; Nakamura, Y; Shiosakai, K, 2014)	1.43
"Memantine is a well-tolerated N-methyl-D-aspartate glutamate receptor antagonist in common use for Alzheimer disease."	( Memantine enhances recovery from stroke. Ao, Y; Brennan, KC; Carmichael, ST; Charles, AC; Clarkson, AN; López-Valdés, HE; Sofroniew, MV, 2014)	2.57
"Memantine is an NMDA receptor antagonist that has been shown to reverse changes in memory and synaptic plasticity in animal models."	( The effects of propofol and memantine on erythrocyte deformability. Alkan, M; Arslan, M; Comu, FM; Emik, U; Pampal, HK; Unal, Y, 2014)	1.42
"Memantine is an uncompetitive N-methyl D-aspartate glutamatergic receptors antagonist and has shown beneficial effect on cognitive function especially in Alzheimer's disease."	( Modification of hippocampal markers of synaptic plasticity by memantine in animal models of acute and repeated restraint stress: implications for memory and behavior. Ali, MM; Amin, SN; Attia, YM; El-Aidi, AA; Rashed, LA, 2015)	1.38
"Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that is a well-established treatment option for moderate to severe dementia of the Alzheimer's type, either alone or in combination with cholinesterase inhibitors. "	( Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. Plosker, GL, 2015)	3.3
"Memantine is an N-methyl-D-aspartate glutamate receptor antagonist that may improve cognitive functions in patients with Alzheimer's disease. "	( Memantine-associated hyperkalaemia in a patient with Alzheimer's disease. Tsukamoto, T; Uchimura, N; Yamada, H, 2013)	3.28
"Memantine is a promising option for the treatment of CRPS. "	( EFFECTS OF MEMANTINE ON PAIN IN PATIENTS WITH COMPLEX REGIONAL PAIN SYNDROME--A RETROSPECTIVE STUDY. Ahmad-Sabry, MH; Shareghi, G, 2015)	2.25
"Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used to treat Alzheimer's disease. "	( Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD, 2016)	2.2
"Memantine is a low-affinity voltage-dependent noncompetitive antagonist at glutamatergic NMDA receptors."	( Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. Akishita, M; Ogawa, S; Ota, H; Ouchi, Y, 2015)	1.39
"Memantine is an open channel blocker that antagonizes NMDA receptors reducing the inappropriate calcium (Ca(2+)) influx occurring in presence of moderately increased glutamate levels. "	( Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. Bagetta, V; Cacace, F; Calabresi, P; Ghiglieri, V; Mancini, M; Mineo, D; Pendolino, V; Picconi, B; Vannelli, A, 2016)	3.32
"Memantine is an uncompetitive antagonist of NMDA receptors with a favorable pharmacokinetic profile, and is therefore clinically well tolerated."	( Memantine and Kynurenic Acid: Current Neuropharmacological Aspects. Majláth, Z; Toldi, J; Török, N; Vécsei, L, 2016)	2.6
"Memantine is an uncompetitive N-methyl-d-aspartic acid receptor antagonist and is approved for the management of moderate-to-severe AD."	( Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach. Daulatzai, MA, 2016)	1.38
"Memantine is a low-moderate affinity and uncompetitive N-methyl-d-aspartate receptor (NMDAR) antagonist, which is also a potential neuroprotectant in acute ischemic stroke for its particular action profiles. "	( Memantine mediates neuroprotection via regulating neurovascular unit in a mouse model of focal cerebral ischemia. Chen, ZZ; Ji, J; Sun, XL; Yan, H; Yang, DD; Zhao, Z, 2016)	3.32
"Memantine is an N-methyl-D-aspartate receptor antagonist, approved for the treatment of Alzheimer's dementia in a number of countries."	( Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial. Banaschewski, T; Buitelaar, JK; Dijkhuizen, RM; Dittmann, RW; Franke, B; Häge, A; Lythgoe, DJ; Mechler, K; Williams, SC, 2016)	1.16
"Memantine is an FDA-approved drug for treating Alzheimer's disease, and also was shown to be neuroprotective in rodents following a single, moderate to severe TBI."	( Memantine Reduced Cell Death, Astrogliosis, and Functional Deficits in an in vitro Model of Repetitive Mild Traumatic Brain Injury. Effgen, GB; Morrison, B, 2017)	2.62
"Memantine is a N-Methyl-d-aspartate receptor antagonist that has shown benefit in pain syndromes."	( Memantine for the Treatment of Phantom Limb Pain: A Systematic Review. Britt, RB; Brown, JN; Loy, BM, 2016)	2.6
"Memantine is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of moderate to severe dementia including the symptoms of Alzheimer's disease (AD). "	( Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport. Balaguer-Fernández, C; Calatayud-Pascual, MA; Del Río-Sancho, S; Femenía-Font, A; Kalia, YN; López-Castellano, A; Merino, V; Sebastián-Morelló, M; Serna-Jiménez, CE, 2017)	2.17
"Memantine is an uncompetitive "	( Memantine-induced chorea and dystonia. Bonakdarpour, B; Borges, LG, 2017)	3.34
"Memantine is a NMDA antagonist receptor clinically used for treating Alzheimer's disease. "	( In vitro effects of the anti-Alzheimer drug memantine on the human erythrocyte membrane and molecular models. Jemiola-Rzeminska, M; Strzalka, K; Suwalsky, M; Villena, F; Zambrano, P, 2017)	2.16
"Memantine is a symptomatic treatment that partially prevents cognitive decline in Alzheimer disease (AD). "	( Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study. Annweiler, C; Beaudenon, M; Brangier, A; Duval, GT; Lemire, P, 2018)	2.23
"Memantine acts as an antagonist of N-methyl-D-aspartate (NMDA) type receptors, which is thought to reduce abnormal activation of glutamate neurotransmission."	( Memantine for dementia in people with Down syndrome. Bennett, C; Carpenter, PK; Mohan, M, 2009)	2.52
"Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate receptors, approved for the treatment of moderate to severe Alzheimer's disease (AD). "	( Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Graham, SM; Grossberg, GT; Miller, ML; Pejović, V, 2009)	3.24
"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor. "	( Memantine: a comprehensive review of safety and efficacy. Kavirajan, H, 2009)	3.24
"Memantine was confirmed to be a moderate affinity (IC(50) at -70 mV of 0.79+/-0.02 microM, Hill=0.92+/-0.02), strongly voltage-dependent (delta=0.90+/-0.09) uncompetitive antagonist of human GluN1/GluN2A receptors."	( Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Gilling, KE; Hechenberger, M; Jatzke, C; Parsons, CG, 2009)	1.27
"Memantine is a safe non-competitive NMDA receptor blocker characterized by its low affinity and fast unblocking kinetics."	( Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury. Lin, N; Liu, C; Qiu, Y; Wu, B, 2009)	1.37
"Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). "	( Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. Alley, GM; Bailey, JA; Banerjee, PK; Chen, D; Lahiri, DK; Puli, LK; Ray, B; Tanila, H, 2010)	3.25
"Memantine (which is an inhibitor of the N-metil-D-aspartate receptor) is used in the middle and severe stages of AD and it can be effectively combined with AChEIs."	( [Therapy of Alzheimer disease]. Kovács, T, 2009)	1.07
"Memantine is an uncompetitive, moderate-affinity NMDA receptor antagonist that is indicated for the treatment of moderate to severe Alzheimer's disease. "	( Memantine: a review of its use in moderate to severe Alzheimer's disease. McKeage, K, 2009)	3.24
"Memantine is an N-methyl-d-aspartate (NMDA) glutamate receptor antagonist used to treat Alzheimer's disease. "	( Memantine prevents cardiomyocytes nuclear size reduction in the left ventricle of rats exposed to cold stress. Abreu, LC; F Filho, C; Ferreira, C; Ferreira, M; Meneghini, A; Murad, N; Valenti, VE, 2009)	3.24
"Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. "	( Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Grossberg, GT; Thomas, SJ, 2009)	3.24
"Memantine is an N-methyl-d-aspartate receptor antagonist that is approved for the treatment of moderate to severe Alzheimer's disease (AD). "	( Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Albrecht, M; Banerjee, P; Billings, LM; Green, KN; Gupta, S; Kitazawa, M; LaFerla, FM; Martinez-Coria, H; Parsons, CG; Rammes, G, 2010)	3.25
"Memantine is a low-affinity NMDA receptor antagonist that is used in the treatment of Alzheimer's disease to alleviate the cognitive symptoms of the disease. "	( Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats. Carlson, S; Näätänen, R; Neuvonen, T; Pertovaara, A; Ruusuvirta, T; Savioja, K; Tikhonravov, D, 2010)	2.11
"Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD). "	( Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Bimonte-Nelson, H; Boger, H; Granholm, AC; Lockrow, J, 2011)	2.13
"Memantine is an NMDA receptor antagonist that has been recently approved in EU for the treatment of moderate to severe Alzheimer's disease. "	( Effects of the uncompetitive nmda receptor antagonist memantine on recognition memory in rats. Beselia, G; Burjanadze, M; Chkhikvishvili, N; Dashniani, M; Naneishvili, T, 2010)	2.05
"Memantine is an approved symptomatic treatment for moderate to severe Alzheimer's disease that reduces the excitotoxic effects of hyperactive glutamatergic transmission. "	( Effect of memantine on resting state default mode network activity in Alzheimer's disease. Alessandrini, F; Beltramello, A; Caltagirone, C; Canu, E; Costardi, D; Cotelli, M; Frisoni, GB; Lorenzi, M; Mercuri, NB; Pizzini, FB; Rosini, S; Zoccatelli, G, 2011)	2.21
"Memantine is a low- to moderate-affinity, non-competitive NMDA receptor antagonist that is currently approved for the treatment of moderate to severe AD."	( Memantine in dementia: a review of the current evidence. Herrmann, N; Lanctôt, K; Li, A, 2011)	2.53
"Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). "	( Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. Chirikdjian, JJ; Erb, C; Jagsch, C; Mucke, HA; Rainer, M; Wuschitz, A, 2011)	3.25
"Memantine is a potential treatment for ET particularly given its neuroprotective efficacy."	( The effect of memantine in harmaline-induced tremor and neurodegeneration. Akman, O; Ates, N; Erturk, S; Gullu, KM; Iseri, PK; Karson, A; Kokturk, S; Yardýmoglu, M, 2011)	1.45
"Memantine is an aminoadamantane drug useful in neurodegenerative diseases, with beneficial effects on cognitive functions. "	( Effects of memantine, a non-competitive N-methyl-D-aspartate receptor antagonist, on genomic stability. Cappelari, SE; Flores, ÉM; Pereira, P; Picada, JN, 2011)	2.2
"Memantine is a highly unspecific blocker of many channels and how memantine may be of benefit in AD remains a mystery."	( Acute pharmacokinetics of memantine in the mouse. Roder, JC; Saab, BJ, 2011)	1.39
"Memantine is an uncompetitive, low-affinity NMDA receptor antagonist clinically used for the treatment of cognitive deficits in moderate to severe Alzheimer's disease. "	( Memantine potentiates hippocampal θ oscillations at a therapeutic dose in anesthetized mice: a mechanistic link to its cognitive-enhancing properties. Bundgaard, C; Egebjerg, J; Francis, PT; Guadagna, S; Hovelsø, N; Sotty, F; Volbracht, C, 2012)	3.26
"Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist and several studies have pointed to the NMDA receptor antagonists as a potential therapeutic target for the treatment of depression. "	( Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Abelaira, HM; Fries, GR; Kapczinski, F; Quevedo, J; Réus, GZ; Stringari, RB, 2012)	3.26
"Memantine is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist that has been approved for the treatment of the cognitive deficits noted in Alzheimer's disease. "	( Memantine facilitates memory consolidation and reconsolidation in the day-old chick. Crowe, SF; Hazi, A; Samartgis, JR; Schachte, L, 2012)	3.26
"Memantine is an uncompetitive antagonist of NMDA receptors and is widely prescribed for treatment of Alzheimer's disease treatment."	( The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. Brown, WT; Dobkin, C; Li, X; Malik, M; Sheikh, AM; Wei, H, 2012)	1.4
"Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist. "	( Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit. Chiapella, L; Malinverni, P; Pasotti, C; Sinforiani, E; Zucchella, C, 2012)	3.26
"Memantine is a N-methyl-D-aspartic acid receptor (NMDAR) channel blocker that binds to dizocilpine sites and appears well tolerated during chronic use. "	( Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine. Chen, Y; Evola, M; Young, AM, 2013)	3.28
"Memantine is an NMDA-receptor antagonist that has shown promising results in the treatment of other behavioral addictions and substance addictions."	( Memantine reduces stealing behavior and impulsivity in kleptomania: a pilot study. Chamberlain, SR; Grant, JE; Odlaug, BL; Schreiber, LR; Won Kim, S, 2013)	2.55
"Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist."	( A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Möbius, HJ; Stöffler, A; Wilcock, G, 2002)	1.28
"Memantine is an uncompetitive NMDA receptor antagonist under clinical development for the treatment of AD."	( Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Alvarez, XA; Cacabelos, R; Miguel-Hidalgo, JJ; Quack, G, 2002)	1.36
"Memantine is a safe drug and may be useful for treating Alzheimer's, vascular,and mixed dementia of all severities. "	( Memantine for dementia. Areosa, SA; Sherriff, F, 2003)	3.2
"Memantine is an NMDA receptor antagonist that has recently been approved in Europe for treatment of moderately severe to severe AD and is under investigation in the United States."	( Current treatment for Alzheimer disease and future prospects. Federoff, HJ; Tariot, PN, )	0.85
"Memantine is an uncompetitive (channel blocking) NMDA receptor antagonist."	( The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. Rogawski, MA; Wenk, GL, 2003)	1.3
"Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. "	( Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Farlow, MR; Gergel, I; Graham, SM; Grossberg, GT; McDonald, S; Tariot, PN, 2004)	3.21
"Memantine acts as a neuroprotective agent in various animal models based on both neurodegenerative and vascular processes as it ameliorates cognitive and memory deficits."	( NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Haen, E; Koch, HJ; Szecsey, A, 2004)	1.38
"Memantine is a second-line option, as its adverse effects differ from those of anticholinesterases."	( Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease. , 2003)	2.48
"Memantine is an NMDA receptor antagonist with moderate affinity, which results in neuroprotective potential due to reducing overstimulation caused by glutamate (excitotoxicity) and simultaneous lack of adverse events (especially psychosis) typical for an antagonist with higher affinity like phencyclidine. "	( [The clinical relevance of memantine use]. Sobów, T, )	1.87
"Memantine is a similar uncompetitive NMDA-receptor antagonist to MK-801 and phencyclidine (PCP), and it prevents nerve cell death induced by the ischemia which induces as excessive release of glutamate."	( [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801]. Kato, T, 2004)	1.96
"Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. "	( Memantine: pharmacological properties and clinical uses. Kumar, S, 2004)	3.21
"Memantine is an uncompetitive N-methyl-D: -aspartate (NMDA) receptor antagonist. "	( The effects of memantine on lipid peroxidation following closed-head trauma in rats. Cobanoğlu, S; Görgülü, A; Kiriş, T; Ozsüer, H, 2005)	2.12
"Memantine is a noncompetitive NMDA antagonist that is considered a neuroprotective drug."	( Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Lladó, A; Molinuevo, JL; Rami, L, )	2.3
"Memantine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist."	( Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Wang, R; Zhang, D, 2005)	2.49
"Memantine acts as an uncompetitive antagonist of NMDA receptors and therefore compensates for this overactivation."	( Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia. Fischer-Barnicol, D; Koch, HJ; Uyanik, G, 2005)	2.49
"Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease. "	( Mechanism of action of memantine. Johnson, JW; Kotermanski, SE, 2006)	2.09
"Memantine is a drug with neuroprotective and cognition-enhanced properties, which can be combined with other treatments for AD."	( [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia]. Alfaro, V; Tanović, A, )	1.1
"Memantine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist."	( Memantine augmentation for refractory obsessive-compulsive disorder. Biondi, M; Pasquini, M, 2006)	2.5
"Memantine is an effective pharmacotherapeutic agent, and currently the only approved option, for the treatment of moderate to severe Alzheimer's disease."	( Memantine: a review of its use in Alzheimer's disease. Keating, GM; Robinson, DM, 2006)	2.5
"Memantine is a selective noncompetitive NMDA receptor antagonist that has been shown to decrease alcohol craving in moderate drinkers."	( A pilot double-blind treatment trial of memantine for alcohol dependence. Brooks, DJ; Evans, SM; Garawi, F; Levin, FR, 2007)	1.33
"Memantine is an NMDA receptor antagonist that has been demonstrated to be effective in the treatment of patients with Alzheimer's disease."	( Effects of NMDA receptor antagonist memantine on mismatch negativity. Kähkönen, S; Kicić, D; Korostenskaja, M; Nikulin, VV; Nikulina, AV, 2007)	1.34
"Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist which is registered in both Europe and the USA for the treatment of Alzheimer's disease (AD). "	( Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine. Gilling, KE; Jatzke, C; Parsons, CG, 2007)	1.99
"Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist currently approved for the treatment of moderate to severe Alzheimer's disease (AD). "	( Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Bakchine, S; Loft, H, 2007)	3.23
"Memantine is a moderate affinity N-methyl-D-aspartate receptor antagonist approved for treatment of Alzheimer's disease (AD). "	( Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Basun, H; Degerman Gunnarsson, M; Kilander, L; Lannfelt, L, 2007)	2.05
"Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD."	( [Alzheimer Disease]. Massoud, F, 2007)	1.06
"Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist with strong voltage-dependency and fast kinetics."	( Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Danysz, W; Parsons, CG; Stöffler, A, 2007)	2.5
"Memantine is a non-competitive N-methyl-d-aspartate receptor antagonist, which has been employed in the clinic as a neuroprotective agent for the treatment of several dementias, particularly Alzheimer's disease. "	( Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. Gavioli, EC; Machado, RA; Martins, MR; Quevedo, J; Réus, GZ; Valvassori, SS, 2008)	2.07
"Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist currently approved for the treatment of moderate to severe Alzheimer's disease (AD). "	( Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Bakchine, S; Loft, H, 2008)	3.23
"Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with therapeutic potential in dementia, spasticity and Parkinson's disease. "	( Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Kornhuber, J; Quack, G, 1995)	1.95
"Memantine appears to be an interesting prototype for centrally acting cardioprotective drugs devoid of serious side effects."	( MK-801 and memantine inhibit a centrally induced increase in myocardial oxygen demand in rabbits. Bousquet, P; Feldman, J; Monassier, L; Roegel, JC; Tibiriça, E, 1996)	1.41
"Memantine, which is a low affinity uncompetitive NMDA receptor antagonist, has been used in the treatment of Parkinson's disease in Europe."	( Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Hashimoto, K; Minabe, Y; Narita, N; Sakamoto, A; Tamura, A; Tomitaka, S, 1996)	2.46
"Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist which blocks the NMDA receptor with moderate-affinity in a use- and voltage dependent manner. "	( Dopamine release in the prefrontal cortex in response to memantine following sub-chronic NMDA receptor blockade with memantine: a microdialysis study in rats. Breimer, DD; Danysz, W; De Boer, AG; Hesselink, MB, 1999)	1.99
"Memantine is a moderate-affinity, voltage-dependent, uncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors. "	( Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Möbius, HJ, )	1.87
"Memantine acts as a neuroprotective agent against this pathomechanism, which is also implicated in vascular dementia."	( Evaluation of memantine for neuroprotection in dementia. Jain, KK, 2000)	1.39
"Memantine is a noncompetitive NMDA receptor antagonist and it has been used for the treatment of various cerebral disorders with relatively few side effects."	( Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Cobanoglu, S; Görgülü, A; Izgi, NI; Kinş, T; Küçük, M; Unal, F; Yanik, B, 2000)	1.3
"Memantine is a blocker of Ca(2+)-permeable glutamate and nicotinic acetylcholine receptors (nAChR). "	( Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. Fakler, B; Ludwig, J; Oliver, D; Reisinger, E; Ruppersberg, JP; Zoellner, W, 2001)	3.2
"Memantine is a medium-affinity uncompetitive N-methyl-d-aspartate receptor antagonist and has been clinically used as a neuroprotective agent to treat Alzheimer's and Parkinson's diseases. "	( The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Castrén, E; Lakso, M; Marvanová, M; Nawa, H; Pirhonen, J; Wong, G, 2001)	2.05
"Memantine is a 1-amino-adamantane derivative which has been proposed to be useful in the treatment of Parkinson's disease. "	( Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. Korczyn, AD; Nissipeanu, P; Rabey, JM, 1992)	2.11

Excerpt	Reference	Relevance
"Memantine has an acceptable safety and tolerability in patients with OCD and might have a positive effect on their executive function. "	( Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. Askari, S; Mokhtari, S; Shalbafan, M; Shariat, SV; Shariati, B; Yarahmadi, M, 2022)	3.61
"Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition."	( The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia. Du, G; Fu, Q; Huang, L; Shu, B; Zhang, D; Zhang, X, 2018)	1.2
"Memantine has an adjunctive effect on neurosyphilis-related neuropsychiatric disorder via modulation of the glutamatergic neurotransmission and microglia-induced neuroinflammation."	( Memantine Rescues Neurosyphilis-Related Schizophrenic-like Features and Cognitive Deficit. Chen, IC; Chen, PA; Chen, WC; Chen, YC; Wang, HY, )	3.02
"Memantine has a relatively favorable side-effect profile, at least under controlled trial conditions."	( A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. Buckley, JS; Salpeter, SR, 2015)	1.14
"Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change)."	( Memantine: a review of its use in moderate to severe Alzheimer's disease. McKeage, K, 2009)	2.52
"Memantine now has a considerable database of published studies and is associated with benefits in aspects of behaviour, cognition and communication, and on clinical progression. "	( A review of the effects of memantine on clinical progression in Alzheimer's disease. Wilkinson, D, 2012)	2.12
"Memantine has a beneficial effect on the behavioural symptoms of patients with moderate to severe AD, with the most pronounced effect on agitation/aggression."	( Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier, S; Möbius, HJ; Wirth, Y, 2005)	2.16
"Memantine has a tolerability profile similar to placebo."	( Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock, R, )	1.16
"Memantine has a small beneficial effect at six months in moderate to severe AD. "	( Memantine for dementia. Areosa Sastre, A; McShane, R; Minakaran, N, 2006)	3.22
"Memantine has a therapeutic potential in numerous CNS disorders besides dementias which include stroke, CNS trauma, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), epilepsy, drug dependence and chronic pain."	( Evaluation of memantine for neuroprotection in dementia. Jain, KK, 2000)	1.39
"Memantine has an acceptable safety and tolerability in patients with OCD and might have a positive effect on their executive function. "	( Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. Askari, S; Mokhtari, S; Shalbafan, M; Shariat, SV; Shariati, B; Yarahmadi, M, 2022)	3.61
"Memantine has demonstrated potential benefits for neuropathic pains in preclinical studies."	( Management of diabetic neuropathy with memantine: A randomized clinical trial. Aghamohammadzadeh, N; Beheshtirouy, S; Ghaffary, S; Jafarzadeh, E; Sarbakhsh, P; Shaseb, E, )	1.12
"Memantine (MEM) has been used to treat patients with Alzheimer' disease though inhibition of reactive oxygen species (ROS), Ca"	( Effects of homocysteine and memantine on oxidative stress related TRP cation channels in Nazıroğlu, M; Övey, İS, 2021)	2.36
"Memantine has demonstrated beneficial effects on several types of brain insults via therapeutic mechanisms mainly related to its activity as a receptor antagonist of N-methyl-d-aspartate. "	( Memantine protects blood-brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3 Chen, M; Chen, X; Chen, Z; Gao, Z; Huang, H; Mou, Y; Song, M; Xiang, X; Xie, T; Xie, X, 2021)	3.51
"Memantine has shown efficacy in reducing alcohol and opiate craving, consumption, and withdrawal severity."	( Mechanistic insights into the efficacy of memantine in treating certain drug addictions. Abulseoud, OA; Angebrandt, A; Montemitro, C; Pettorruso, M; Wang, TY, 2021)	1.61
"Memantine has shown clinical utility in preventing radiation-induced cognitive impairment, but the mechanisms underlying its protective effects remain unknown. "	( Memantine prevents acute radiation-induced toxicities at hippocampal excitatory synapses. Cham, H; Dinh, J; Duman, JG; Grosshans, DR; Mavratsas, VC; McGovern, SL; Mulherkar, S; Paveškovic, M; Tolias, KF; Zhou, W, 2018)	3.37
"Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition."	( The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia. Du, G; Fu, Q; Huang, L; Shu, B; Zhang, D; Zhang, X, 2018)	1.2
"Memantine has consistently shown promise in both in-vitro and in-vivo studies as a neuroprotective agent that may improve cognitive outcomes in patients undergoing whole brain radiotherapy."	( Preservation of cognitive function following whole brain radiotherapy in patients with brain metastases: Complications, treatments, and the emerging role of memantine. Lynch, M, 2019)	1.43
"Memantine has been shown to have analgesic properties in pre-clinical and small clinical studies."	( A systematic review and meta-analysis of memantine for the prevention or treatment of chronic pain. Kurian, R; Raza, K; Shanthanna, H, 2019)	1.5
"Memantine has an adjunctive effect on neurosyphilis-related neuropsychiatric disorder via modulation of the glutamatergic neurotransmission and microglia-induced neuroinflammation."	( Memantine Rescues Neurosyphilis-Related Schizophrenic-like Features and Cognitive Deficit. Chen, IC; Chen, PA; Chen, WC; Chen, YC; Wang, HY, )	3.02
"Memantine has been proven to reduce brain injury in several types of brain insults."	( Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage. Cheng, YY; Chio, CC; Huang, CY; Pan, CH; Shan, YS; Tsai, KJ; Wang, HK; Wang, LC, 2015)	2.58
"Memantine (MEM) has been indicated to dramatically increase hippocampal neurogenesis by promoting the proliferation of RGLs."	( Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease. Bao, X; Cai, Y; Chen, J; Fan, X; Huang, J; Huang, W; Sun, D; Xu, H; Zhao, J, 2015)	1.36
"Memantine has a relatively favorable side-effect profile, at least under controlled trial conditions."	( A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. Buckley, JS; Salpeter, SR, 2015)	1.14
"Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer's disease (AD). "	( The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. Cheng, Y; Du, H; Shi, FD; Wei, C; Zhang, N, 2015)	2.22
"Memantine has been approved for moderate to severe AD, but evidence indicates that it does not modify disease progression."	( Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit. Bahramian, A; Moosavi, M; Namavar, MR; Rastegar, K, 2016)	1.41
"Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss."	( Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. Banerjee, P; Douadi, M; Li, YS; Quartermain, D; Scholtzova, H; Sigurdsson, EM; Wadghiri, YZ; Wisniewski, T, 2008)	2.51
"Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change)."	( Memantine: a review of its use in moderate to severe Alzheimer's disease. McKeage, K, 2009)	2.52
"Memantine has been used to treat several neurological diseases, including those associated with excessive glutamate release. "	( Memantine depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase C in rat cerebral cortex nerve terminals: an NMDA receptor-independent mechanism. Lin, TY; Lu, CW; Wang, SJ, 2010)	3.25
"Memantine has shown modest benefits in cognition, function, global and behavioural measures, and has shown little potential for drug-drug interactions."	( Memantine in dementia: a review of the current evidence. Herrmann, N; Lanctôt, K; Li, A, 2011)	2.53
"Memantine has comparable efficacy to buprenorphine in the suppression of objective signs of naloxone-precipitated acute opioid withdrawal; however, its role in the suppression of subjective symptoms is debatable."	( A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. Dhawan, A; Jain, K; Jain, R, )	1.82
"Memantine has been approved to treat moderate to severe Alzheimer disease (AD), which is characterized by cognitive impairment."	( Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats. An, LW; Duan, RS; Jia, LJ; Li, ZP; Wang, WP; Zhen, JL, 2011)	2.53
"Memantine has shown clinical benefits in the key domains of AD, both as monotherapy and in combination with a cholinesterase inhibitor (ChEI)."	( A review of the effects of memantine on clinical progression in Alzheimer's disease. Wilkinson, D, 2012)	1.4
"Memantine now has a considerable database of published studies and is associated with benefits in aspects of behaviour, cognition and communication, and on clinical progression. "	( A review of the effects of memantine on clinical progression in Alzheimer's disease. Wilkinson, D, 2012)	2.12
"Memantine, therefore, has the potential to be a safe, effective, and well-tolerated antitussive agent."	( Antitussive effects of memantine in guinea pigs. Canning, BJ; Hilton, ECY; Saulsberry, L; Smith, JA, 2012)	1.41
"Memantine has the indication for moderate to severe AD, and can be prescribed with one choline esterase inhibitor."	( [New anti-AD drugs--their possibilities and issues]. Nakamura, Y, 2012)	1.1
"Memantine has been reported to have positive effects on visual hallucinations and cognition in patients with dementia with Lewy bodies (DLB). "	( The effects of memantine on a patient having preclinical dementia with Lewy bodies. Kimura, R; Matsunaga, H; Matsusaka, K; Takaya, M; Yanagida, M, )	1.93
"Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). "	( Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Boxer, AL; Fields, S; Graf-Radford, N; Grossman, M; Kaufer, DI; Kerwin, D; Klepac, K; Knopman, DS; Koestler, M; Kramer, JH; Lerner, A; Lipowski, K; Mendez, M; Merrilees, J; Mesulam, MM; Miller, BL; Neuhaus, J; Onyike, C; Shapira, J; Sullivan, K; Ullah, J; Wu, CK, 2013)	3.28
"Memantine has neuroprotective actions in several in vitro and in vivo models."	( Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Alvarez, XA; Cacabelos, R; Miguel-Hidalgo, JJ; Quack, G, 2002)	1.36
"Memantine has been demonstrated to be safe and effective in the symptomatic treatment of Alzheimer's disease (AD). "	( The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. Rogawski, MA; Wenk, GL, 2003)	2.02
"Memantine has been shown to improve symptoms and reduce the rate of clinical deterioration among patients with moderate-to-severe AD and was approved in the US for this indication in October 2003."	( Evaluation of memantine for the treatment of Alzheimer's disease. Ferris, SH, 2003)	1.4
"Memantine has shown to be effective and safe in the treatment of dementia, particularly Alzheimer's disease, in controlled clinical trials."	( NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia. Haen, E; Koch, HJ; Szecsey, A, 2004)	1.38
"Memantine also has neuroprotective properties and can inhibit Abeta-induced neurodegeneration."	( What is the rationale for new treatment strategies in Alzheimer's disease? Rogawski, MA, 2004)	1.04
"Memantine has been shown to cause modest improvement in clinical symptoms in severe stages of AD and may retard the disease progression."	( Memantine: pharmacological properties and clinical uses. Kumar, S, 2004)	2.49
"Memantine's capacity has been demonstrated in preclinical studies, and it is considered a useful symptomatic treatment for AD."	( Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Lladó, A; Molinuevo, JL; Rami, L, )	2.3
"Memantine has a beneficial effect on the behavioural symptoms of patients with moderate to severe AD, with the most pronounced effect on agitation/aggression."	( Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier, S; Möbius, HJ; Wirth, Y, 2005)	2.16
"Memantine has been clinically used in the treatment of organic disorders in Germany for over ten years and has now been approved in Europe and also in the US for moderate to severe Alzheimer's disease. "	( Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia. Fischer-Barnicol, D; Koch, HJ; Uyanik, G, 2005)	3.21
"Memantine has a tolerability profile similar to placebo."	( Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock, R, )	1.16
"Memantine has a small beneficial effect at six months in moderate to severe AD. "	( Memantine for dementia. Areosa Sastre, A; McShane, R; Minakaran, N, 2006)	3.22
"Memantine use has shown some benefit in moderate-to-severe Alzheimer's disease or for vascular dementia."	( Magnesium supplementation in the treatment of dementia patients. Cillier, AE; Ozturk, S, 2006)	1.06
"Memantine has been used clinically in the treatment of Parkinson's disease and spasticity for a number of years."	( Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Le, DA; Lipton, SA; Sathi, S; Stieg, PE; Warach, S, 1999)	1.26
"Memantine has been investigated extensively in animal studies and following this, its efficacy and safety has been established and confirmed by clinical experience in humans."	( Evaluation of memantine for neuroprotection in dementia. Jain, KK, 2000)	1.39

Excerpt	Reference	Relevance
"Memantine inhibited the increase of phosphorylated GluN2A and ERK1/2 resulting from social interaction behavior."	( Memantine ameliorates the impairment of social behaviors induced by a single social defeat stress as juveniles. Hasegawa, S; Mamiya, T; Mouri, A; Noda, Y; Ozaki, N; Suzuki, C; Taniguchi, M; Yoshida, M; Yoshimi, A, 2022)	2.89
"Memantine followed a slower release profile from the NPs against the free drug solution, allowing to reduce drug administration frequency in vivo."	( Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. Calpena, AC; Camins, A; Cano, A; Carmona, N; Egea, MA; Espina, M; Ettcheto, M; García, ML; Sánchez-López, E; Silva, AM; Souto, EB, 2018)	2.64
"Memantine promotes oxime-induced erythrocyte enzyme reactivation on the model of mice poisoning with anticholinesterase compound (0.8 LD50)."	( [Specific features of the anticonvulsant effect of memantine in mice intoxicated with a model organic phosphate]. Bykov, VN; Chepur, SV; Iudin, MA; Ivanov, IM; Kurpiakova, AF; Nikiforov, AS; Subbotina, SN, 2013)	1.36
"Memantine did not cause a significant change in GPIAS."	( The effect of the NMDA channel blocker memantine on salicylate-induced tinnitus in rats. de Corso, E; Eramo, SL; Fetoni, AR; Paciello, F; Paludetti, G; Podda, MV; Ralli, M; Salvi, R; Troiani, D, 2014)	1.39
"Memantine and ketamine inhibit NMDA receptors with similar affinity and kinetics."	( Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. Johnson, JW; Kotermanski, SE; Wood, JT, 2009)	2.52
"Memantine also showed lower reductions in BADLs (p < 0.05) and IADLs (p < 0.001), for observed cases, compared with placebo."	( Memantine benefits functional abilities in moderate to severe Alzheimer's disease. Aström, D; Gauthier, S; Stender, K; Winblad, B, 2010)	2.52
"Memantine, shown to cause cognitive and functional improvement, is not an ChE inhibitor and does not interact with marketed ChE inhibitors."	( What is the rationale for new treatment strategies in Alzheimer's disease? Rogawski, MA, 2004)	1.04

Excerpt	Reference	Relevance
"Memantine treatment did not affect compulsive checking nor frontostriatal structural and functional connectivity in the quinpirole-induced adolescent rat model. "	( Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior. Blezer, ELA; Buitelaar, JK; Dijkhuizen, RM; Glennon, JC; Otte, WM; Smeele, CE; Straathof, M; van der Toorn, A; van Heijningen, C, 2022)	3.61
"Memantine treatment is effective and safe to treat headache."	( Effectiveness and Safety of Memantine for Headache: A Meta-analysis of Randomized Controlled Studies. Tang, Y; Zhou, T; Zhu, H, )	1.87
"Memantine treatment also protected against axon damage assessed by NF-l expression."	( Memantine Mitigates Oligodendrocyte Damage after Repetitive Mild Traumatic Brain Injury. Conley, G; Hashim, J; Liu, C; Ma, G; Mannix, R; Meehan, WP; Morriss, N; Qiu, J, 2019)	2.68
"Memantine treatment can prevent okadaic acid induced impairment of hippocampal-dependent spatial memory and accompanied by modulation of the expression level of α7 subunit of nACh and NR2B subunit of NMDA receptors in the hippocampus."	( Memantine treatment prevents okadaic acid induced neurotoxicity at the systemic and molecular levels. Beselia, GV; Burjanadze, MA; Chighladze, MR; Chkhikvishvili, NC; Dashniani, MG; Kandashvili, M; Kruashvili, LB; Solomonia, RO, 2020)	2.72
"Memantine treatment was able both to reverse the memory deficits and to reduce the excessive intake of palatable diet and the withdrawal-induced hypophagia in food cycling rats."	( Withdrawal from Extended, Intermittent Access to A Highly Palatable Diet Impairs Hippocampal Memory Function and Neurogenesis: Effects of Memantine. Abdullatif, AA; Cottone, P; Ferragud, A; Sabino, V; Velázquez-Sánchez, C, 2020)	1.48
"Memantine treatment reduced the expression of cardiac TNF-α in comparison to Iso group."	( Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies. Abbaszadeh, S; Jannesar, K; Malekinejad, H; Soraya, H, 2020)	1.57
"Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients. "	( Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019)	2.22
"Memantine treatment decreased GSK3B protein expression levels in tumor tissue samples."	( Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model. Albayrak, G; Bagriacik, EU; Bali, EB; Korkmaz, FD, 2021)	1.64
"Memantine treatment may benefit to the control of migraine."	( The Efficacy of Memantine for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies. Chen, L; Chen, X; Jin, S; Xu, Z; Yang, B, )	1.92
"Memantine add-on treatment may be beneficial for treating psychopathological symptoms (especially negative symptoms) in schizophrenia patients. "	( Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Iwata, N; Kishi, T; Matsuda, Y, 2017)	3.34
"Memantine treatment reduced the ethanol-induced increase of intracellular calcium, caspase-3 activation, apoptosis, and the ethanol-induced decrease in cell viability."	( Memantine Can Reduce Ethanol-Induced Caspase-3 Activity and Apoptosis in H4 Cells by Decreasing Intracellular Calcium. Chen, J; Feng, C; Wang, C; Wang, H; Wang, P; Wang, X; Wu, X; Xu, G; You, J; Yu, H; Zhang, G; Zhao, R, 2017)	2.62
"Memantine is a viable treatment option for patients with AD presenting not only with cognitive impairment, but also with a broader range of symptoms, including the behavioral and psychological symptoms of dementia."	( Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses. Fukuchi, Y; Kamata, T; Matsui, D; Matsumoto, T; Okuizumi, K; Saito, K, 2018)	3.37
"Memantine treatment stabilized ventricular enlargement in both low and high dose groups."	( Memantine treatment of juvenile rats with kaolin-induced hydrocephalus. Del Bigio, MR; Di Curzio, DL; Mao, X; Nagra, G, 2018)	2.64
"Memantine pretreatment (18 mg/kg sc) produced in rats poisoned with soman significantly better protective ratios (PRs) than the two carbamates - 1.25 when administered alone and 2.3 when combined with atropine pretreatment and 6.33 and 7.23 with atropine/HI-6 and atropine/HI-6/diazepam post-exposure therapy, respectively. "	( Prophylactic potential of memantine against soman poisoning in rats. Bokonjić, D; Jokanović, M; Kilibarda, V; Škrbić, R; Stojiljković, MP; Vulović, M, 2019)	2.26
"Memantine treatment ameliorated the spatial memory deficits induced, as evidenced by the MWM tests."	( N-(p-amylcinnamoyl) anthranilic acid attenuates remedial effects of memantine on memory deficits following intracerebroventricular streptozotocin administration in rats. Demiryürek, AT; Demiryürek, Ş; Göl, M; Kaplan, DS; Örkmez, M; Saracaloğlu, A, 2019)	1.47
"Memantine as an adjunct treatment appears to have significant efficacy in improving negative symptoms in schizophrenia. "	( Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. Cai, DB; He, SH; Ng, CH; Ning, YP; Peng, XJ; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W; Zhou, YL; Zhu, XM, 2019)	2.35
"Memantine pretreatment improved the LPS-induced ALI lung tissue morphological changes, reduced their lung wet/dry ratio, the levels of TNF-α and LDH activity in BALF, and also reduced the MPO and MDA content in the lung tissue."	( [Protective effect of NMDA receptor antagonist memantine on acute lung injury in mice]. Cheng, Q; Feng, D; Han, J; Li, Y; Liu, W; Luo, Z; Ma, L; Yue, S, 2014)	2.1
"Memantine pretreatment was able to prevent the cognitive impairment caused by SD in both age groups, while it had no negative effect on CTL animals."	( Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Blin, O; Bordet, R; Canovi, M; Cella, M; Estrada, C; Fernández-Villalba, E; Gobbi, M; Gonzalez-Cuello, A; Guiso, G; Herrero, MT; Lamberty, Y; Lopez, D; Pifferi, F; Richardson, JC; Ros, CM; Tarragon, E, 2014)	2.57
"Oral memantine pretreatment is protective against spinal cord ischemia, and can be an additional strategy for the prevention of paraplegia during thoracoabdominal aortic surgeries."	( Paraplegia prevention by oral pretreatment with memantine in a rabbit model. Ikemura, M; Itoda, Y; Morota, T; Motomura, N; Ono, M; Panthee, N; Saito, A; Suzuki, H; Tanaka, T; Yamamoto, T, 2014)	1.17
"Memantine treatment resulted in an increase in cerebral metabolism in FM patients, suggesting its utility for the treatment of the illness."	( Changes in metabolites after treatment with memantine in fibromyalgia. A double-blind randomized controlled trial with magnetic resonance spectroscopy with a 6-month follow-up. Andrés, E; Fayed, N; Garcia-Campayo, J; Herrera-Mercadal, P; López del Hoyo, Y; Magallon, R; Olivan-Blázquez, B; Pérez-Yus, MC; Puebla-Guedea, M; Viguera, L, 2014)	2.11
"Memantine-treated patients were younger than those not receiving memantine (mean 75.9 and 78.8 years, respectively), with a lower screening Mini-Mental State Examination (8.6 and 9.2, respectively). "	( Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor. Farlow, MR; Grossberg, GT; Meng, X; Velting, DM, 2015)	2.08
"Memantine treatment showed similar effects, regardless of the baseline cognitive functions, but showed better effects on ABS for higher baseline cognitive functions."	( Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II). Abe, K; Deguchi, K; Hishikawa, N; Koike, M; Kono, S; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T, 2015)	1.46
"Memantine (studies=4; treated=152 vs."	( Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016)	1.43
"Memantine treatment was generally well tolerated and was not associated with any serious adverse events."	( A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder. Biederman, J; Chan, J; Conroy, K; Faraone, SV; Fried, R; Furtak, S; Grimsley, E; Joshi, G; Kilcullen, JR; Woodworth, KY; Wozniak, J, 2016)	1.43
"In Memantine treatment groups, a single dose of agent (5 and 10 mg/kg) was administered daily."	( The Effect of Memantine on Functional Recovery of the Sciatic Nerve Crush Injury in Rats. Abdolmaleki, A; Behnam-Rassouli, M; Ghayour, MB, 2017)	1.33
"Memantine treatment significantly increased RGC survival in glaucomatous DBA/2J mice and increased the 75-kDa OPA1 isoform, but did not alter the 80- and 90-kDa isoforms. "	( Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Angert, M; Duong-Polk, KX; Ellisman, MH; Ju, WK; Kim, KY; Lindsey, JD; Weinreb, RN, 2009)	3.24
"Memantine treatment significantly protected cultured neurons against Abeta-induced toxicity by attenuating tau-phosphorylation and its associated signaling mechanisms."	( Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Baker, GB; Kar, S; Rauw, G; Song, MS, 2008)	2.51
"Memantine treatment substantially attenuated motor impairment induced by an acute challenge with diazepam (6 mg/kg, i.p.), as assessed by the rotarod test and the horizontal wire test."	( Memantine treatment reduces the expression of the K(+)/Cl(-) cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA(A) receptor activation in mice. Battaglia, G; Bruno, V; Di Menna, L; Molinaro, G; Nicoletti, F; Rampello, L; Riozzi, B, 2009)	2.52
"Memantine treatment of AD patients results in significant benefits for language function. "	( Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Ferris, S; Gatz, G; Gauthier, S; Ihl, R; Robert, P; Tennigkeit, F; Winblad, B, 2009)	2.11
"Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau."	( Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Albrecht, M; Banerjee, P; Billings, LM; Green, KN; Gupta, S; Kitazawa, M; LaFerla, FM; Martinez-Coria, H; Parsons, CG; Rammes, G, 2010)	2.52
"Memantine--treated patients showed significantly less deterioration in their functionality. "	( [Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil]. Chiriţă, R; Chiriţă, V; Creţu, O; Szalontay, AS, )	1.96
"Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls."	( Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Bimonte-Nelson, H; Boger, H; Granholm, AC; Lockrow, J, 2011)	1.41
"Memantine treatment was associated with diminished gambling and improved cognitive flexibility."	( Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Chamberlain, SR; Grant, JE; Kim, SW; Odlaug, BL; Potenza, MN, 2010)	2.52
"Memantine-treated patients had less decline from baseline on the ADL14 total score, compared with placebo (p < 0.001) at study end."	( Memantine benefits functional abilities in moderate to severe Alzheimer's disease. Aström, D; Gauthier, S; Stender, K; Winblad, B, 2010)	2.52
"Memantine treatment was also associated with superior performances on the Boston Naming Test (P = .034) and the Trail Making Test, Part B (P = .001), but also with a higher number of errors (i.e., repetitions and intrusions) on the California Verbal Learning Test."	( Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. Fridman, M; Graham, SM; Hofbauer, RK; Hsu, HA; Li, S; Perhach, JL; Sadowsky, C; Saxton, J; Suhy, J; Weiner, MW; Yu, SY, 2011)	1.32
"Memantine treatment significantly improved the course of CIA, reducing synovitis (p = 0.007) and the frequency of erosions (p = 0.007)."	( The N-methyl-d-aspartic acid receptor antagonist memantine ameliorates and delays the development of arthritis by enhancing regulatory T cells. Bokarewa, MI; Hellvard, A; Jonsson, IM; Lindblad, SS; Mydel, P, 2012)	1.35
"Memantine treatment reversed anhedonia and the increase of adrenal gland weight, normalized corticosterone levels and increased BDNF protein levels in the prefrontal cortex in stressed rats."	( Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Abelaira, HM; Fries, GR; Kapczinski, F; Quevedo, J; Réus, GZ; Stringari, RB, 2012)	2.54
"Memantine treatment was associated with diminished impulsive buying and improvements on cognitive tasks of impulsivity."	( Open-label pilot study of memantine in the treatment of compulsive buying. Grant, JE; Kim, SW; Mooney, M; O'Brien, R; Odlaug, BL, 2012)	1.4
"Memantine treated volunteers showed an increased emotion-potentiated startle, and a reduced bias for negative items in emotional recognition memory."	( Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine. Cowen, LG; Cowen, PJ; Harmer, CJ; McTavish, SF; Parsons, E; Pringle, A, 2012)	1.3
"Memantine treatment of Fmr1-KO CGCs promoted cell adhesion properties."	( The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. Brown, WT; Dobkin, C; Li, X; Malik, M; Sheikh, AM; Wei, H, 2012)	1.4
"Memantine, used for treatment of Alzheimer disease, is an antagonist for N-methyl-d-aspartate receptors."	( Memantine improves safety of thrombolysis for stroke. Agin, V; Ali, C; Gauberti, M; Hébert, M; Jullienne, A; Le Béhot, A; Lesept, F; Louessard, M; Maubert, E; Montagne, A; Orset, C; Vivien, D, 2012)	2.54
"Memantine treatment was associated with lower axial motor symptom and dyskinesia scores but did not improve gait. "	( Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. Allorge, D; Blum, D; Bordet, R; Defebvre, L; Delval, A; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Hossein-Foucher, C; Moreau, C; Petyt, G; Sablonnière, B; Schraen, S; Tiffreau, V, 2013)	3.28
"Memantine treatment had no effect on either the NPI (mean difference 2·2, 95% CI -3·9 to 8·3, p=0·47) or CGIC (mean difference 0·0, -0·4 to 0·4, p=0·90) after 26 weeks of treatment."	( Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Boxer, AL; Fields, S; Graf-Radford, N; Grossman, M; Kaufer, DI; Kerwin, D; Klepac, K; Knopman, DS; Koestler, M; Kramer, JH; Lerner, A; Lipowski, K; Mendez, M; Merrilees, J; Mesulam, MM; Miller, BL; Neuhaus, J; Onyike, C; Shapira, J; Sullivan, K; Ullah, J; Wu, CK, 2013)	2.55
"Memantine treatment showed no benefit in patients with FTD. "	( Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Boxer, AL; Fields, S; Graf-Radford, N; Grossman, M; Kaufer, DI; Kerwin, D; Klepac, K; Knopman, DS; Koestler, M; Kramer, JH; Lerner, A; Lipowski, K; Mendez, M; Merrilees, J; Mesulam, MM; Miller, BL; Neuhaus, J; Onyike, C; Shapira, J; Sullivan, K; Ullah, J; Wu, CK, 2013)	3.28
"Memantine treated animals had significant reductions in the amount of neuronal degeneration, pyknotic nuclei, and GFAP immunostaining as compared with vehicle treated animals."	( Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Alvarez, XA; Cacabelos, R; Miguel-Hidalgo, JJ; Quack, G, 2002)	1.36
"Memantine-treated animals suffered less amplitude reduction for these measures than did vehicle-treated animals, though this treatment effect on the ERG measures was observed only at the early time points (3 and 5 months post IOP elevation)."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004)	1.36
"Memantine-treated HIVE mice showed significant improvements in synaptic function during frequency facilitation tests and LTP induced by high-frequency stimulation when compared with untreated animals."	( Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. Anderson, ER; Gendelman, HE; Xiong, H, 2004)	2.49
"Memantine treatment also has demonstrated significant improvement of cognitive performance in patients suffering from vascular dementia."	( Memantine hydrochloride: pharmacological and clinical profile. Graham, SM; Möbius, HJ; Stöffler, A, 2004)	2.49
"Memantine treatment significantly reduced lipid peroxidation levels in the treatment group compared with other groups (P<0.01)."	( The effects of memantine on lipid peroxidation following closed-head trauma in rats. Cobanoğlu, S; Görgülü, A; Kiriş, T; Ozsüer, H, 2005)	1.4
"Memantine treatment showed a significant beneficial effect in comparison to placebo treatment in the NPI agitation/aggression domain in both studies (p = 0.008; p = 0.001)."	( Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier, S; Möbius, HJ; Wirth, Y, 2005)	1.44
"Memantine could be a treatment for some patients with moderate to severe degrees of dementia, while acetylcholinesterase inhibitors could be useful for some patients with mild to moderate degrees of dementia of the Alzheimer type."	( [Assessment of dementia and use of anti-dementia drugs in nursing homes]. Engedal, K, 2005)	1.05
"Memantine treatment markedly decreased appetite within few hours and complete suppressed the binge-eating disorder within 24 h."	( A new anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Hermanussen, M; Tresguerres, JA, 2005)	1.26
"Memantine treatment significantly delayed the disease progression and increased the life span of SOD1(G93A) mice, from 121.4 +/- 5.5 to 129.7 +/- 4.5 days (P = 0.032)."	( Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Wang, R; Zhang, D, 2005)	2.49
"Memantine treatment reduced the total cortical levels of membrane-bound amyloid precursor protein (45-55%) in both transgenic and nontransgenic mice, which eventually may decrease the level of Abeta."	( Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice. Hedberg, MM; Nordberg, A; Svedberg, MM; Unger, C; Yu, WF, 2006)	1.33
"Memantine- and vehicle-treated glaucoma groups were compared using t tests and analysis of covariance."	( Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006)	2.5
"Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up."	( Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. Birbaumer, N; Konrad, CJ; Schaller, HE; Schley, M; Schmelz, M; Topfner, S; Wiech, K, 2007)	2.01
"Memantine-treated patients without agitation/aggression at baseline evidenced significantly less emergence of this symptom compared with similar patients receiving placebo."	( Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006)	1.37
"Memantine-treated rats showed normal recognition memory while the saline group showed long-term recognition memory deficits."	( Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Budni, P; Constantino, L; Dal-Pizzol, F; Dornelles, A; Garcia, VA; Martins de Lima, MN; Pietá Dias, C; Presti-Torres, J; Rewsaat Guimarães, M; Schröder, N; Siciliani Scalco, F, 2007)	2.5
"Memantine-treated patients showed statistically significant improvement relative to placebo at weeks 12 and 18, and numerical superiority at week 24 on both efficacy scales."	( Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Bakchine, S; Loft, H, 2007)	2.5
"Memantine treatment provided benefits in cognitive, functional, and global outcomes in these patients and for their agitation/aggression."	( Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008)	2.51
"Memantine-treated patients showed statistically significant improvement relative to placebo at weeks 12 and 18, and numerical superiority at week 24 on both efficacy scales."	( Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Bakchine, S; Loft, H, 2008)	2.51
"Memantine treatment alone had no effect on ganglion cell survival."	( Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Dreyer, EB; Hyman, BT; Lipton, SA; Sabel, BA; Vorwerk, CK; Zurakowski, D, 1996)	1.24
"Memantine treatment (n=9) reduced the brain water content significantly in the cortex compared to saline treatment (n=8; 83."	( Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Dempsey, RJ; Dogan, A; Eras, MA; Rao, VL, 1999)	1.34
"Memantine pretreatment (5 and 10 mg/kg, but not 2.5 mg/kg), given 30 min prior to each morphine dose during the development of tolerance period, inhibited the rightward shift of morphine cumulative dose-response curve."	( Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test. Kozela, E; Popik, P, )	1.12
"Treatment with memantine and vitamin D can protect cortical axons from exposure to amyloid-β and glutamate toxicity, suggesting this combination may mitigate altered gait in AD."	( Effects of Memantine and High Dose Vitamin D on Gait in Male APP/PS1 Alzheimer's Disease Mice Following Vitamin D Deprivation. Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Montero-Odasso, M; Wong, D, 2022)	1.45
"Treatment with memantine and vitamin D, but not memantine alone, prevented this impairment."	( Effects of Memantine and High Dose Vitamin D on Gait in Male APP/PS1 Alzheimer's Disease Mice Following Vitamin D Deprivation. Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Montero-Odasso, M; Wong, D, 2022)	1.45
"Treatment with memantine, a non-competitive NMDAR antagonist, reversed impairment in hippocampal pattern separation networks as detected by functional magnetic resonance imaging. "	( Recovery from the damage of cranial radiation modulated by memantine, an NMDA receptor antagonist, combined with hyperbaric oxygen therapy. Fujiwara, K; Hokama, Y; Ishiuchi, S; Katagiri, C; Nishimura, M; Takagi, H; Usugi, R, 2023)	1.51
"Treatment with memantine resulted in significant improvement (p < 0.05) in sensorimotor development, preservation of spatial memory, reduction of astrocytic reaction in the corpus callosum, cortex, and germinal matrix."	( Memantine associated with ventricular-subcutaneous shunt promotes behavioral improvement, reduces reactive astrogliosis and cell death in juvenile hydrocephalic rats. Almeida, TAL; Beggiora, PDS; da Silva, SC; Lopes, LDS; Machado, HR; Rodrigues, KP; Sampaio, GB; Silva, GAPM, 2022)	2.5
"Treatment with memantine prevented the chorea movement and the progression of Huntington's disease."	( Memantine administration prevented chorea movement in Huntington's disease: a case report. Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023)	2.69
"Treatment with memantine also corresponded to normal NMDAR expression after rmTBI."	( Memantine improves outcomes after repetitive traumatic brain injury. Alcon, S; Hashim, J; Mannix, R; Meehan, WP; Mei, Z; Qiu, J; Rotenberg, A; Sun, Y, 2018)	2.26
"Rats treated with memantine and/or rosuvastatin showed significant improvement in Morris water maze task and long-term potentiation (LTP) in the hippocampus, compared with untreated 2VO model rats."	( Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion. Cheng, Y; Gordon, ML; Luo, L; Song, C; Xing, M; Zhang, N; Zhao, B, 2017)	1.02
"Treatment with memantine increase latency to SE onset only in groups treated 3 h before or concomitant with pilocarpine."	( Memantine decreases neuronal degeneration in young rats submitted to LiCl-pilocarpine-induced status epilepticus. de Oliveira, DL; Dos Santos, TG; Kalinine, E; Mussulini, BHM; Portela, LVC; Zenki, KC; Zimmer, ER, 2018)	2.26
"Pretreatment with memantine offered protection to both juvenile and adult animals."	( Radiation induces age-dependent deficits in cortical synaptic plasticity. Bronk, L; Dougherty, PM; Duman, JG; Grosshans, DR; Lam, TT; Ma, D; Wang, Q; Weng, C; Zhang, D; Zhou, W, 2018)	0.8
"Treatment with memantine had a strong effect on normalizing the SC and reducing ALFF while slightly increasing other connectivity measures and restoring the rsFC-SC coupling, which is consistent with its effect on alleviating hyper-excitability and improving the coordinated neural growth."	( Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model. Chang, WT; Chuang, KH; Garcia-Miralles, M; Koh, KB; Pouladi, MA; Puspitasari, F; Tan, LJ; Tay, HC; Yeow, LY, 2018)	0.82
"Pre-treatment with memantine 20 mg/kg significantly reduced myocardial edematous, MPO activity and malondialdehyde (MDA) levels in comparison to HF group (p < 0.05, p < 0.05 and p < 0.001 respectively)."	( Memantine, an NMDA receptor antagonist, attenuates cardiac remodeling, lipid peroxidation and neutrophil recruitment in heart failure: A cardioprotective agent? Abbaszadeh, S; Askari, B; Janssen, PML; Javidmehr, A; Soraya, H, 2018)	2.24
"Pretreatment with memantine assured higher AChE activity in brain and diaphragm than in unpretreated rats (46% vs 28% and 68% vs."	( Prophylactic potential of memantine against soman poisoning in rats. Bokonjić, D; Jokanović, M; Kilibarda, V; Škrbić, R; Stojiljković, MP; Vulović, M, 2019)	1.14
"Pretreatment with memantine at a dose of 5 μmol/kg significantly prevented MeHg-induced alterations of Glu metabolism and oxidative stress, alleviated neurocyte apoptosis, and pathological injury."	( Protective effects of memantine against methylmercury-induced glutamate dyshomeostasis and oxidative stress in rat cerebral cortex. Deng, Y; Liu, W; Wei, Y; Xu, B; Xu, Z; Yang, T, 2013)	1.03
"The treatment with memantine reduced both the magnitude and frequency of SWI (the former significantly), but did not modified neurological conditions or saccade parameters."	( Ocular-motor profile and effects of memantine in a familial form of adult cerebellar ataxia with slow saccades and square wave saccadic intrusions. Federico, A; Federighi, P; Leigh, RJ; Piu, P; Pretegiani, E; Rosini, F; Rufa, A; Serra, A, 2013)	0.98
"Pre-treatment with memantine did not prevent MDMA-induced memory impairment in these two tasks."	( Memory and mood during MDMA intoxication, with and without memantine pretreatment. de la Torre, R; de Sousa Fernandes Perna, EB; Farre, M; Heckman, P; Kuypers, KP; Ramaekers, JG; Theunissen, EL, 2014)	0.96
"Treatment with memantine or E2 significantly reduced infarct volume by >40% and significantly improved neurological function while treatment with TMP had no effect."	( The neuroprotective effect of 17β-estradiol is independent of its antioxidative properties. Gröger, M; Plesnila, N, 2014)	0.76
"Pretreatment of memantine hydrochloride (10-30 mg/kg., i.p.) dose-dependently delayed the onset of different phases of convulsions induced by NMDA."	( Memantine delayed N-methyl-D-aspartate -induced convulsions in neonatal rats. Chopra, K; Dhir, A, 2015)	2.19
"Treatment with memantine significantly decreased the NPI score (5.8±4.3, p<0.01)."	( The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer's disease. Ando, N; Ishikawa, I; Mori, T; Nakamura, Y; Shinno, H, 2016)	1.13
"Treatment with memantine (1-10 μM) improved STZ-induced neurotrophic factor decline (BDNF, GDNF) along with IR dysfunction as evidenced by a significant increase in IR protein expression, phosphorylation of IRS-1, Akt, and GSK-3 α/β in astrocytes."	( Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes. Hanif, K; Nath, C; Rajasekar, N; Shukla, R, 2016)	1.09
"Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer's disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer's disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats."	( Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. Blanchard, J; Grundke-Iqbal, I; Iqbal, K; Wang, X, 2015)	2.2
"Treatment with memantine has significantly attenuated prenatal valproic acid-induced reduction in social interaction, spontaneous alteration, exploratory activity intestinal motility, serotonin levels and prefrontal cortex mitochondrial complex activity."	( Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats. Kumar, H; Sharma, B, 2016)	2.22
"Treatment with memantine was associated with significant reduction on informant-rated (SRS-A, -28 ± 25; P < 0.001) and clinician-rated (Clinical Global Impression-Improvement subscale ≤2, 83%) measures of autism severity."	( A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder. Biederman, J; Chan, J; Conroy, K; Faraone, SV; Fried, R; Furtak, S; Grimsley, E; Joshi, G; Kilcullen, JR; Woodworth, KY; Wozniak, J, 2016)	1.05
"Treatment with memantine appeared to have differential effects on cognitive performance in a population of women with putative risk factors for AD. "	( Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. Holcomb, M; Kenna, HA; Lazzeroni, L; Powers, BN; Rasgon, NL; Williams, KE; Wroolie, TE, 2009)	1.02
"Pre-treatment with memantine (N-methyl-D-aspartate receptor antagonist) significantly improved survival of rat neurons exposed to glutamate and its effect was associated with overall decrease of reactive oxygen species (ROS) in both transgenic and nontransgenic neurons."	( Memantine prevents sensitivity to excitotoxic cell death of rat cortical neurons expressing human truncated tau protein. Cente, M; Filipcik, P; Mandakova, S, 2009)	2.11
"Co-treatment with memantine reversed the activation of the astrocytes and microglia, thus attenuating the PAD2 increment."	( Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine. Arif, M; Kato, T, 2009)	0.87
"Treatment with memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist significantly attenuated Abeta(25-35)-induced changes of neuropeptides, their metabolizing enzymes, glial marker proteins, and activation of iNOS."	( Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. Ahmed, MM; Arif, M; Chikuma, T; Kato, T; Nakazato, M; Smith, MA, 2009)	1.08
"Treatment with memantine was well tolerated and reduced agitation/aggression, irritability, and appetite eating disturbances in patients who were agitated at baseline and delazed its emergence in those who were free of agitation at baseline."	( [Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil]. Chiriţă, R; Chiriţă, V; Creţu, O; Szalontay, AS, )	0.87
"Pre-treatment with memantine 10 microM or epicatechin 15 microM reversed loss of cell viability in catechol 150 microM-treated cultures (22.3%, p<0.01 and 17.8%, p<0.05), respectively."	( Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro. Gupta, N; Kenney, MC; Kuppermann, BD; Limb, GA; Luczy-Bachman, G; Mansoor, S, 2010)	0.99
"Treatment with memantine was safe and effective. "	( [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)]. Agüera-Ortiz, LF, 2010)	1.62
"Treatment with memantine significantly improves life as a whole compared to placebo and improves total QOL, body function and structure."	( Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Aarsland, D; Engedal, K; Larsson, V; Londos, E; Minthon, L; Wattmo, C, 2011)	0.99
"Pretreatment with memantine was somewhat effective in preventing changes to the culture synchronization but was unable to fully protect the synchronization of electrical activity between neurons that showed high levels of synchronization prior to injury."	( Protection from glutamate-induced excitotoxicity by memantine. Firestein, BL; Kutzing, MK; Luo, V, 2012)	0.95
"Pretreatment with memantine significantly attenuated formalin-induced pain behavior (p < 0.01) and the sensory threshold for VFMF (p < 0.001). "	( Influence of memantine on nociceptive responses of the trigeminocervical complex after formalin injection. Park, GE; Park, JW; Shin, HE; Suh, GI, 2012)	1.08
"Treatment with memantine in addition to donepezil versus treatment with donepezil alone showed an ICER range from a dominant value to 6818.33 euros per QALY."	( Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Dams, J; Dodel, R; Neumann, A; Pouryamout, L; Wasem, J, 2012)	0.72
"Treatment with memantine delays clinical worsening in patients with moderate to severe AD when compared with placebo. "	( Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Hartmann, S; Hellweg, R; Janetzky, W; Wirth, Y, 2012)	1.11
"Treatment with memantine plus vitamin D was associated with improvement in the MMSE score compared to memantine or vitamin D alone after adjustment for covariables (P < 0.01)."	( Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Annweiler, C; Beauchet, O; Brugg, B; Fantino, B; Herrmann, FR, 2012)	0.99
"Treatment with memantine/ChEI combination therapy in moderate-to-severe AD produces consistent benefits that appear to increase over time, and that are beyond those of ChEI treatment alone."	( Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Gauthier, S; Molinuevo, JL, 2013)	1
"Treatment with memantine à 20 mg/d lasted for 6 months and was preceded by one week à 10 mg/d."	( [Use of memantine in progressive glaucoma. Case report]. Erb, C; Schröder, A, 2002)	1.09
"Pretreatment with memantine attenuated the craving for alcohol before alcohol administration, but not after alcohol was given. "	( Acute effects of memantine in combination with alcohol in moderate drinkers. Bisaga, A; Evans, SM, 2004)	1
"Treatment with memantine reduces the global costs of the disease by lightening the burden on helpers and delaying institutionalisation of patients."	( [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease]. Gallarda, T; Lôo, H, )	0.47
"Treatment with memantine, 20 mg/kg/day during 14 days, significantly increased the number of [(125)I]alphabungarotoxin (alpha7 nAChR) binding sites in the frontal- and retrosplenial cortex of hAChE-Tg mice and synaptophysin- and LMW MAP-2 levels in the cortex of both hAChE-Tg and FVB/N controls."	( Effect of memantine on the alpha 7 neuronal nicotinic receptors, synaptophysin- and low molecular weight MAP-2 levels in the brain of transgenic mice over-expressing human acetylcholinesterase. Bednar, I; Nordberg, A; Schutte, M; Svedberg, MM; Unger, C, 2005)	1.07
"Treatment with memantine, an NMDA receptor antagonist, also increased the serine-phosphorylation of both GSK3 isoforms in mouse brain."	( In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Bijur, GN; De Sarno, P; Jope, RS; Li, X; Zmijewska, AA, 2006)	0.67
"Treatment with memantine reduced agitation/aggression, irritability, and appetite/eating disturbances. "	( Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006)	1
"Treatment with memantine resulted in a significant reduction in RGC loss and NR1 expression in the eyes of rats COHT."	( Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension. Jung, SW; Kim, JH; Lee, NY; Park, CK, 2007)	0.68
"Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region."	( Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. de Leon, MJ; De Santi, S; Glodzik, L; Gonen, O; King, KG; Liu, S, 2008)	2.13
"The treatment with memantine resulted in steady-state serum levels of 1.2 mu M which, based on in vitro data, should assure inhibition of NMDA receptors and are similar to levels seen in the serum of demented patients treated with this agent."	( Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. Danysz, W; Frankiewicz, T; Misztal, M; Parsons, CG, 1996)	0.83
"Treatment with memantine resulted in a complete reversal of these behavioral impairments."	( Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Lukoyanov, NV; Paula-Barbosa, MM, 2001)	2.09
"Pretreatment with memantine HCl (MEM, 18 mg/kg, sc) together with atropine sulfate (ATS, 16 mg/kg, sc), 60 min and 15 min, respectively, prior to nerve agents attenuated AChE inhibition, prevented myonecrosis, and muscle fasciculations as well as other signs of cholinergic toxicity."	( Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX. Dettbarn, WD; Gupta, RC, 1992)	0.98
"Pretreatment with memantine hydrochloride (18 mg/kg, i.p.) 30 min, and atropine sulfate (16 mg/kg, i.p.) 15 min before methyl parathion administration, completely prevented the expected toxic signs and significantly (P less than 0.01) attenuated the induced inhibition of acetylcholinesterase."	( Methyl parathion acute toxicity: prophylaxis and therapy with memantine and atropine. Gupta, RC; Kadel, WL, )	0.7

Excerpt	Reference	Relevance
" Low micromolar concentrations of memantine, levels known to be tolerated by patients receiving the drug for the treatment of Parkinson's disease, prevent NMDA receptor-mediated neurotoxicity in cultures of rat cortical and retinal ganglion cell neurons; memantine also appears to be both safe and effective in a rat stroke model."	( Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. Aggarwal, SK; Chen, HS; Jensen, FE; Lei, SZ; Lipton, SA; Pellegrini, JW; Warach, S, 1992)	0.8
" dose of 5 mg/kg methyl parathion, showed the toxic signs of hypercholinergic (anticholinesterase) activity with maximal severity, including muscle fasciculations and convulsions within 15 to 30 min, persisting for about 2 hr."	( Methyl parathion acute toxicity: prophylaxis and therapy with memantine and atropine. Gupta, RC; Kadel, WL, )	0.37
"9 LD50 dose of soman reduced the severity of convulsions and increased survival."	( Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. Deshpande, SS; Filbert, MG; Smith, CD, 1995)	0.51
" Methotrexate alone was not toxic to astrocytes, neurons, or the neurite networking."	( MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Finiels-Marlier, F; Marini, AM; Martin, B; Paul, SM; Weller, M, 1993)	0.68
" Due to its widespread use in agriculture, contamination of food, water, and air has become imminent, and consequently adverse health effects are inevitable in humans, animals, wildlife, and fish."	( Carbofuran toxicity. Gupta, RC, 1994)	0.29
"It is well known that acute exposure to high concentrations of glutamate is toxic to central mammalian neurons."	( Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Dreyer, EB; Hyman, BT; Lipton, SA; Sabel, BA; Vorwerk, CK; Zurakowski, D, 1996)	0.52
"These data suggest that minor elevations in glutamate concentration can be toxic to ganglion cells if this elevation is maintained for 3 months."	( Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Dreyer, EB; Hyman, BT; Lipton, SA; Sabel, BA; Vorwerk, CK; Zurakowski, D, 1996)	0.52
" Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium."	( Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Camicioli, R; Ganzini, L; Young, BK, 1997)	0.3
"Glutamate can be toxic to neurons although it is a neurotransmitter."	( Neurons depend on astrocytes in a coculture system for protection from glutamate toxicity. Brown, DR, 1999)	0.3
" Previous studies have shown that N-methyl-D-aspartate (NMDA) receptor antagonists can inhibit glutathione depletion and neurotoxicity induced by PrP(TSE) and a toxic prion protein peptide, PrP106-126, in vitro."	( Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. Beyreuther, K; Cappai, R; Collins, SJ; Jobling, MF; Maher, F; Masters, CL; Needham, BE; Stewart, LR; Thyer, J; White, AR, 2001)	0.31
" We therefore explored whether a glutamate congener was toxic if applied directly within the optic nerve, or if toxicity depended upon an interaction at the cell body level."	( Excitotoxicity can be mediated through an interaction within the optic nerve; activation of cell body NMDA receptors is not required. Dreyer, EB; McDermott, LM; Naskar, R; Quinto, KM; Schuettauf, F; Vorwerk, CK; Zurakowski, D, 2001)	0.31
" Memantine was well tolerated with a frequency of adverse events comparable to placebo."	( Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Forette, F; Möbius, HJ; Orgogozo, JM; Rigaud, AS; Stöffler, A, 2002)	1.54
"To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004)	0.85
"Systemic treatment with memantine, a compound which does not lower intraocular pressure, was both safe and effective for reduction of functional loss associated with experimental glaucoma."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004)	0.94
"To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004)	0.87
"Histologic measurements of RGC survival as well as tomographic measurements of nerve head topography show that systemic treatment with memantine, a compound which does not lower intraocular pressure, is both safe and effective to reduce changes associated with experimental glaucoma."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004)	0.84
" However, many investigators doubt that NMDA antagonists are safe and effective for treating persons with AD because they have failed in stroke and trauma programs."	( Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury? Albensi, BC; Igoechi, C; Ilkanich, E; Janigro, D, )	0.13
" Thus, memantine does not stop or reverse AD, but its moderating effect in protecting the brain from the toxic levels of calcium, allows normal signaling among brain neurons."	( [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia]. Alfaro, V; Tanović, A, )	0.83
" Mild and transient adverse events were observed in 6% of akatinol memantine group."	( [Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial]. Hu, HT; Ji, CJ; Tang, HC; Wang, YH; Xu, T; Yao, JL; Yu, HZ; Zhang, ZX, 2006)	0.83
"As a safe and effective medicine, akatinol memantine, which has a similar effect as donepezil for AD, can remarkably improve the cognition, behavior, and mood of AD patients."	( [Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial]. Hu, HT; Ji, CJ; Tang, HC; Wang, YH; Xu, T; Yao, JL; Yu, HZ; Zhang, ZX, 2006)	0.86
" These results indicate that antagonists of NMDA-type glutamate receptors are protective during the toxic outcome associated with mitochondrial dysfunction."	( 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. Bahr, BA; Baude, AS; Brown, QB; Karanian, DA; Parsons, CG, 2006)	0.33
" Safety and tolerability were assessed by the number of withdrawals, adverse events (AEs) and monitoring of vital signs."	( Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007)	0.58
"Cardiovascular disorders are the most frequently reported adverse effects of drugs used to treat Alzheimer's disease."	( Anti-Alzheimer drugs: life-threatening adverse effects. , 2007)	0.34
"There were no discontinuations due to adverse events (AEs), serious AEs, deaths, or suicides."	( A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Findling, RL; Graham, SM; Mann, A; Maxhimer, R; McNamara, NK; Periclou, A; Stansbrey, RJ, 2007)	0.56
"This pilot study suggests that a memantine dose of 20 mg/day may be a safe and possibly effective treatment for pediatric ADHD."	( A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Findling, RL; Graham, SM; Mann, A; Maxhimer, R; McNamara, NK; Periclou, A; Stansbrey, RJ, 2007)	0.84
"Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be safe and to have beneficial effects on cognition, function, behavior, and global patient status in patients with Alzheimer's disease (AD) in studies lasting 3-6 months."	( Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007)	2.01
" Safety outcome measures included treatment-emergent adverse events (AEs), deaths, vital signs, electrocardiograms, and laboratory parameters."	( Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007)	0.56
"Memantine monotherapy in patients with mild to moderate AD is safe and well tolerated for at least one year."	( Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007)	2.01
" Trial methods, clinical characteristics, outcomes, and adverse events were extracted and checked."	( Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Kavirajan, H; Schneider, LS, 2007)	0.58
" Compared with placebo, more dropouts and adverse events (anorexia, nausea, vomiting, diarrhoea, and insomnia) occurred with the cholinesterase inhibitors, but not with memantine."	( Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Kavirajan, H; Schneider, LS, 2007)	0.77
"The analysis revealed that adverse events occurring during both short- and long-term memantine treatment were minimal, and similar in type and frequency to those reported for placebo-treated patients."	( Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Alva, G; Farlow, MR; Graham, SM, 2008)	2.01
"Consistent with the favourable tolerability profile of memantine observed in clinical use, this analysis of pooled safety data indicates that both short- and long-term memantine treatment of patients with AD is safe and well tolerated, with an adverse event profile similar to that of placebo."	( Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Alva, G; Farlow, MR; Graham, SM, 2008)	2.04
" However, most of these agents have adverse side effects."	( Alcohol withdrawal-induced hippocampal neurotoxicity in vitro and seizures in vivo are both reduced by memantine. Barron, S; Farook, JM; Kaplan, E; Kowalski, A; Littleton, JM; Stepanyan, TD, 2008)	0.56
" This study investigates the effects of the PCB mixture Aroclor 1254 (A1254) and two PCB congeners (coplanar, non-ortho PCB 126, and non coplanar PCB 99) on the expression of N-methyl-D-aspartate receptors (NMDARs) and the subsequent toxic effects using a human SHS5-SY neuroblastoma cell line."	( Role of N-methyl-D-aspartate receptors in polychlorinated biphenyl mediated neurotoxicity. Chan, HM; Ndountse, LT, 2009)	0.35
" Available data indicate that across a range of clinical applications, memantine is a safe and well-tolerated drug."	( Memantine: a comprehensive review of safety and efficacy. Kavirajan, H, 2009)	2.03
" Treatment-emergent adverse events were reported in 19 patients (54."	( Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Hsu, HA; Keck, PE; Papadakis, K; Russo, J, )	1.57
" The most common adverse events were nausea, vomiting, and dizziness."	( Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P, 2010)	0.61
"Results from this study suggest the combination of rivastigmine capsule and memantine in patients with moderate AD is safe and tolerable."	( Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P, 2010)	0.84
" Memantine is a safe and effective drug that merits further research on several topics."	( Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Grossberg, GT; Thomas, SJ, 2009)	2.71
" Drug safety and tolerability is paramount in maximising efficacy and optimising patient and carer quality of life, as patients are vulnerable to adverse events (AEs) and/or compliance difficulties."	( A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Jones, RW, 2010)	0.61
"This study evaluates the toxic effects of catechol (a component from cigarette smoke) on Müller cells (MIO-M1) in vitro, and investigates the inhibitors memantine and epicatechin to determine if they can reverse the catechol toxic effects."	( Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro. Gupta, N; Kenney, MC; Kuppermann, BD; Limb, GA; Luczy-Bachman, G; Mansoor, S, 2010)	0.87
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Finally, we demonstrated that slices from mice heterozygous for NR2B receptor) in the forebrain are not susceptible to the toxic effects of Aβ(1-42) oligomers but express normal LTP (138 ± 6%)."	( Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Deussing, JM; Hasenjäger, A; Parsons, CG; Rammes, G; Sroka-Saidi, K, 2011)	0.37
" Rates of treatment-emergent adverse events (AEs) were higher for donepezil 23 mg/day with memantine (80."	( Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Doody, RS; Farlow, MR; Geldmacher, DS; Mackell, J; Moline, M; Sun, Y, 2012)	0.79
" Donepezil 23 mg was generally safe and well tolerated among patients receiving donepezil alone and among patients receiving a combination of donepezil and memantine therapy."	( Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Doody, RS; Farlow, MR; Geldmacher, DS; Mackell, J; Moline, M; Sun, Y, 2012)	0.77
" Memantine did not significantly affect discontinuation caused by serious adverse events but did increase the risk for somnolence, weight gain, confusion, hypertension, nervous system disorders, and falling."	( Effectiveness and safety of memantine treatment for Alzheimer's disease. Yang, Z; Zhang, Q; Zhou, X, 2013)	1.59
" Safety and tolerability were assessed through adverse events and physical and laboratory examinations."	( The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. Allegri, RF; Gloger, S; Graham, SM; Grossberg, GT; Gutiérrez-Robledo, LM; Jia, XD; Manes, F; Miller, ML; Pejović, V; Perhach, JL; Xie, L, 2013)	0.64
" Adverse events with a frequency of ≥5."	( The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. Allegri, RF; Gloger, S; Graham, SM; Grossberg, GT; Gutiérrez-Robledo, LM; Jia, XD; Manes, F; Miller, ML; Pejović, V; Perhach, JL; Xie, L, 2013)	0.64
" The administration of NMDA antagonists has been shown to prevent, at least to some extent, toxic damage to hair cells in guinea pigs, treated with aminoglycoside antibiotics."	( Memantine's action against aminoglycoside-induced ototoxicity. Apostolidou, E; Kekes, G; Kouvelas, D; Maurer, J; Pavlidis, P, 2014)	1.85
" Presently only Memantine is considered a safe NMDAR antagonist and is used clinically."	( Development of NMDAR antagonists with reduced neurotoxic side effects: a study on GK11. Hirbec, H; Nesic, O; Perez-Polo, R; Prieto-Cappellini, M; Privat, A; Teigell, M; Ulmann, L; Vandame, D; Vignon, J, 2013)	0.74
" Compared with placebo, more dropouts and adverse events occurred with the cholinesterase inhibitors, but not with memantine."	( Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC, 2014)	0.85
" The overall incidence of adverse events and adverse reactions was similar between groups."	( Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Homma, A; Kitamura, S; Matsui, D; Nakamura, Y; Shiosakai, K, 2014)	0.71
" We selected global impression and cognitive function as primary efficacy outcomes, and dropouts and adverse events as safety outcomes."	( Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Tang, SW; Wang, C; Wang, HF; Yu, JT, 2015)	0.67
" Participants were evaluated every month by Severe Cognitive Impairment Rating Scale (SCIRS) and Functional Assessment Staging (FAST) in addition to recording the probable adverse events."	( Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Akhondzadeh, S; Alimardani, R; Farokhnia, M; Farsad, F; Gougol, A; Iranpour, N; Kamalipour, M; Shafiee Sabet, M; Yekehtaz, H, 2014)	0.64
" The frequency of adverse events was not significantly different between the two groups as well."	( Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Akhondzadeh, S; Alimardani, R; Farokhnia, M; Farsad, F; Gougol, A; Iranpour, N; Kamalipour, M; Shafiee Sabet, M; Yekehtaz, H, 2014)	0.64
" In clinical trials, a high dropout rate and numerous adverse events associated with memantine have been observed."	( Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. Jiang, H; Jiang, J, 2015)	0.92
" Moreover, its use is less toxic and safer."	( Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine. Gmiro, VE; Serdyuk, SE; Veselkina, OS, 2015)	0.64
"In our study, it was observed that memantine concentrations at 70 ng/ml and 150 ng/ml are safe when administered intravitreally; however, doses of 400 ng/ml produced retinal structural changes."	( Intravitreal memantine retinal toxicity in rabbits. Hernández Ayuso, I; Moreno Páramo, D; Quiroz Mercado, H; Reyna Vielma, S; Rodríguez Reyes, A, 2016)	1.08
"There was one serious adverse event (SAE) (affective disorder, with memantine) in the 12 week study and one SAE (lobar pneumonia) in the 48 week extension; both were deemed unrelated to treatment."	( Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension. Aman, MG; Findling, RL; Gage, AT; Graham, SM; Hardan, AY; Hendren, RL; Hsu, HA; Katz, E; Kehinde-Nelson, O; Melmed, RD; Palmer, RH; Perhach, JL; Trugman, JM, 2017)	1
" In addition, many adverse reactions were observed in these patients."	( Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. Brassat, D; Brochet, B; Cabre, P; Castelnovo, G; Clavelou, P; Coman, I; Creveuil, C; Daplaud, D; De Seze, J; Debouverie, M; Defer, G; Dupuy, B; Hautecoeur, P; Heinzlef, O; Lebiez, P; Lebrun-Frenay, C; Pelletier, J; Peyro Saint Paul, L; Sartori, É; Tourbah, A; Vermersch, P, 2016)	0.72
" The safety was assessed by the number of adverse events."	( Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. Brassat, D; Brochet, B; Cabre, P; Castelnovo, G; Clavelou, P; Coman, I; Creveuil, C; Daplaud, D; De Seze, J; Debouverie, M; Defer, G; Dupuy, B; Hautecoeur, P; Heinzlef, O; Lebiez, P; Lebrun-Frenay, C; Pelletier, J; Peyro Saint Paul, L; Sartori, É; Tourbah, A; Vermersch, P, 2016)	0.72
" Neurological and psychiatric adverse events were significantly higher in the memantine group than in the placebo group, and these parameters were higher than those reported in the product literature of memantine."	( Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. Brassat, D; Brochet, B; Cabre, P; Castelnovo, G; Clavelou, P; Coman, I; Creveuil, C; Daplaud, D; De Seze, J; Debouverie, M; Defer, G; Dupuy, B; Hautecoeur, P; Heinzlef, O; Lebiez, P; Lebrun-Frenay, C; Pelletier, J; Peyro Saint Paul, L; Sartori, É; Tourbah, A; Vermersch, P, 2016)	0.95
" Although these compounds are extremely toxic agents, the search for novel antidotes remains extremely limited."	( Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies. Ambert, N; Barbier, L; Baudry, M; Bischoff, S; Bouteiller, JM; Dadak, S; Dorandeu, F; Fagni, L; Greget, R; Lauga, F; Legendre, A; Linossier-Pierre, S; Moussaoui, S; Pernot, F, 2016)	0.43
"Methylmercury (MeHg) is an extremely dangerous environmental pollutant that induces severe toxic effects in the central nervous system."	( Memantine, a Low-Affinity NMDA Receptor Antagonist, Protects against Methylmercury-Induced Cytotoxicity of Rat Primary Cultured Cortical Neurons, Involvement of Ca Deng, Y; Feng, S; Liu, W; Xu, B; Xu, Z; Yang, T, 2017)	1.9
" Primary outcomes were all-cause discontinuation, discontinuation due to adverse events (AE) and efficacy on cognitive function."	( Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients. Blanco-Silvente, L; Capellà, D; Castells, X; Garre-Olmo, J; Vilalta-Franch, J, 2018)	0.73
" Although memantine monotherapy and combination therapy are associated with a few individual adverse events such as somnolence, it is well-tolerated and its safety (all-cause discontinuation) is comparable or superior to that of the placebo (agitation)."	( The efficacy and safety of memantine for the treatment of Alzheimer's disease. Ikuta, T; Iwata, N; Kishi, T; Matsunaga, S; Nomura, I; Okuya, M; Sakuma, K, 2018)	1.18
" Based on these studies, donepezil has been shown to be effective and safe in Chinese AD patients and may impact AD biomarkers, such as hippocampal atrophy, Aβ, and tau."	( Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. Gordon, ML; Zhang, N, 2018)	0.48
" The primary outcomes were the mean overall changes in cognitive function and responders who had any adverse events."	( Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Cao, XP; Dou, KX; Guo, QH; Hou, XH; Mok, V; Tan, CC; Tan, L; Tan, MS; Yu, JT, 2018)	0.71
" One of the major adverse effects of cisplatin is its neurotoxicity."	( Effect of memantine hydrochloride on cisplatin-induced neurobehavioral toxicity in mice. Al-Baggou, BK; Salih, NA, 2020)	0.96
" No withdrawal was observed due to the drugs' adverse effects."	( Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial. Abbasinazari, M; Badri, T; Ghassab-Sahebkar, A; Keshvari, N; Qobadighadikolaei, R; Sarraf, N, 2020)	0.81
" No serious adverse events were reported, except for dizziness and sedation in four patients in the experimental arm, which resulted in discontinuation."	( Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial. Agah, E; Aghamollaii, V; Balali, P; Dehghani, R; Falsafi, Z; Fouladi, Z; Ghaffarpour, M; Harirchian, MH; Mojarrad, M; Mousavi, SV; Pourghaz, B; Tafakhori, A, 2020)	0.87
" Although memantine was generally well-tolerated, adverse events were among the major causes of dropout in this study."	( Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial. Agah, E; Aghamollaii, V; Balali, P; Dehghani, R; Falsafi, Z; Fouladi, Z; Ghaffarpour, M; Harirchian, MH; Mojarrad, M; Mousavi, SV; Pourghaz, B; Tafakhori, A, 2020)	1.27
" There is a caution to refrain from administrating memantine in combination with some specific drugs such as amantadine or dextromethorphan due to potential interactions that might augment the adverse effects of memantine."	( Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. Iwata, A; Mano, T; Sato, K; Toda, T, 2021)	1.28
"We conducted a disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database reported between April 2004 and March 2019 for detecting the neuropsychiatric adverse event (AE) signals associated with memantine and other potentially interactive drugs including amantadine, dextromethorphan, cimetidine, ranitidine, procainamide, quinidine, acetazolamide, citrate, and bicarbonate."	( Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. Iwata, A; Mano, T; Sato, K; Toda, T, 2021)	1.21
" Linear mixed effect models were fit to data from 149 (81%) participants, 73 in the memantine group and 76 in the placebo group, after 11 people (eight in the memantine group and three in the placebo group) discontinued due to COVID-19 restrictions, illness of their caregiver, adverse events, or low compliance."	( Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial. Abreu-Silveira, G; Abrishamcar, S; Assir, FF; Barrionuevo, VL; Bederman, I; Boada, R; Brandão, AC; Costa, ACS; Hüls, A; Johnson, MW; Mustacchi, Z; Prendergast, E; Roberto, MP; Roizen, NJ; Roth, E; Ruedrich, S; Salmona, P; Scheidemantel, T; Stasko, MR; Taylor, HG, 2022)	1.22
"00001) but revealed no significant influence on days for acute pain medications, adverse events, or nausea/vomiting."	( Effectiveness and Safety of Memantine for Headache: A Meta-analysis of Randomized Controlled Studies. Tang, Y; Zhou, T; Zhu, H, )	0.43
"Memantine treatment is effective and safe to treat headache."	( Effectiveness and Safety of Memantine for Headache: A Meta-analysis of Randomized Controlled Studies. Tang, Y; Zhou, T; Zhu, H, )	1.87
"We included trials assessing cognition with the Mini-Mental State Examination (MMSE), and adverse events."	( Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA, 2022)	0.72
" This case demonstrates the safe use of memantine as an adjunctive agent in an adolescent with catatonia."	( Safe Use of Memantine in a Pediatric Patient With Catatonia. Chaffkin, J; Josephs, IA; Katz, ER, 2022)	1.37
"Dysphagia has been reported as an adverse event for patients receiving rivastigmine for Alzheimer's disease (AD) treatment."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"The purpose of this study was to determine the association between dysphagia and the usage of rivastigmine by using the pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS)."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.96
"Patients prescribed rivastigmine were at greater risk of reporting dysphagia as an adverse event than patients prescribed many other medicines."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"The cognitive adverse effects (AEs) of electroconvulsive therapy (ECT) limit the wider use of the treatment."	( Reconsideration of the Benefits of Pharmacological Interventions for the Attenuation of the Cognitive Adverse Effects of Electroconvulsive Therapy. Andrade, C, 2022)	0.72

Excerpt	Reference	Relevance
"To determine whether an in vivo pharmacokinetic interaction exists between memantine and the acetylcholinesterase (AChE) inhibitor donepezil."	( Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Abramowitz, WT; Periclou, AP; Rao, N; Sherman, T; Ventura, D, 2004)	0.79
" Assessments included pharmacokinetic as well as safety parameters."	( Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Abramowitz, WT; Periclou, AP; Rao, N; Sherman, T; Ventura, D, 2004)	0.56
"Data from 19 subjects who completed the study indicated no significant pharmacokinetic interactions between a single dose of memantine and multiple doses of donepezil."	( Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Abramowitz, WT; Periclou, AP; Rao, N; Sherman, T; Ventura, D, 2004)	0.77
"The pharmacokinetic and pharmacodynamic data from this study indicated a lack of interaction between memantine and donepezil, suggesting that memantine and donepezil may be safely and effectively used in combination."	( Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Abramowitz, WT; Periclou, AP; Rao, N; Sherman, T; Ventura, D, 2004)	0.78
" The pharmacokinetic profile and parameters of galantamine at steady state were similar after administration of a 16-mg dose of galantamine once daily alone and after administration with a 10-mg dose of memantine twice daily."	( Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. Gold, M; Nye, JS; Padmanabhan, M; Ramael, S; Raoufinia, A; Verhaeghe, T; Walschap, Y; Yao, C; Zhao, Q, 2005)	0.75
" Given the renal tubular transport and extensive urinary excretion of memantine and metformin, it was of interest to assess the pharmacokinetic and pharmacodynamic interaction with glyburide/metformin."	( Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005)	0.79
"The primary goal of this study was to determine whether an in vivo pharmacokinetic or pharmacodynamic interaction exists between memantine (an uncompetitive, moderate-affinity, N-methyl-D-aspartate receptor antagonist with fast blocking/unblocking kinetics that is available in the United States for moderate to severe AD) and glyburide/metformin (a combination pharmacotherapy formulation approved for glycemic control in patients with type 2 diabetes mellitus)."	( Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005)	0.76
" Assessments included determination of pharmacokinetic parameters for memantine and the antidiabetic agents when administered alone and in combination, pharmacodynamic measurements of blood glucose levels, and analyses of tolerability."	( Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005)	0.79
" No significant pharmacokinetic or pharmacodynamic interactions were observed between memantine and glyburide/metformin."	( Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005)	0.78
"No pharmacokinetic interactions between memantine and glyburide/metformin were detected in this study of healthy young volunteers."	( Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Abramowitz, W; Chou, T; Rao, N; Ventura, D, 2005)	0.82
" Assessments included pharmacokinetic and safety measures."	( Pharmacokinetic study of memantine in healthy and renally impaired subjects. Abramowitz, W; Periclou, A; Rao, N; Ventura, D, 2006)	0.64
" Safety data and blood samples for pharmacokinetic analyses were collected."	( A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Findling, RL; Graham, SM; Mann, A; Maxhimer, R; McNamara, NK; Periclou, A; Stansbrey, RJ, 2007)	0.56
" Pharmacokinetic analyses suggest response to memantine may be dose-dependent beyond an initial threshold concentration."	( A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Findling, RL; Graham, SM; Mann, A; Maxhimer, R; McNamara, NK; Periclou, A; Stansbrey, RJ, 2007)	0.82
"This prospective study used a full population pharmacokinetic sampling design."	( Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Bleich, S; Kennepohl, EM; Kornhuber, J; Kraus, T; Meineke, I; Reulbach, U; Wiltfang, J, 2007)	1.78
" Compared with the basic model, the final population pharmacokinetic model explained 61% of the interindividual variance of the apparent clearance."	( Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Bleich, S; Kennepohl, EM; Kornhuber, J; Kraus, T; Meineke, I; Reulbach, U; Wiltfang, J, 2007)	1.78
"The population pharmacokinetic model that was developed identified a set of sources of variability in the apparent clearance of memantine, which can be used as a reference in order to optimise memantine therapy in Western European patients."	( Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Bleich, S; Kennepohl, EM; Kornhuber, J; Kraus, T; Meineke, I; Reulbach, U; Wiltfang, J, 2007)	1.99
" The patients spent the baseline period and day 35 at the study centre, where plasma samples for pharmacokinetic evaluation were taken at specified time intervals over a 10-hour time period."	( Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J, 2008)	0.55
" At each dose level of rivastigmine, the area under the concentration-time curve (AUC) values of rivastigmine and its metabolite as well as the metabolite-to-parent AUC ratios were unaffected by co-administration of memantine, confirming the absence of a meaningful pharmacokinetic drug-drug interaction."	( Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J, 2008)	0.73
"This study consisted of 2 phases: development of a liquid chromatography-tandem mass spectrometry (LC/MS) method for determination of memantine in human plasma and characterization of single-dose and multiple-dose pharmacokinetic profiles of memantine in healthy Chinese volunteers using the LC/MS method."	( Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ, 2008)	0.8
"An analytic method of LC/MS for determination of memantine in human plasma was developed and validated and was applied to this single-center, open-label, single-dose and multiple-dose pharmacokinetic study conducted in healthy native Chinese volunteers."	( Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ, 2008)	0.85
" The multiple-dose pharmacokinetic parameters (other than C(max)) were nearly similar compared with the single-dose administration."	( Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ, 2008)	0.6
" The proposed method was successfully applied to study the pharmacokinetic interaction between MT and methazolamide."	( Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. Abdel-Wadood, HM; Emara, KM; Hassan, MG; Ikeda, R; Kuroda, N; Mohamed, HA; Nakashima, K; Wada, M, 2012)	0.72
" Here, we present an acute pharmacokinetic analysis of memantine in mouse brain tissue and blood serum for a variety of experimentally relevant doses."	( Acute pharmacokinetics of memantine in the mouse. Roder, JC; Saab, BJ, 2011)	0.92
" Pharmacokinetic blood sampling was performed to assess the primary endpoints of the 90% confidence intervals (CIs) for the geometric mean ratios of the areas under the plasma concentration-time curves (AUCs) for memantine, dextromethorphan, dextrorphan - the dextromethorphan metabolite - and quinidine during concomitant therapy versus monotherapy."	( A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Bartlett, C; Pope, LE; Schoedel, KA; Sellers, EM, 2012)	0.78
"25) for memantine, dextromethorphan and dextrorphan, indicating no pharmacokinetic DDI."	( A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Bartlett, C; Pope, LE; Schoedel, KA; Sellers, EM, 2012)	1.03
"Minimal pharmacokinetic and pharmacodynamic interactions were observed between memantine and DMQ, suggesting they can be coadministered without dose adjustment."	( A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Bartlett, C; Pope, LE; Schoedel, KA; Sellers, EM, 2012)	0.82
" Mean memantine plasma elimination half-life increased according to increasing renal impairment (61."	( Effect of renal impairment on the pharmacokinetics of memantine. Akizawa, T; Fujitani, T; Fukuoka, T; Furukawa, S; Harada, K; Hashimoto, M; Hashizume, Y; Hasunuma, T; Honda, H; Imai, H; Imanaga, J; Iwaki, H; Kitazawa, K; Kobori, T; Kotegawa, T; Kumagai, Y; Kuroki, A; Makino, S; Matsumoto, N; Matsumura, T; Matsuura, B; Miura, J; Miyoshi, K; Morimoto, T; Moritoyo, H; Moritoyo, T; Mukai, M; Nagai, M; Nakamura, J; Nakamura, M; Nishikawa, N; Nomoto, M; Ohashi, K; Ohnuma, K; Okudaira, T; Okura, T; Sato, F; Shibata, T; Takasu, M; Tanaka, K; Tanaka, Y; Tateishi, T; Tsujii, T; Watanabe, M; You, K; Yuji, K, 2012)	1.11
"A population pharmacokinetic study was performed including data from 108 patients recruited in a naturalistic setting."	( Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Alnawaqil, AM; Csajka, C; Eap, CB; Ebbing, K; Eyer, S; Giannakopoulos, P; Guidi, M; Maurer, S; Michon, A; Noetzli, M; Thomazic, V; von Gunten, A; Wilhelm, L; Zumbach, S, 2013)	0.66
" Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different pharmacodynamic and pharmacokinetic profiles."	( Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Eap, CB; Noetzli, M, 2013)	0.39
" Steady-state pharmacodynamic differences between these blockers have been reported, but it is unclear whether the compounds differentially affect dynamic physiologic signaling."	( Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Eisenman, LN; Emnett, CM; Izumi, Y; Mennerick, S; Taylor, AM; Zorumski, CF, 2013)	0.61
"Vitreous pharmacokinetic analysis was performed on female New Zealand (NZ) albino rabbits after PST, INT, and INV administration and calculating the pharmacokinetic parameters that describe memantine vitreous distribution."	( Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. Bregante, MA; García, MA; Pablo, LE; Pérez, S; Prieto, E, 2014)	0.85
" Vitreous pharmacokinetics following INV administration was also characterized by a fast absorption process, a terminal half-life significantly longer than the subtenon route, and low area under the curve values."	( Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. Bregante, MA; García, MA; Pablo, LE; Pérez, S; Prieto, E, 2014)	0.66
" pharmacokinetic profile of a drug is unchanged in the presence of CD."	( The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds. Leong, NJ; Mcintosh, MP; Prankerd, RJ; Shackleford, DM, 2015)	0.42
" The maximum plasma concentration was lower and the half-life longer after patch administration than oral and IV administration."	( Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD, 2016)	0.76
" We analysed pharmacokinetic properties of memantine, particularly its distribution in blood, brain and liver in the Ts65Dn mouse model of DS and euploid F1 hybrid mice after single intraperitoneal administrations of increasing doses of this drug."	( Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome. Bederman, IR; Costa, ACS; Victorino, DB, 2017)	1.01
" A transdermal physiologically based pharmacokinetic (TPBPK) model was developed and was integrated in a compartmental pharmacokinetic model to predict the plasma drug concentrations in rats."	( In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations. Arfi, S; Bhatta, RS; Mishra, PR; Mittapelly, N; Pandey, G; Tulsankar, SL, 2018)	0.71
" The pharmacokinetic parameters of memantine were calculated using non-compartmental analysis."	( Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies. Hasegawa, S; Ishizuka, H; Ishizuka, T; Maekawa, Y; Shiosakai, K, 2019)	1.06
" The gamma scintigraphy studies showed higher uptake of the drug in the target site through the intranasal route and pharmacodynamic studies indicated that nanoparticles were able to inhibit the spatial memory impairment significantly as compared to the control group."	( A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles. Dang, S; Kaur, A; Nigam, K; Tyagi, A, 2022)	0.95
" In pharmacodynamic studies, the efficacy of NE administered via the IN route was higher when compared with other groups in neurobehavioral, biochemical estimation, and gene expression studies."	( Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies. Bhatta, RS; Handa, M; Palkhade, R; Patil, GP; Sanap, SN; Shukla, R; Singh, DP, 2023)	1.16
" Unfortunately, it showed a suboptimal pharmacokinetic profile, which required intracerebroventricular administration for in vivo studies."	( Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties. Armirotti, A; Bartolini, M; Basagni, F; Bedeschi, M; Bertorelli, R; Bertozzi, SM; Bottegoni, G; Cavalli, A; Lembo, V; Mellor, IR; Minarini, A; Ortega, JA; Rosini, M; Summa, M, 2023)	1.29

Excerpt	Reference	Relevance
" Therefore, its combination with acetylcholinesterase inhibitors (AChEIs) is anticipated."	( Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Hartmann, S; Möbius, HJ, 2003)	0.66
"Memantine was well tolerated in combination with alcohol."	( Acute effects of memantine in combination with alcohol in moderate drinkers. Bisaga, A; Evans, SM, 2004)	2.11
" In this setting, drug-drug interaction may represent a serious and even life-threatening clinical condition."	( Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Calsolaro, V; Monzani, F; Pasqualetti, G; Polini, A; Tognini, S, 2015)	0.42
" To alleviate the pill burden and swallowing difficulties associated with the condition, a fixed drug combination of extended-release memantine and donepezil was developed."	( Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia. Owen, RT, 2016)	2.08
" Since neuronal death following HIE occurs by a cascade of events triggered by activation of glutamate receptors, we used in vitro and in vivo models of HIE to examine whether the AMPA/kainate receptor antagonist topiramate and the NMDA receptor antagonist memantine could exert neuroprotective effects, alone or in combination with hypothermia."	( Neuroprotective effects of topiramate and memantine in combination with hypothermia in hypoxic-ischemic brain injury in vitro and in vivo. Catarzi, S; Filippi, L; Gerace, E; Guerrini, R; Landucci, E; Pellegrini-Giampietro, DE, 2018)	0.93
"Several basic pharmacokinetic and pharmacological studies were conducted as part of a group of studies to clarify the drug-drug interaction (DDI) between memantine (MEM), a drug used to treat Alzheimer's disease, and yokukansan (YKS), a traditional Japanese Kampo medicine used to treat behavioral and psychological symptoms of dementia."	( Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan. Ikarashi, Y; Kawakami, Z; Matsumoto, T; Mizoguchi, K; Sekiguchi, K; Watanabe, J; Yamamoto, M, 2018)	0.94
" This study investigated the effect of scalp electroacupuncture combined with Memantine in VaD."	( The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study. Gao, J; Han, X; Huang, L; Mao, E; Wu, G; Yue, A; Zhou, B, 2020)	1.04
" This was not observed when memantine treatment was combined with vitamin D enrichment."	( Effect of Memantine Treatment and Combination with Vitamin D Supplementation on Body Composition in the APP/PS1 Mouse Model of Alzheimer's Disease Following Chronic Vitamin D Deficiency. Annweiler, C; Bartha, R; Beauchet, O; Bellyou, M; Broberg, DN; Doad, J; Holdsworth, DW; Montero-Odasso, M; Norley, CJD; Umoh, JU; Wong, D, 2021)	1.32
" There is a caution to refrain from administrating memantine in combination with some specific drugs such as amantadine or dextromethorphan due to potential interactions that might augment the adverse effects of memantine."	( Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. Iwata, A; Mano, T; Sato, K; Toda, T, 2021)	1.28
" Drug-drug interactions between memantine and these drugs were assessed using multiplicative and additive models."	( Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. Iwata, A; Mano, T; Sato, K; Toda, T, 2021)	1.31
"The real-world JADER data did not raise the concern about the interactive increase in the neuropsychiatric AEs in patients with dementia taking memantine in combination with amantadine or dextromethorphan, suggesting there may be no urgent need to prohibit the co-administration of these drugs presently."	( Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. Iwata, A; Mano, T; Sato, K; Toda, T, 2021)	1.22
" Thus, we studied the efficacy of prophylactic use of memantine alone or in combination with clinically used reversible acetylcholinesterase inhibitors (pyridostigmine, donepezil, rivastigmine) against soman."	( Memantine and Its Combination with Acetylcholinesterase Inhibitors in Pharmacological Pretreatment of Soman Poisoning in Mice. Karasova, JZ; Kassa, J, 2021)	2.31
" Neuromodulation combined with the administration of hyperbaric oxygen therapy and memantine during radiotherapy facilitated the restoration of hippocampal function and white matter integrity, and improved higher cognitive function in patients receiving cranial radiation."	( Recovery from the damage of cranial radiation modulated by memantine, an NMDA receptor antagonist, combined with hyperbaric oxygen therapy. Fujiwara, K; Hokama, Y; Ishiuchi, S; Katagiri, C; Nishimura, M; Takagi, H; Usugi, R, 2023)	1.38

Excerpt	Reference	Relevance
" AUC(0-72h) or even AUC(0-48h), can be adequately used in assessing the relative bioavailability of long terminal half-life drugs."	( The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. Erkent, U; Koytchev, R, 2008)	0.55
"This study evaluated the vitreous pharmacokinetics and vitreous bioavailability of memantine following posterior-subtenon administration (PST) compared to intravitreal (INT) and intravenous routes (INV) in rabbits."	( Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. Bregante, MA; García, MA; Pablo, LE; Pérez, S; Prieto, E, 2014)	0.88
" The vitreous bioavailability (F) and the relative vitreous bioavailability of memantine was estimated after posterior-subtenon administration (Frel (pst/int)) and after intravenous route (Frel (inv/int)) compared with intravitreal administration."	( Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. Bregante, MA; García, MA; Pablo, LE; Pérez, S; Prieto, E, 2014)	0.88
" High vitreous bioavailability after PST was observed, and the relative vitreous bioavailability of memantine following PST administration (0."	( Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. Bregante, MA; García, MA; Pablo, LE; Pérez, S; Prieto, E, 2014)	0.87
" A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake."	( A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. Boinpally, R; Chen, L; Hofbauer, RK; McClure, N; Periclou, A; Zukin, SR, 2015)	0.92
" There was no significant food effect on the bioavailability of the FDC components."	( A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. Boinpally, R; Chen, L; Hofbauer, RK; McClure, N; Periclou, A; Zukin, SR, 2015)	0.68
"An FDC capsule containing 28 mg memantine ER and 10 mg donepezil is bioequivalent to commercially available memantine ER and donepezil, and bioavailability is not affected by food intake or sprinkling of capsule contents on applesauce."	( A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. Boinpally, R; Chen, L; Hofbauer, RK; McClure, N; Periclou, A; Zukin, SR, 2015)	0.96
" Memantine bioavailability was 41 and 63% for oral and patch administration, respectively."	( Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD, 2016)	1.67
" The results of our study suggested that the implementation of mechanistic modeling along with IVIVC can be a valuable tool to evaluate the relative effects of formulation variables on the bioavailability from transdermal delivery systems."	( In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro/in Vivo Correlations. Arfi, S; Bhatta, RS; Mishra, PR; Mittapelly, N; Pandey, G; Tulsankar, SL, 2018)	0.71
" In the dog model, relative memantine bioavailability approaches 100% with sustained plasma levels of memantine over seven days and profiles that can be tuned by varying components of the formulation."	( A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease. Bellinger, AM; Bhise, N; Bishoff, M; Carter, B; DeBenedictis, B; Grant, T; Kanasty, R; Low, S; Moorthy, S; Peeke, E; Schwarz, M; Simses, C; Wright, J; Yang, J, 2019)	1.05
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Drug delivery systems that not only show efficacy through multiple therapeutic pathways but also facilitate patient drug use and exhibit a high bioavailability profile represent a promising strategy in the treatment of Alzheimer's disease (AD)."	( A novel multi-target strategy for Alzheimer's disease treatment via sublingual route: Donepezil/memantine/curcumin-loaded nanofibers. Aydemir, O; Bocekci, VG; Cam, ME; Duruksu, G; Ertas, B; Guler, E; Gunduz, O; Gurbuz, F; Ozcan, GS; Sahin Cam, C; Topal, F; Yazir, Y, 2022)	0.94

Excerpt	Relevance	Reference
" Dizocilpine was active in this model at a dosage of 1 mg/kg."	( Neuroprotective effect of memantine demonstrated in vivo and in vitro. Krieglstein, J; Mennel, HD; Peruche, B; Rossberg, C; Seif el Nasr, M, 1990)	0.58
" The tolerance of the preparation was good in virtually all cases and a gradually increasing dosage is recommended."	( Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study. Ambrozi, L; Danielczyk, W, 1988)	0.51
"5 mg/kg, respectively, in a bell-shaped dose-response relationship."	( Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Danysz, W; Frankiewicz, T; Parsons, CG; Zajaczkowski, W, 1997)	0.3
" The aim of the present study was to assess the effects of restraint stress and memantine on the dose-response curve of ethanol discrimination."	( Ethanol discrimination in the rat: lack of modulation by restraint stress and memantine. Bienkowski, P; Danysz, W; Koros, E; Kostowski, W, 1999)	0.76
" The relative drug potencies cannot be directly compared, because of differences in dosage and the route of administration."	( [Neuroprotection in ischemia of the retina in an animal model]. Feuerstein, TJ; Lagrèze, WA; Otto, T, 1999)	0.3
"9-fold rightward shift of the cumulative dose-response curves."	( Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Danysz, W; Kozela, E; Popik, P, 2000)	0.56
" The dosage of drug was increased from 5 to 20 mg/d."	( Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Gottrup, H; Jensen, TS; Kristensen, AG; Nikolajsen, L, 2000)	1.75
" The noncompetitive antagonist MK-801 and a glycine-site blocker were equally neuroprotective in both normal and reduced conditions, but there was a significant rightward shift in the dose-response curves of the competitive antagonists APV and CPP and the uncompetitive antagonist memantine."	( Reducing conditions significantly attenuate the neuroprotective efficacy of competitive, but not other NMDA receptor antagonists in vitro. Eshak, M; Iannotti, F; Pringle, AK; Self, J, 2000)	0.48
" active placebo [lorazepam]) and (2) dose-response trial of the preferred active drug in responders from the first study (0% vs."	( Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Booher, S; Gilron, I; Max, MB; Parada, S; Sang, CN, 2002)	0.63
" Extended studies revealed that, after cessation of memantine treatment using either dosing regime, any subsequent appearance of disease was suppressed in severity and duration."	( Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. Bolton, C; Paul, C, 2002)	0.76
"Morphine antinociceptive activity was tested twice, before and after chronic morphine administration, in the tail-flick test using a cumulative dose-response protocol."	( Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Kozela, E; Pilc, A; Popik, P, 2003)	0.57
" The administration of a higher dosage is probably not tolerable."	( Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial. Dertwinkel, R; Hosbach, I; Maier, C; Mansourian, N; Schwenkreis, P; Senne, I; Skipka, G; Tegenthoff, M; Zenz, M, 2003)	0.58
" Although the conclusions regarding the clinical effect are limited because of the small sample size, the data indicate that in the studied dosage the NMDA receptor antagonist memantine is ineffective in the treatment of chronic PLP and is also ineffective for the reduction of associated neural plasticity in the primary SI."	( A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Birbaumer, N; Braun, C; Flor, H; Kiefer, RT; Preissl, H; Töpfner, S; Unertl, K; Wiech, K, 2004)	0.73
" Beginning on day 22, the donepezil dosage was doubled for 22 days to the target dose of 10 mg once daily, with the last donepezil dose concomitantly administered with memantine 10 mg on day 43."	( Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Abramowitz, WT; Periclou, AP; Rao, N; Sherman, T; Ventura, D, 2004)	0.76
"To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004)	0.85
" Nine animals were orally dosed daily with 4 mg/kg memantine while the other nine animals received an oral dose of vehicle only."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004)	0.89
"To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004)	0.87
" Nine animals were daily orally dosed with 4 mg/kg memantine while the other nine animals received vehicle only."	( Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004)	0.89
" Three head-to-head trials of ChEIs in the treatment of AD have been published to date, but are limited due to their open-label design, rates of titration, and the drug dosage levels utilised."	( The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Herrmann, N; Lanctôt, KL; Thompson, S, 2004)	0.32
" Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose-response curves described for cholinomimetics."	( Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D, 2005)	0.57
" Both agents produced a marked downward shift in the nicotine dose-response curve."	( Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats. Bespalov, AY; Danysz, W; Zakharova, ES, 2005)	0.33
" The present experiments were carried out to compare the dose-response for memantine's predictive therapeutic and side-effects in a variety of tests in C57BL/6J/Han mice, and to elucidate if tolerance may develop to them."	( A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice. Kos, T; Popik, P, 2005)	0.77
" In a randomised double-blinded cross over study design we therefore administered placebo or memantine either as a single dosage or as an ascending dosage over 8 days."	( The NMDA antagonist memantine affects training induced motor cortex plasticity--a study using transcranial magnetic stimulation. Malin, JP; Pleger, B; Schwenkreis, P; Tegenthoff, M; Witscher, K, 2005)	0.87
" A single dosage of memantine had no significant effect on this training-induced plasticity, whereas memantine administered in an ascending dosage over 8 days was able to block the cortical effect of the motor training."	( The NMDA antagonist memantine affects training induced motor cortex plasticity--a study using transcranial magnetic stimulation. Malin, JP; Pleger, B; Schwenkreis, P; Tegenthoff, M; Witscher, K, 2005)	0.98
" Data on several compounds that achieve therapeutic posterior segment concentrations after topical dosing is presented."	( Topical and systemic drug delivery to the posterior segments. Chang-Lin, JE; Hughes, PM; Olejnik, O; Wilson, CG, 2005)	0.33
" Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily."	( Pharmacokinetic study of memantine in healthy and renally impaired subjects. Abramowitz, W; Periclou, A; Rao, N; Ventura, D, 2006)	0.64
"On the basis of the predicted steady-state plasma concentrations with the use of the current dosing regimen of 10 mg twice daily, no dosage adjustments are needed for patients with mild or moderate renal impairment."	( Pharmacokinetic study of memantine in healthy and renally impaired subjects. Abramowitz, W; Periclou, A; Rao, N; Ventura, D, 2006)	0.64
" The anticonvulsive activity of the dicationic phenylcyclohexyl derivative IEM-1925, which could block both types of glutamate receptors, differed from the activity of the monocationic derivative by having a more complex dose-response relationship."	( Effects of ionotropic glutamate receptor channel blockers on the development of pentylenetetrazol kindling in mice. Gmiro, VE; Gorbunova, LV; Lavrent'eva, VV; Lukomskaya, NY; Magazanik, LG; Starshinova, LA; Tikhonova, TB; Zhabko, EP, 2007)	0.34
"To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD)."	( Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007)	0.81
"This 12-week, randomised, double-blind study, investigated three dosing schedules of memantine: OD1 (20 mg once daily with a 1-step up-titration); OD3 (20 mg once daily with a 3-step up-titration); and BID3 (10 mg twice daily with a 3-step up-titration as currently recommended in the memantine labelling)."	( Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007)	0.81
" Most AEs were mild or moderate, and typical for the population studied; no clinically important differences in AEs or vital signs were observed between the different dosing schedules."	( Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007)	0.58
"Although relatively small in size, the study indicates that once-daily dosing and twice-daily dosing of memantine are similar in terms of safety and tolerability."	( Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007)	0.8
" Furthermore, published reports support reduced dosing in patients with significant renal disease."	( A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Cooper, G; Ryan, M; Schmitt, F, 2007)	0.58
" Following an 8-week double-blind dose titration phase (used to assess the tolerability of different dosing regimens), subjects were assigned to continuous open label memantine (10 mg, bi."	( Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007)	0.76
" Discontinuations due to AEs were similar in the once-daily dosing groups compared to the twice-daily dosing groups."	( Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007)	0.56
" Once-daily dosing during titration and short-term maintenance therapy is safe and well tolerated."	( Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Blake, LM; Kagan, E; Ott, BR; Resnick, M, 2007)	0.56
" The mean dosage across all weeks was 18."	( An open-label, flexible-dose study of memantine in major depressive disorder. Ferguson, JM; Shingleton, RN, )	0.4
" In a first dose-response study, post-training administration of memantine (10 and 20, but not 3 mg/kg) antagonized recognition memory deficits in the rat, suggesting that memantine modulates storage and/or retrieval of information."	( Memantine and recognition memory: possible facilitation of its behavioral effects by the nitric oxide (NO) donor molsidomine. Pitsikas, N; Sakellaridis, N, 2007)	2.02
"Seven schizophrenia patients, were included in a six-week open-label study, with weekly increasing dosage (5, 10, 15, 20 mg) of memantine added to their on-going antipsychotic treatment."	( Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008)	0.93
" When administered 20 min before acquisition, memantine elicited an inverted U-shape dose-response relationship, with low doses (0."	( The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. Lichtman, AH; Wise, LE, 2007)	0.83
"In these healthy Chinese subjects, the t(1/2) and MRT values were fixed and did not increase following the increased dose, and the AUC(infinity) and C(max) values increased following the increasing dosage of memantine."	( Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Liu, MY; Meng, SN; Wang, S; Wei, MJ; Wu, HZ, 2008)	0.79
" Patients were divided into 2 groups: 14 patients who received memantine in dosage 20 mg/d and 9 patients of a control group."	( [Efficacy and safety of memantine in dementia with Lewy bodies]. Amosova, NA; Batukaeva, LA; Levin, OS; Smolentseva, IG, 2008)	0.89
" After treatment, a positive dose-response relationship of increasing NMDARS, increasing caspase-3 activity and cell death was observed in all PCB compounds."	( Role of N-methyl-D-aspartate receptors in polychlorinated biphenyl mediated neurotoxicity. Chan, HM; Ndountse, LT, 2009)	0.35
"To examine the dosing of memantine in patients with dementia admitted to an inpatient geriatric psychiatry ward and review the published literature regarding the pharmacologic and clinical need to dose adjust memantine."	( Memantine dosing in patients with dementia. Dolder, C; McKinsey, J; Nelson, M, 2009)	2.1
"Appropriate dosing of memantine in patients with dementia is important in an effort to maximize the medication's safety and efficacy."	( Memantine dosing in patients with dementia. Dolder, C; McKinsey, J; Nelson, M, 2009)	2.11
" The drug was prescribed to 15 patients at first in a single dosage of 5 mg daily for one week, then the dosage was increased to 10 mg daily (one week), after to 15 mg daily (one week) and from the 4th week - to 20mg daily."	( [Efficacy of memantine in Parkinson's disease with dementia]. Batukaeva, LA; Levin, OS, 2008)	0.72
" Acatinol was prescribed in dosage 10 mg daily and piracetam in dosage 1200 mg daily at baseline, after 3 and 6 months of treatment."	( [Efficacy of acatinol memantine in mild cognitive disorder]. Dudarova, MA; Iunishchenko, NA; Levin, OS, 2009)	0.67
"Donepezil 5 mg daily, donepezil 10 mg daily, galantamine 16-24 mg daily, rivastigmine flexible dosing up to 6 mg twice daily, or memantine 10 mg twice daily versus standard care."	( Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. Anis, AH; Bansback, N; Lee, PE; Wong, CL, 2009)	0.81
"The goal of this article is to review the once-daily memantine ER 28 mg formulation for the treatment of Alzheimer's disease, which, by simplifying the dosage regimen, decreases the problems of medication adherence."	( Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Bassil, N; Grossberg, GT; Thaipisuttikul, P, 2010)	2.05
" These experiments showed that the rats' sleep during the first hour after dosage consisted only of short episodes of superficial slow-wave sleep, and that even this sleep disappeared completely 54."	( Effects of memantine on convulsive reactions and the organization of sleep in krushinskii-molodkina rats with an inherited predisposition to audiogenic convulsions. Lukomskaya, NY; Magazanik, LG; Oganesyan, GA; Vataev, SI; Zhabko, EP, 2010)	0.75
" Nevertheless, such a memantine dosing regimen did not affect dopamine metabolism in mPFC and Acb."	( Memantine abolishes the formation of cocaine-induced conditioned place preference possibly via its IL-6-modulating effect in medial prefrontal cortex. Cherng, CG; Lin, KY; Lin, LC; Lu, RB; Yang, FR; Yu, L, 2011)	2.13
" A group of male and female rats was treated with one of these compounds for 15 days, after which a single dosage of scopolamine was administered."	( Comparative protective action of curcumin, memantine and diclofenac against scopolamine-induced memory dysfunction. Ali, EH; Arafa, NM, 2011)	0.63
" Forty patients of the main group received akatinol memantine as an add-on drug during 90 days in the initial dosage 5-10 mg/day with the gradual increase to 20 mg/day (10 mg twice a day); the control group included 10 patients."	( [The use of akatinol memantine in the residual phase of stroke]. Luk'ianiuk, EV; Maliukova, NG; Saiadian, KhS; Shklovskiĭ, VM, 2010)	0.93
" Larger placebo-controlled studies are needed to ascertain optimal timing and dosing for memantine augmentation of lamotrigine in BD-D."	( Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012)	0.89
"0) on stable donepezil dosing participated in two task-related fMRI sessions consisting of a face-name paired associative encoding memory paradigm 24 weeks apart during a randomized placebo-controlled pharmaco-fMRI drug study."	( Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. Atri, A; Deluca, AN; Diamond, EL; McLaren, DG; Mitchell, MB; O'Brien, JL; Rentz, DM; Sperling, RA; Sreenivasan, A; Van Dijk, KR, 2012)	0.38
"31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33."	( Effect of renal impairment on the pharmacokinetics of memantine. Akizawa, T; Fujitani, T; Fukuoka, T; Furukawa, S; Harada, K; Hashimoto, M; Hashizume, Y; Hasunuma, T; Honda, H; Imai, H; Imanaga, J; Iwaki, H; Kitazawa, K; Kobori, T; Kotegawa, T; Kumagai, Y; Kuroki, A; Makino, S; Matsumoto, N; Matsumura, T; Matsuura, B; Miura, J; Miyoshi, K; Morimoto, T; Moritoyo, H; Moritoyo, T; Mukai, M; Nagai, M; Nakamura, J; Nakamura, M; Nishikawa, N; Nomoto, M; Ohashi, K; Ohnuma, K; Okudaira, T; Okura, T; Sato, F; Shibata, T; Takasu, M; Tanaka, K; Tanaka, Y; Tateishi, T; Tsujii, T; Watanabe, M; You, K; Yuji, K, 2012)	0.86
" Demographic variables, quantity and rate of prescriptions, dosage forms and strengths were analyzed."	( [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. Arizaga, RL; Demey, I; Rojas, G, 2013)	0.39
" The main group (30 patients, aged 64-86 years) was treated with noojerone in addition to standard therapy according to dosage scheme during 6 months."	( [Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment]. Litvinenko, IV; Lobzin, VY; Lupanov, IA; Vorob'ev, SV, 2013)	0.39
" Further longitudinal studies may be required to assess dose-response relationships regarding treatment with psychotropics for patients with dementia."	( Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease. Bertolucci, PH; Chen, ES; de Oliveira, FF; Smith, Mde A, 2014)	0.4
" The duration of the study for each patient was 6 months, the target dosage of acatinol was 20 mg."	( [The use of acatinol in the treatment of stable patients with schizophrenia with predominance of behaviour disorganization and subcatatonic features]. Arsenieva, TB; Beniashvili, AG; Burminsky, DS; Cheremin, RA; Kozhekin, IG; Lepilkina, TA; Morozova, MA; Onegina, EY; Potanin, SS; Rupchev, GE; Shvedova, AK; Yachmenev, VN, 2014)	0.4
"A randomised double-blind, placebo-controlled, 24-week three centre trial of memantine (20 mg/day) was conducted in which tests of attention (simple and choice reaction time) and word recognition (immediate and delayed) from the CDR System were administered prior to dosing and again at 12 and 24 weeks."	( Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Aarsland, D; Ballard, C; Londos, E; Wesnes, KA, 2015)	2.09
"2 mg/kg) increased the GBO power, exhibiting an inverted U-shape dose-response curve; at higher doses (0."	( Differential effects of NMDA receptor antagonists at lower and higher doses on basal gamma band oscillation power in rat cortical electroencephalograms. Chaki, S; Hiyoshi, T; Kambe, D; Karasawa, J, 2014)	0.4
" These results imply that the combination of MEM and HBO therapy not only prolongs the therapeutic window of HBO treatment, but also lowers the dosage requirement of MEM."	( Combination of HBO and Memantine in Focal Cerebral Ischemia: Is There a Synergistic Effect? Huang, Y; Kinden, R; Lei, C; Liang, W; Qu, Y; Sang, H; Wang, F; Xie, Y; Xiong, L, 2015)	0.73
" The immediate-release (IR) formulations of memantine (tablets and oral solution) have been available in numerous countries, including the USA, for more than a decade and are administered orally twice daily at a maximum recommended total daily dosage of 20 mg/day."	( Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. Plosker, GL, 2015)	2.12
" They shall help to ensure proper dosage switching among various formulations."	( Discontinuation of memantine standard release and its impact on patient therapy. Lam, S; Mondiello, T, 2015)	0.75
"Combining two standard-of-care medications for Alzheimer's disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden."	( A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. Boinpally, R; Chen, L; Hofbauer, RK; McClure, N; Periclou, A; Zukin, SR, 2015)	0.68
" After intrathecally injecting the rats with five doses of each drug, the dose-response curves of memantine and lidocaine were constructed."	( Memantine elicits spinal blockades of motor function, proprioception, and nociception in rats. Chen, YW; Chiu, CC; Hung, CH; Liu, KS; Wang, JJ, 2015)	2.08
" Original memantine and generic medication dosage (5 mg daily) was titrated according to the manufacturer's recommendations."	( [A comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer's disease]. Cherenkova, EV; Fedorova, EY; Goncharova, OV; Kuznetsova, NA; Polozova, TM; Shapovalov, DL; Shiryaev, OY, 2015)	1.06
" In neuropharmacological studies their functioning strongly depends on testing conditions and the dosage of NMDAR antagonists."	( MK-801 and memantine act differently on short-term memory tested with different time-intervals in the Morris water maze test. Duda, W; Nekovarova, T; Ostaszewski, P; Stuchlik, A; Vales, K; Wesierska, M, 2016)	0.82
" Transdermal drugs are proposed as an alternative remedy to overcome the disadvantages of current pharmaceutical dosage options for this chronic disorder."	( Current advances in transdermal delivery of drugs for Alzheimer's disease. Giau, VV; Nguyen, TT; Vo, TK, )	0.13
"The objective of the present study was to evaluate the effectiveness of dosed physical exercises for the combined treatment of the patients presenting with mild to moderate dementia associated with Alzheimer's disease (AD)."	( [The role of dosed walking in the combination with elements of cognitive training in the comprehensive treatment of the patients presenting with Alzheimer's disease]. Cherkasova, VG; Kosareva, PV; Zimushkina, NA, )	0.13
" Two treatment modalities were applied, one being conventional therapy with the use of memantine at the average effective dose, the other with the combination of memantine and dosed physical exercises including elements of cognitive training."	( [The role of dosed walking in the combination with elements of cognitive training in the comprehensive treatment of the patients presenting with Alzheimer's disease]. Cherkasova, VG; Kosareva, PV; Zimushkina, NA, )	0.35
" The most pronounced effects were documented in the women who had received combined therapy with the inclusion of dosed physical exercises in the form of walking."	( [The role of dosed walking in the combination with elements of cognitive training in the comprehensive treatment of the patients presenting with Alzheimer's disease]. Cherkasova, VG; Kosareva, PV; Zimushkina, NA, )	0.13
"The prescription of dosed physical exercises with elements of cognitive training to be applied for the treatment of the patients presenting with dementia of different severity associated with Alzheimer's disease makes it possible to optimize the outcome of the conventional medical treatment and thereby to improve the results of scoring assessments of cognitive performances based on the MMSE, FAB, and CDT scales."	( [The role of dosed walking in the combination with elements of cognitive training in the comprehensive treatment of the patients presenting with Alzheimer's disease]. Cherkasova, VG; Kosareva, PV; Zimushkina, NA, )	0.13
" The development of oral dosage forms that can be infrequently dosed, and therefore improve adherence rate and facilitate direct observed therapy, has been a goal for decades."	( A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease. Bellinger, AM; Bhise, N; Bishoff, M; Carter, B; DeBenedictis, B; Grant, T; Kanasty, R; Low, S; Moorthy, S; Peeke, E; Schwarz, M; Simses, C; Wright, J; Yang, J, 2019)	0.76
"Two single-dose, randomized, open-label, two-period, two-group, crossover studies were conducted to assess the bioequivalence of a test product [dry syrup, 2%, 1 g (containing 20 mg of memantine hydrochloride)] to a reference product (film-coated tablet) under two dosing conditions: administration of the test product as a suspension in water (Study I) and as granules taken with water (Study II)."	( Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies. Hasegawa, S; Ishizuka, H; Ishizuka, T; Maekawa, Y; Shiosakai, K, 2019)	0.97
"The new dry syrup formulation containing memantine hydrochloride showed bioequivalence to the film-coated tablet under the two dosing conditions."	( Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies. Hasegawa, S; Ishizuka, H; Ishizuka, T; Maekawa, Y; Shiosakai, K, 2019)	1.05
" Study durations ranged from 3 to 13 weeks, and memantine dosing ranged from 5 to 60 mg/day."	( Adjunctive memantine for opioid use disorder treatment: A systematic review. Brown, JN; Elias, AM; Pepin, MJ, 2019)	1.16
" In both groups memantine dosage was 10-20 mg/day according to its tolerability."	( The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia. Cotroneo, AM; Gareri, P; Orsitto, G; Putignano, S, )	0.48
" Medical charts were reviewed, including diagnosis, dosage of antidementia medicines, neuropsychological testing scores, and the further questionnaires were conducted via face-to-face or telephone, included duration of treatment, types of antidementia drugs, and reasons for treatment discontinuation."	( Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China. Lü, Y; Yang, W; Yu, W; Yu, X, 2020)	0.56
" Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms."	( Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management. Bülbül, EÖ; Karantas, ID; Mutlu, G; Okur, ME; Okur, NÜ; Siafaka, PI, 2020)	0.56
" Pharmacological treatment often lead to severe complications and require drug dosage adjustment."	( The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study. Gao, J; Han, X; Huang, L; Mao, E; Wu, G; Yue, A; Zhou, B, 2020)	0.81
"The proposed method was applied successfully for the analysis of the cited drugs in pure and dosage forms."	( Non-extractive spectrophotometric determination of memantine HCl, clomipramine HCl and fluvoxamine maleate in pure form and in pharmaceutical products by ion-pair complex formation with rose bengal. El-Alfy, W; El-Mammli, MY; Ismaiel, OA; Sayed, RA; Shalaby, A, 2021)	0.87
" Repeated dosing of memantine did not show clinically significant QT interval changes after treatment."	( Effect of Memantine on QT/QTc Interval in a Healthy Korean Population. Kim, KA; Park, JW; Park, JY, 2021)	1.35
" The aim of the study was the pharmaceutical development of the combined tablet dosage form formulation with modified release of citicoline and memantine for the treatment of cognitive impairments."	( [PHARMACEUTICAL DEVELOPMENT OF TABLETS WITH MODIFIED RELEASE OF CYTICOLINE AND MEMANTINE]. Salakhetdinov, D; Sysuev, B, 2021)	1.05
" Given the limitations of a smaller sample size, variables such as severity of disease, renal and liver impairment as well as medication dosing were not significant predictors (Table 3) for those reporting side effects on combination therapy."	( Tolerability of memantine monotherapy versus adding memantine as combination therapy. Isaac, E; Keith, S; Lippa, C; Ney, D; Serruya, M; Sperling, MR, 2022)	1.07
" Memantine demonstrated a bell-shaped dose-response curve of NP against NMDA."	( Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult. Eterovic, VA; Ferchmin, PA; Ferrer-Acosta, Y; Martins, AH; Pérez, D; Rodriguez-Massó, S, 2022)	3.07
" Dosage of memantine was based on the child's weight and ranged from 3 mg to 15 mg per day."	( Memantine for autism spectrum disorder. Brignell, A; Marraffa, C; May, T; Williams, K, 2022)	2.55
" Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments of new strategies and combined treatments are expected to occur within the next decade and will positively impact the way the disease is managed."	( Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. Boada, M; Jofresa, S; Morató, X; Pytel, V; Ruiz, A, 2022)	0.72
"This work focuses on developing nanoemulsions using a low-energy emulsification method for the codelivery of donepezil and memantine in one dosage form intended to be administered via the intranasal route for enhanced brain delivery."	( Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies. Bhatta, RS; Handa, M; Palkhade, R; Patil, GP; Sanap, SN; Shukla, R; Singh, DP, 2023)	1.37
"The current work is focused on developing mannose-coated PLGA nanoparticles for delivering Donepezil and Memantine in one dosage form."	( Combining donepezil and memantine via mannosylated PLGA nanoparticles for intranasal delivery: Characterization and preclinical studies. Bhatta, RS; Ghose, S; Handa, M; Patil, GP; Sanap, SN; Shukla, R; Singh, DP, 2023)	1.43

Role	Description
dopaminergic agent	A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
antiparkinson drug	A drug used in the treatment of Parkinson's disease.
NMDA receptor antagonist	Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
neuroprotective agent	Any compound that can be used for the treatment of neurodegenerative disorders.
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
adamantanes	Compounds containing an adamantane skeleton.
primary aliphatic amine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	0.7943	0.1000	20.8793	79.4328	AID588456
GLI family zinc finger 3	Homo sapiens (human)	Potency	16.7855	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	33.4915	0.0002	21.2231	8,912.5098	AID743042; AID743054
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	25.1567	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	14.9601	0.0017	23.8393	78.1014	AID743083
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	29.8493	0.0003	23.4451	159.6830	AID743065; AID743067
huntingtin isoform 2	Homo sapiens (human)	Potency	35.4813	0.0006	18.4198	1,122.0200	AID1688
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	6.5614	0.0037	8.6189	23.2809	AID2668
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	25.0999	0.0056	12.3677	36.1254	AID624044
lamin isoform A-delta10	Homo sapiens (human)	Potency	14.1254	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	27.2000	0.2100	5.5537	10.0000	AID386625
Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)	Ki	0.5400	0.0012	0.7025	6.0000	AID156805; AID1691903
Acetylcholinesterase	Electrophorus electricus (electric eel)	IC50 (µMol)	10.0000	0.0000	0.9453	9.9400	AID480448
Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)	Ki	0.5400	0.0012	0.7025	6.0000	AID156805; AID1691903
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.1100	7.1903	10.0000	AID1449628
Neuronal acetylcholine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	6.0000	0.0030	0.7770	6.0000	AID1766051
Neuronal acetylcholine receptor subunit beta-4	Rattus norvegicus (Norway rat)	IC50 (µMol)	6.0000	0.0030	0.8869	6.0000	AID1766051
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	0.0049	0.0000	0.9332	10.0000	AID1766053
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	20.3900	0.0007	1.6003	10.0000	AID1511114; AID1691899; AID1909434; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.8666	6.6900	AID143463
Neuronal acetylcholine receptor subunit alpha-6	Rattus norvegicus (Norway rat)	IC50 (µMol)	6.0000	0.0020	0.6904	6.0000	AID1766051
5-hydroxytryptamine receptor 7	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	27.2000	2.0300	5.5313	9.9000	AID386625
Cholinesterase	Equus caballus (horse)	IC50 (µMol)	10.0000	0.0000	2.2214	9.4000	AID480449
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	20.3900	0.0007	1.6306	10.0000	AID1511114; AID1691899; AID1909434; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.6805	6.6900	AID143463
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	22.5444	0.0006	1.5257	10.0000	AID1511114; AID1691899; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.7071	6.6900	AID143463
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	IC50 (µMol)	22.5444	0.0007	1.7472	10.0000	AID1511114; AID1691899; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.8196	6.6900	AID143463
Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)	IC50 (µMol)	4.3212	0.0010	1.8877	9.8000	AID1124803; AID1241461; AID1241463; AID1766049; AID292616; AID292617; AID341425; AID480453; AID480455; AID755470
Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)	Ki	0.6933	0.0012	0.4824	6.0000	AID1511115; AID156805; AID1691903
Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)	IC50 (µMol)	3.6620	0.0010	1.9958	9.8000	AID1124803; AID1241461; AID1766049; AID292616; AID480453; AID755470
Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)	Ki	0.5400	0.0012	0.6205	6.0000	AID156805; AID1691903
Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)	IC50 (µMol)	5.3100	0.0040	1.3325	9.8000	AID1241463; AID292617; AID341425; AID480455
Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)	Ki	0.6933	0.0012	0.3268	6.0000	AID1511115; AID156805; AID1691903
Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)	Ki	0.5400	0.0012	0.7025	6.0000	AID156805; AID1691903
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	IC50 (µMol)	22.5444	0.0007	1.7411	10.0000	AID1511114; AID1691899; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.7072	6.6900	AID143463
Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)	Ki	0.5400	0.0012	0.7025	6.0000	AID156805; AID1691903
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	IC50 (µMol)	22.5444	0.0007	1.7411	10.0000	AID1511114; AID1691899; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.7072	6.6900	AID143463
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	IC50 (µMol)	22.5444	0.0007	1.7411	10.0000	AID1511114; AID1691899; AID388526; AID388528; AID410125; AID410126; AID416368; AID456466; AID456467
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	Ki	0.7000	0.0003	0.7072	6.6900	AID143463
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 2	Homo sapiens (human)	Km	34.0000	0.0289	1.0407	2.6000	AID679500
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
startle response	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
brain development	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
adult locomotory behavior	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
calcium-mediated signaling	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
regulation of synaptic plasticity	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
regulation of neuronal synaptic plasticity	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
regulation of sensory perception of pain	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
calcium ion transmembrane import into cytosol	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
excitatory chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
regulation of presynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
regulation of monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
cellular response to L-glutamate	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
long-term synaptic potentiation	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
protein insertion into membrane	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
regulation of calcium ion transport	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
calcium ion transmembrane transport	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
regulation of presynaptic membrane potential	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
modulation of chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
cellular response to amyloid-beta	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
monoatomic cation transport	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
brain development	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
visual learning	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
positive regulation of calcium ion transport into cytosol	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
propylene metabolic process	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
calcium-mediated signaling	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
regulation of membrane potential	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
response to ethanol	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
regulation of synaptic plasticity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
regulation of neuronal synaptic plasticity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
protein heterotetramerization	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
calcium ion homeostasis	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
calcium ion transmembrane import into cytosol	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
excitatory chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic process	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
regulation of monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
response to glycine	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
cellular response to amyloid-beta	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
startle response	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
response to amphetamine	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
brain development	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
learning or memory	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
memory	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
visual learning	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
response to xenobiotic stimulus	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
response to wounding	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
sensory perception of pain	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
calcium-mediated signaling	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
neurogenesis	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
protein catabolic process	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
sleep	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
directional locomotion	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
negative regulation of protein catabolic process	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
dopamine metabolic process	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
serotonin metabolic process	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
positive regulation of apoptotic process	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
response to ethanol	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
regulation of synaptic plasticity	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
regulation of neuronal synaptic plasticity	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
activation of cysteine-type endopeptidase activity	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
calcium ion transmembrane import into cytosol	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
excitatory chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
protein localization to postsynaptic membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
regulation of monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
long-term synaptic potentiation	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
brain development	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
learning or memory	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
calcium-mediated signaling	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
response to ethanol	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
regulation of synaptic plasticity	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
regulation of neuronal synaptic plasticity	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
protein heterotetramerization	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
calcium ion transmembrane import into cytosol	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
excitatory chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
regulation of presynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
negative regulation of dendritic spine maintenance	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
regulation of monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
long-term synaptic potentiation	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
brain development	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
response to wounding	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
calcium-mediated signaling	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
directional locomotion	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
negative regulation of protein catabolic process	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
regulation of synaptic plasticity	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
regulation of neuronal synaptic plasticity	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
neuromuscular process controlling balance	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
calcium ion transmembrane import into cytosol	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
excitatory chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
protein localization to postsynaptic membrane	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
regulation of monoatomic cation transmembrane transport	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
long-term synaptic potentiation	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
excitatory postsynaptic potential	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
calcium ion transport	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
dendrite development	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
response to ethanol	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
rhythmic process	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
prepulse inhibition	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
negative regulation of dendritic spine development	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
calcium ion transmembrane transport	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
synaptic transmission, glutamatergic	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
modulation of chemical synaptic transmission	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
glutamate-gated receptor activity	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
protein binding	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
glutamate binding	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
voltage-gated monoatomic cation channel activity	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
glutamate-gated calcium ion channel activity	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
calcium channel activity	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
monoatomic cation channel activity	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
glycine binding	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
neurotransmitter receptor activity	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
glutamate receptor activity	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
calcium channel activity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
amyloid-beta binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
calcium ion binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
protein binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
calmodulin binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
glycine binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
glutamate binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
glutamate-gated calcium ion channel activity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
protein-containing complex binding	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
signaling receptor activity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
ligand-gated monoatomic ion channel activity	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
amyloid-beta binding	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
protein binding	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
zinc ion binding	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
glutamate-gated calcium ion channel activity	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
amyloid-beta binding	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
protein binding	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
zinc ion binding	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
glycine binding	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
glutamate binding	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
glutamate-gated calcium ion channel activity	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
protein binding	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
glutamate-gated calcium ion channel activity	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
NMDA glutamate receptor activity	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
calcium channel activity	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
protein binding	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
glycine binding	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
identical protein binding	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
protein phosphatase 2A binding	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
glutamate receptor activity	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
postsynaptic membrane	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
presynaptic active zone membrane	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
glutamatergic synapse	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
postsynaptic density membrane	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)
neuronal cell body	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
postsynaptic density membrane	Glutamate receptor ionotropic, NMDA 3B	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
cytoplasm	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
synaptic vesicle	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
cell surface	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
postsynaptic density	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
dendrite	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
neuron projection	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
synaptic cleft	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
terminal bouton	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
dendritic spine	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
synapse	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
postsynaptic membrane	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
excitatory synapse	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
synaptic membrane	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
synapse	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
neuron projection	Glutamate receptor ionotropic, NMDA 1	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
synaptic vesicle	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
cell surface	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
postsynaptic density	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
cytoplasmic vesicle membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
presynaptic membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
dendritic spine	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
postsynaptic membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
synaptic membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
glutamatergic synapse	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
postsynaptic density membrane	Glutamate receptor ionotropic, NMDA 2A	Homo sapiens (human)
cytoplasm	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
lysosome	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
late endosome	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
cytoskeleton	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
cell surface	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
postsynaptic density	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
neuron projection	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
postsynaptic membrane	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
synaptic membrane	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
postsynaptic density membrane	Glutamate receptor ionotropic, NMDA 2B	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
postsynaptic membrane	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
glutamatergic synapse	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
postsynaptic density membrane	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
membrane	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
neuron projection	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
neuronal cell body	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
synapse	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
presynapse	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
glutamatergic synapse	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
NMDA selective glutamate receptor complex	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
plasma membrane	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
postsynaptic density membrane	Glutamate receptor ionotropic, NMDA 3A	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1247108	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 30 uM spermine to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 30 uM spermine	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID1663425	Antialzheimer activity in scopolamine-induced impairment in ICR mouse assessed as total distance to platform at 15 mg/kg, ip administered once a day for 10 days pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1415304	Neuroprotective activity against glutamate-induced excitotoxicity in mouse primary cerebellar granule neurons assessed as increase in cell viability at 1 uM preincubated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID1853379	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as reduction in necrosis rate incubated for 24 hrs by Annexin V-FITC/propidium iodide staining flow cytometry	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1909450	Effect on locomotory activity in transgenic Caenorhabditis elegans CL2006 model of paralysis assessed as reduction in defective locomotion by measuring motor index at 0.1 to 10 uM by motor behaviour assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1511118	Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID710417	Neuroprotective activity in mouse hippocampal neurons assessed as Abeta-induced neuronal apoptosis at 30 uM pre-incubated for 4 hrs before Abeta challenge for 72 hrs by TUNEL assay (Rvb = 100%)	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor.
AID637741	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei 427 after 48 hrs by hemocytometer analysis	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.
AID1247112	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 50 mM K+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 50 mM K+	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID1853363	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 25 uM incubated for 24 hrs by MTT assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID305670	Displacement of [3H]MK-801 from NMDA receptor in ICR mouse synaptoneurosome at 100 uM	2007	Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3	Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
AID388541	Inhibition of [3H]dopamine uptake in Wistar rat striatum synaptosomes at 100 uM by scintillation spectrometry	2008	Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23	Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1247114	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 1.3 mM Mg2+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 1.3 mM Mg2+	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID1236289	Cytoprotective activity against MPP+-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 20 uM after 24 hrs by MTT assay	2014	MedChemComm, Oct-01, Volume: 5, Issue:10	Cytoprotective effects of hydrogen sulfide-releasing
AID1741563	Displacement of [3H]MK801 from NMDA receptor in human brain by radioligand binding assay	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP
AID1892513	Antioxidant activity in mouse HT-22 cells cocultured with BV-2 cells assessed as ROS scavenging activity at 5 uM incubated for 48 hrs by DCFH-DA staining based microplate reader analysis	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID1853365	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 100 uM incubated for 24 hrs by MTT assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1691900	Cytotoxicity against HEK293 cells assessed as reduction in cell viability by MTT assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
AID480463	Cytotoxicity against mouse L12-G10 cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1369089	Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 150 mins by solid scintillation counting	2018	Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2	2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID1853371	Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease of TOS level at 25 uM	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1407632	Reversal of okadaic acid-mediated PP2A catalytic subunit C Ser/Thr phosphatase activity inactivation in human SH-SY5Y cells assessed as recovery of PP2A activity at 0.1 uM preincubated for 24 hrs followed by cotreatment with PPA2 inhibitor okadaic acid fo	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection.
AID1853380	Genotoxicity in human blood assessed as frequency of sister chromatid exchange at 0.1 to 100 uM by BrdU/Giemsa staining based fluorescence assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID410125	Inhibition of NMDA receptor in rat cerebellar granule neurons assessed as glutamate-induced intracellular calcium increase	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID1909459	Upregulation of PSD in hippocampus of 5XFAD transgenic AD mouse model at 5 mg/kg, po by Western blot analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1892511	Cytotoxicity against mouse HT-22 cells assessed as cell viability at 5 uM after 48 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID1766051	Inhibition of human GluN1-1a/NR2B receptor expressed in transgenic mouse fibroblast cells assessed as inhibition of L-glutamate-induced excitotoxicity by measuring LDH activity by cell based assay	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID1555543	Oral bioavailability in Alzheimer's disease patient at 2 mg/ml	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Multi-target design strategies for the improved treatment of Alzheimer's disease.
AID122559	Modification of circling behavior in mice with unilateral striatal lesions produced by 6-hydroxydopamine injection was measured at a dose of 0.15 mmol/kg	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1909430	Inhibition of eGFP-tagged rat GluN1/GluN2A transfected in human tsA201 cells assessed as blockade of glycine/NMDA-induced current at 10 uM treated for 40 secs measured at +60 mV holding potential applied for 5 secs by whole-cell patch-clamp method relativ	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID311933	Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID707697	Inhibition of mouse recombinant GST-tagged CLK3 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID1635768	Suppression of okadaic acid-induced inhibition of PP1/PP2A in human SHSY-5Y cells at 0.1 uM using pNPP as substrate assessed as remaining Ser/Thr phosphatase activity incubated for 30 mins in presence of tyrosine phosphatase inhibitor sodium orthovanadate	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Gramine Derivatives Targeting Ca(2+) Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases.
AID1691903	Binding affinity to NMDAR (unknown origin)	2020	European journal of medicinal chemistry, May-15, Volume: 194	Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
AID1511114	Antagonist activity at NMDA receptor in rat CGN cells assessed as increase in intracellular calcium level incubated for 30 mins in presence of Fura-2AM followed by NMDA/glycine stimulation by fluorescence spectrometer analysis	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1241471	Inhibition of human recombinant MAOA	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID156805	The compound was tested for its ability to block PCP N-methyl-D-aspartate glutamate receptor at the PCP (phencyclidine) binding site in postmortem human frontal cortex.	1998	Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3	Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.
AID1337746	Neuroprotective activity against NMDA-induced toxicity in human SH-SY5Y cells assessed as cell viability at 5 uM incubated for 48 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity.
AID480449	Inhibition of equine serum BChE by modified Ellman's method	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1909434	Inhibition of eGFP-tagged rat GluN1-1a/GluN2A transfected in human tsA201 cells assessed as inhibition glutamate-induced current measured at -65 mV holding potential applied for 10 secs by whole-cell patch-clamp method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1853374	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as protection against amyloid beta (1 to 42)-induced nuclear integrity damage at 25 uM incubated for 24 hrs by Hoechst 33258 staining	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1076768	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rela	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID386625	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1247109	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 10 to 50 mM Tris to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 10 to 50 mM Tris	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID1909452	Recovery of cognitive function in 5XFAD transgenic AD mouse model assessed as long term memory by measuring increase in discrimination index at 5 mg/kg/day, po for 4 weeks measured after 5 days of habituation by novel object recognition test	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1857755	Permeability of compound in PBS buffer at 500 uM incubated for 18 hrs by PAMPA assay	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Selective
AID292618	Cytotoxicity in mouse FM3A cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.
AID111354	Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.0125 mmol/kg)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID710414	Inhibition of radioligand binding to N-methyl D-aspartate receptor phencyclidine binding site at 10 uM	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor.
AID1853373	Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease of TOS level at 50 uM	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID480455	Inhibition of dexamethasone-induced human NR1-1a/NR2B receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L13-E6 cells assessed as LDH release after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1241472	Inhibition of human recombinant MAOB	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID755468	Antithrombotic activity in photochemically-induced thrombosis C57B/L mouse model assessed as decrease in brain infarction size at 10 mg/kg, iv after 24 hrs	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	In vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers.
AID1853366	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 25 uM incubated for 24 hrs by LDH release assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1407639	Neuroprotective activity against okadaic acid-induced oxidative stress in human SH-SY5Y cells assessed as increase in cell viability at 0.1 uM preincubated for 24 hrs followed by OA addition measured after 20 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection.
AID707051	Inhibition of AChE in Wistar rat brain homogenates using acetylthiocholine iodide and DTNB as substrate at 10 uM after 10 mins by Ellman method	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID536042	Displacement of [3H]-(+)-MK-801 from NMDA receptor phencyclidine binding site in guinea pig brain cortex homogenates after 5 mins by scintillation counting	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists.
AID1076764	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rel	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1892512	Antioxidant activity in mouse HT-22 cells cocultured with BV-2 cells assessed as reduction in glutamic acid level at 5 uM incubated for 24 hrs	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID755470	Antagonist activity at recombinant GluN1/GluN2A receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glycine/glutamate-induced inward current at -70mV by two-electrode voltage clamp assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	In vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers.
AID1247107	Displacement of [3H]MK-801 from NMDA receptor in Wistar rat brain membranes by scintillation counting analysis	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID1555544	Half life in Alzheimer's disease patient at 2 mg/ml, po	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Multi-target design strategies for the improved treatment of Alzheimer's disease.
AID1853362	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease in AChE activity at 25 uM incubated for 24 hrs by Colorimetric assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1076767	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rel	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1663422	Neuroprotective activity against amyloid beta (1 to 42 residues) induced cytotoxicity in rat PC12 cells assessed as cell viability at 10 uM incubated for 24 hrs by MTT assay (Rvb = 100%)	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1237859	Displacement of [3H]-(+)-MK-801 from phencyclidine binding site of NMDA receptor in pig membranes after 150 mins by scintillation counting analysis	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
AID305668	Antagonist activity at NMDA receptor in ICR mouse synaptoneurosome assessed as inhibition of NMDA/Gly-mediated 45-calcium influx	2007	Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3	Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
AID1337758	Neurotoxicity against human SH-SY5Y cells assessed as growth inhibition measured after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity.
AID1663424	Antialzheimer activity in scopolamine-induced impairment in ICR mouse assessed as latency time at 15 mg/kg, ip administered once a day for 10 days pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris water maze tes	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1635767	Suppression of okadaic acid-induced inhibition of PP1/PP2A in human SHSY-5Y cells at 0.1 uM using pNPP as substrate assessed as remaining total phosphatase activity incubated for 30 mins by colorimetric assay (Rvb = 68 +/- 2%)	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Gramine Derivatives Targeting Ca(2+) Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases.
AID1909463	Inhibition of human GluN1/N2A expressed in HEK293 cells assessed as NMDA/glycine-induced fraction of total transmembrane voltage field at 10 uM preincubated for 20 secs followed by NMDA treatment for 10 secs by patch-clamp method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1853368	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 100 uM incubated for 24 hrs by LDH release assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID122557	Modification of circling behavior in mice with unilateral striatal lesions produced by 6-hydroxydopamine injection was measured at a dose of 0.05 mmol/kg	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1415323	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as decrease in formation of nitric oxide at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 12 hrs by DAF-FM dye-based fluoresce	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID480464	Cytotoxicity against mouse L12-G10 cells at 50 uM by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID637740	Antagonist activity at NMDAR in rat cerebellar granule neurons assessed as inhibition of NMDA-induced calcium flux after 5 mins using FURA-2AM in presence of glycine	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.
AID1766056	Inhibition of recombinant equine BChE by Ellman's method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID1853372	Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as increase of TAC level at 50 uM by ABTS assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1441499	Increase in acetylcholine level in Wistar rat ventral hippocampus at 1 mg/kg, sc after 4 hrs in presence of 1 mg/kg of donepezil administered sc by LC-MS/MS based microdialysis method relative to control	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1853377	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as inhibition of apoptosis at 50 uM incubated for 24 hrs by Hoechst 33258 staining fluorescence microscopy	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID707052	Displacement of [3H]Ifenprodil from NMDAR-2B in Sprague-Dawley rat frontal cortex homogenates after 2 hrs by liquid scintillation counting	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID24229	Partition coefficient (logP)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1892507	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability at < 5 uM incubated for 24 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID480456	Inhibition of dexamethasone-induced human NR1-1a/NR2B receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L13-E6 cells assessed as LDH release at 25 uM after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1909456	Upregulation of phosphorylated-GluN2B levels at Tyr1472 residue in hippocampus of 5XFAD transgenic AD mouse model at 5 mg/kg, po by Western blot analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID707048	Neuroprotective activity in human SH-SY5Y cells assessed as protection against NMDA-induced cell death after 6 hrs by MTS assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID292616	Antagonist activity at recombinant NR1/NR2A receptor expressed in Xenopus laevis oocytes	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.
AID1663423	Neuroprotective activity in amyloid beta (1 to 42 residues) (unknown origin)-induced ROS production in rat PC12 cells assessed as intracellular ROS level at 10 uM pretreated for 36 hrs followed by incubation with DCFH-DA for 10 mins by flow cytometry anal	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID707053	Displacement of [3H]MK-801 from NMDAR in Sprague-Dawley rat cerebral cortex homogenates after 2 hrs by liquid scintillation counting	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID1857768	Neuroprotective activity in retinoic acid and cAMP differentiated mouse HT-22 cells assessed as decrease in glutamate induced cellular ROS level at 2 ug/ml incubated for 1 hrs by DCFH-DA based fluorescent microscopy	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Selective
AID1909433	Inhibition of eGFP-tagged rat GluN1/GluN2A transfected in human tsA201 cells assessed as weighted time constant for recovery of glycine/NMDA-induced current at 10 uM treated for 40 secs followed by application of +60 mV holding potential for 5 secs measur	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1766049	Inhibition of human GluN1-1a/NR2A receptor expressed in transgenic mouse fibroblast cells assessed as inhibition of L-glutamate-induced excitotoxicity by measuring LDH activity by cell based assay	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID26110	pKa value of compound was calculated by the method of clarke	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1853361	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 50 uM incubated for 24 hrs by MTT assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1415312	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as increase in cell viability at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 24 hrs by FAD/propidium iodide staining-based i	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID480454	Inhibition of dexamethasone-induced human NR1-1a/NR2A receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L12-G10 cells assessed as LDH release at 25 uM after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1124803	Antagonist activity at NR1/NR2A receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glutamate/glycine-induced current at pH 7.6 at -40mV holding potential by two-electrode voltage-clamp electrophysiology	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Some non-conventional biomolecular targets for diamidines. A short survey.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1853367	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 50 uM incubated for 24 hrs by LDH release assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1076775	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 2	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1247110	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of H+ at pH 6.4 to 8.2 to IC50 for NMDA receptor in Wistar rat brain membranes in absence of H+ at pH 6.4 to 8.2	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID456466	Antagonist activity at NMDA receptor in rat cerebellar granule neurons assessed as inhibition of glutamate-induced increase in intracellular calcium level by fluorometric assay	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID1853364	Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 0.1 to 100 uM incubated for 24 hrs by MTT assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1241463	Inhibition of human NR1-1a/NR2B expressed in mouse L13-E6 cells assessed as inhibition of glutamate-induced excitotoxicity incubated for 16 hrs by LDH release assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID1892510	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability at 5 uM after 36 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1511115	Inhibition of recombinant GluN1/GluN2B receptor (unknown origin) expressed in HEK293 cells by patch-clamp method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1909453	Recovery of cognitive function in 5XFAD transgenic AD mouse model assessed as short term memory by measuring increased discrimination index at 5 mg/kg/day, po for 4 weeks measured after 4 days of habituation by novel object recognition test	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1415314	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as decrease in intracellular calcium influx at 5 uM preincubated for 5 min followed by glutamate challenge measured over 280 secs by Fluo-3/AM dye-based fl	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID416367	Antagonist activity against glutamate receptor in rat cerebellar granule neurons assessed as inhibition of glutamate-induced increase in intracellular calcium level by Fura-2 AM dye based fluorimetry	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
AID1655961	Neuroprotective activity against NMDA-induced cell death in human SH-SY5Y cells at 5 uM incubated for 24 hrs by MTT assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents.
AID1909455	Upregulation of phosphorylated-Fyn levels in hippocampus of 5XFAD transgenic AD mouse model at 5 mg/kg, po by Western blot analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1247111	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 3 to 50 mM Na+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 3 to 50 mM Na+	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID1511116	Inhibition of human recombinant amyloid beta (1 to 42) aggregation expressed in Escherichia coli BL21 (DE3) at 10 uM by Thioflavin S steady state fluorescence assay relative to control	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID111359	Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.05 mmol/kg)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1853376	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as inhibition of apoptosis at 25 uM incubated for 24 hrs by Hoechst 33258 staining fluorescence microscopy	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853381	Induction of DNA damage in human blood assessed as increase in 8-OH-dG level at 0.1 to 100 uM incubated for 24 hrs	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID111356	Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.025 mmol/kg)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID480448	Inhibition of electric eel AChE by modified Ellman's method	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1247113	Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 20 mM NH4+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 20 mM NH4+	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID710416	Neuroprotective activity against Abeta-induced neuronal apoptosis in mouse hippocampal neurons assessed as reduction in DNA fragmentation at 30 uM pre-incubated for 4 hrs before Abeta challenge for 72 hrs by immunofluorescence microscopy	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor.
AID456470	Trypanocidal activity against Trypanosoma brucei 427 bloodstream form assessed as decrease in cell density after 48 hrs by hemocytometry	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID1853369	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease in AChE activity at 50 uM incubated for 24 hrs by Colorimetric assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID480451	Inhibition of electric eel AChE at 10 uM by modified Ellman's method	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1415307	Neuroprotective activity against glutamate-induced excitotoxicity in mouse primary cerebellar granule neurons assessed as increase in cell viability preincubated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID1241458	Inhibition of electric eel AChE using acetylthiocholine iodide substrate by Ellman assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID637739	Antagonist activity at NMDAR in rat cerebellar granule neurons assessed as inhibition of glutamate-induced calcium flux after 5 mins using FURA-2AM in presence of glycine	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.
AID704017	Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Enantiomerically pure 1,3-dioxanes as highly selective NMDA and σ₁ receptor ligands.
AID488105	Displacement of [3H]-(+)-MK801 from PCP binding site of NMDA receptor from pig brain cortex after 150 mins by scintillation counting	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
AID416368	Antagonist activity against NMDA receptor in rat cerebellar granule neurons assessed as inhibition of NMDA -induced increase in intracellular calcium level by Fura-2 AM dye based fluorimetry	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
AID707698	Inhibition of mouse recombinant GST-tagged CLK1 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID480453	Inhibition of dexamethasone-induced human NR1-1a/NR2A receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L12-G10 cells assessed as LDH release after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1076766	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relat	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID122558	Modification of circling behavior in mice with unilateral striatal lesions produced by 6-hydroxydopamine injection was measured at a dose of 0.10 mmol/kg	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1853370	Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as increase of TAC level at 25 uM by ABTS assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1415321	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as decrease in formation of hydroxy radicals at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 12 hrs by HPF dye-based fluoresc	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID1892514	Antioxidant activity in mouse HT-22 cells cocultured with BV-2 cells assessed as increase in GSH level at 5 uM incubated for 48 hrs by DCFH-DA staining based microplate reader analysis	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID111363	Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.20 mmol/kg)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID707699	Inhibition of human recombinant GST-tagged DYRK2 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID1415320	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as decrease in H2O2 formation at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 12 hrs by H2DCF-DA dye-based fluorescence assay	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID388528	Antagonist activity at NMDA receptor in cerebellar granule neurons assessed as inhibition of NMDA-induced increase in intracellular calcium concentration by fluorometric assay	2008	Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23	Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID341425	Inhibition of NMDA NR1/NR2B receptor expressed in xenopus oocytes assessed as inhibition of NMDA and glycine-induced current response by two-electrode voltage clamp assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1909432	Inhibition of eGFP-tagged rat GluN1/GluN2A transfected in human tsA201 cells assessed as recovery of glycine/NMDA-induced current at 10 uM treated for 40 secs followed by application of +60 mV holding potential for 5 secs measured after 40 secs of compoun	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1691899	Antagonist activity at NMDAR in embryonic cultures of rat cortical neuron assessed as inhibition of NMDA-induced calcium influx preincubated for 10 mins followed by NMDA addition by Fluo-4/AM dye based fluorescence assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
AID305671	Displacement of [3H]TCP from NMDA receptor in ICR mouse synaptoneurosome at 100 uM	2007	Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3	Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
AID1511113	Inhibition of human serum BChE using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition by spectrophotometry analysis	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1909462	Inhibition of GluN1/N2A (unknown origin) expressed in human tsA201 cells assessed as glutamate-induced change in voltage at -65 mV holding potential for 30 secs by whole-cell patch-clamp method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1076772	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1853378	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as reduction in necrosis rate at 25 to 50 uM incubated for 24 hrs by Annexin V-FITC/propidium iodide staining flow cytometry	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID311935	Partition coefficient, log P of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1909429	Inhibition of eGFP-tagged rat GluN1/GluN2A transfected in human tsA201 cells assessed as blockade of glycine/NMDA-induced current at 10 uM treated for 40 secs measured at -60 mV holding potential after returning from +60 mV application for 5 secs by whole	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID456467	Antagonist activity at NMDA receptor in rat cerebellar granule neurons assessed as inhibition of NMDA-induced increase in intracellular calcium level by fluorometric assay	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1691901	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
AID292617	Antagonist activity at recombinant NR1/NR2B receptor expressed in Xenopus laevis oocytes	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.
AID1236290	Cytoprotective activity against MPP+-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 20 uM after 24 hrs by crystal violet assay	2014	MedChemComm, Oct-01, Volume: 5, Issue:10	Cytoprotective effects of hydrogen sulfide-releasing
AID480458	Inhibition of dexamethasone-induced human NR1-1a/NR2A receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L12-G10 cells assessed as LDH release at 20 uM after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1892506	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability at 10 uM incubated for 24 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID1392175	Inhibition of NMDA receptor in rat cortical embryonic neurons assessed as reduction in NMDA-induced cytosolic calcium level at 10 uM by Fluo-4 AM dye based fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9	Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca
AID388526	Antagonist activity at NMDA receptor in cerebellar granule neurons assessed as inhibition of glutamate-induced increase in intracellular calcium concentration by fluorometric assay	2008	Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23	Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
AID1663426	Antialzheimer activity in scopolamine-induced impairment in ICR mouse assessed as total entries at 15 mg/kg, ip administered once a day for 10 days pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris water maze te	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1076771	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 2	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1853375	Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as protection against amyloid beta (1 to 42)-induced nuclear integrity damage at 50 uM incubated for 24 hrs by Hoechst 33258 staining	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1076762	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 uM by trypan blue exclusion assay	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1511218	Inhibition of diphtheria induced toxicity in human A549 cells assessed as protection fold at 30 uM incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scintillation analysis relative to ABMA	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.
AID1511112	Inhibition of human recombinant AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition by spectrophotometry analysis	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1511117	Inhibition of tau aggregation (unknown origin) expressed in Escherichia coli BL21 (DE3) at 10 uM by Thioflavin S steady state fluorescence assay relative to control	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID480460	Inhibition of human NR1-1a/NR2A receptor-mediated excitotoxicity mouse L12-G10 cells assessed as LDH release after 30 mins in absence of (S)-glutamate/glycine relative to control	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1415326	Neuroprotective activity in rat cortical neurons assessed as inhibition of glutamate-induced decrease in mitochondrial membrane potential at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 12 hrs by JC1 staining-based fluorescen	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID1373201	Antialzheimer disease activity in heterozygous transgenic Alzheimer's disease model fruit fly under control of elav-Gal4'C155 (P35*H29.3) expressing Abeta42 assessed as attenuation of cognitive deterioration by measuring increase in performance index by P	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	New lignans attenuating cognitive deterioration of Aβ transgenic flies discovered in Acorus tatarinowii.
AID707700	Inhibition of human recombinant GST-tagged DYRK1A expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID679500	TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes	1998	Molecular pharmacology, Aug, Volume: 54, Issue:2	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1241461	Inhibition of human NR1-1a/NR2A expressed in mouse L12-G10 cells assessed as inhibition of glutamate-induced excitotoxicity incubated for 16 hrs by LDH release assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID1555545	Drug excretion in Alzheimer's disease patient urine at 2 mg/ml, po	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Multi-target design strategies for the improved treatment of Alzheimer's disease.
AID1892508	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability at higher concentration incubated for 24 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID122561	Modification of circling behavior in mice with unilateral striatal lesions produced by 6-hydroxydopamine injection was measured at a dose of 0.20 mmol/kg	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID710418	Inhibition of imidazole receptor 2 in mouse hippocampal neurons assessed as reduction in tPA-induced Erk1/2 activation at 30 uM pre-incubated for 4 hrs before tPA stimulation by ELISA	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor.
AID1076769	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID410126	Inhibition of NMDA receptor in rat cerebellar granule neurons assessed as NMDA-induced intracellular calcium increase	2008	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23	Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID1277328	Neuroprotective activity against glutamate-induced neuronal cell death in Sprague-Dawley rat brain hippocampal slices assessed as cell viability at 10 uM incubated 4 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Neuroprotective profile of pyridothiazepines with blocking activity of the mitochondrial Na(+)/Ca(2+) exchanger.
AID1909451	Neuroprotective activity against transgenic Caenorhabditis elegans CL2355 assessed as A-beta aggregration-induced reversal of disrupted chemotaxis behaviour by measuring chemotaxis index at 1.5 uM treated for 72 hrs followed by compound washout and odoran	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID143463	Compound with the N-methyl-D-aspartate glutamate receptor blocking activity	1999	Journal of medicinal chemistry, May-06, Volume: 42, Issue:9	Emerging molecular approaches to pain therapy.
AID480452	Inhibition of equine serum BChE at 10 uM by modified Ellman's method	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1511121	Inhibition of human recombinant BACE-1 expressed in baculovirus expression system at 5 uM using panvera peptide as substrate measured after 1 hr by FRET assay relative to control	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID111360	Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.10 mmol/kg)	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID1909431	Inhibition of eGFP-tagged rat GluN1/GluN2A transfected in human tsA201 cells assessed as weighted time constant for blockade of glycine/NMDA-induced current at 10 uM at 1 sec by whole-cell patch-clamp method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1892509	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability at 5 uM after 24 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.
AID710415	Neuroprotective activity against Abeta-induced neuronal apoptosis in mouse hippocampal neurons assessed as reduction in total neuronal nuclei level at 30 uM pre-incubated for 4 hrs before Abeta challenge for 72 hrs by immunofluorescence microscopy	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor.
AID1415322	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as decrease in formation of superoxide anions at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 12 hrs by DHE dye-based fluores	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID1241459	Inhibition of BChE in equine serum using butyrylthiocholine iodide substrate by Ellman assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1415324	Neuroprotective activity against glutamate-induced neuronal damage in rat cortical neurons assessed as decrease in formation of peroxynitrite at 5 uM preincubated for 2 hrs followed by glutamate challenge measured after 12 hrs by DHR123 dye-based fluoresc	2017	MedChemComm, Jan-01, Volume: 8, Issue:1	Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.
AID1909458	Upregulation of calbindin D-28K levels in hippocampus of 5XFAD transgenic AD mouse model at 5 mg/kg, po by Western blot analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1076765	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rela	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1076770	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1766053	Inhibition of recombinant human AChE expressed in HEK293 cells by Ellman's method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	44 (1.73)	18.7374
1990's	162 (6.38)	18.2507
2000's	794 (31.25)	29.6817
2010's	1195 (47.03)	24.3611
2020's	346 (13.62)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	341 (12.70%)	5.53%
Reviews	509 (18.96%)	6.00%
Case Studies	131 (4.88%)	4.05%
Observational	13 (0.48%)	0.25%
Other	1,690 (62.97%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (215)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Psychopharmacotherapy in Multiple Substances Abuse / Dependence - the Pharmacological and Immunological Approach to the New Indication of Memantine [NCT01189214]	Phase 3	200 participants (Actual)	Interventional	2009-03-31	Completed
Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies [NCT03779672]	Phase 4	30 participants (Actual)	Interventional	2019-02-07	Completed
Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity [NCT05834231]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine [NCT03858270]	Phase 3	50 participants (Anticipated)	Interventional	2019-04-01	Recruiting
An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder [NCT00264238]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2006-01-31	Completed
The Potential Therapeutic Effects of add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder [NCT03729128]	Phase 1/Phase 2	85 participants (Actual)	Interventional	2018-07-24	Completed
A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases [NCT03550391]	Phase 3	206 participants (Anticipated)	Interventional	2018-11-22	Recruiting
Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial [NCT01108029]	Phase 4	28 participants (Actual)	Interventional	2009-10-31	Completed
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial [NCT03553875]	Phase 3	100 participants (Anticipated)	Interventional	2018-11-13	Recruiting
Effect of Oral Administration of Memantine in Pre and Post-surgery in the Prevention of Post-mastectomy Neuropathic Pain [NCT03686774]	Phase 2	150 participants (Anticipated)	Interventional	2019-02-15	Not yet recruiting
A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning [NCT01372449]	Phase 2	23 participants (Actual)	Interventional	2011-12-31	Completed
Memantine and Cognitive Dysfunction in Bipolar Disorder [NCT00586066]	Phase 4	72 participants (Actual)	Interventional	2005-11-30	Completed
A Study to Investigate the Effects of Memantine on the Pharmacokinetics of BI 425809 and Vice Versa in Healthy Male and Female Subjects (Non-randomized, Single-arm, Open-label, Three-period, One Fixed Sequence Cross-over Study) [NCT03988803]	Phase 1	16 participants (Actual)	Interventional	2019-07-17	Completed
Series Studies of Bipolar Disorder-Valproate add-on Memantine Treatment [NCT01188148]	Phase 2/Phase 3	219 participants (Actual)	Interventional	2009-08-31	Completed
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial [NCT00255086]	Phase 3	17 participants (Actual)	Interventional	2005-05-31	Completed
A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus [NCT03527472]	Phase 2	80 participants (Anticipated)	Interventional	2018-08-23	Recruiting
Memantine Treatment of Compulsive Buying: An Open-Label Study [NCT00830375]	Phase 2	10 participants (Actual)	Interventional	2008-12-01	Completed
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-C [NCT03316898]	Phase 1	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to Business decision to stop the study.)
A Phase Ib/II Randomized, Open Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma [NCT05664464]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia [NCT04857983]	Phase 2/Phase 3	69 participants (Anticipated)	Interventional	2021-07-06	Recruiting
Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome [NCT02467556]	Phase 4	10 participants (Actual)	Interventional	2011-03-31	Completed
Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18 [NCT02553928]	Phase 4	62 participants (Actual)	Interventional	2015-10-31	Completed
Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders [NCT02353130]		0 participants (Actual)	Observational	2015-07-31	Withdrawn(stopped due to Protocol did not continue once Investigator relocated to another institution)
Interventional, Randomized, Single-dose, Open-label, Crossover, Bioequivalence Study in Healthy Subjects to Compare Two Pharmaceutical Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions [NCT03670095]	Phase 1	64 participants (Actual)	Interventional	2018-08-28	Completed
An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder [NCT02258828]	Phase 4	26 participants (Actual)	Interventional	2005-07-31	Completed
Effects of Memantine on Event-related Potential in the Comparison of Patients With Early Schizophrenia and Healthy Subjects [NCT02233556]		20 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers [NCT02288000]	Phase 1	30 participants (Anticipated)	Interventional	2016-09-14	Recruiting
Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine [NCT00649220]	Phase 4	19 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Study terminated due to too slow enrollment)
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial [NCT04302870]	Phase 2/Phase 3	800 participants (Anticipated)	Interventional	2020-02-27	Recruiting
Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial [NCT04801342]	Phase 2	72 participants (Anticipated)	Interventional	2021-04-01	Recruiting
P2X7 Receptor, Inflammation and Pathophysiology of Neurodegenerative Diseases [NCT03918616]		50 participants (Actual)	Observational	2017-02-20	Completed
A Double-Blind, Placebo-Controlled Trial of the Effectiveness of Memantine in Treating Cocaine Dependence [NCT00134901]	Phase 2	81 participants (Actual)	Interventional	2003-03-31	Completed
A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies [NCT00630500]	Phase 2	75 participants (Actual)	Interventional	2006-02-28	Completed
Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of 10mg Memantine in the Treatment of Memory, Concentration or Attention Problems in the Absence of Dementia [NCT01261741]	Phase 2	299 participants (Actual)	Interventional	2010-11-30	Completed
A Study Designed to Determine the Gastro-Retentive and Modified Release Properties of Memantine Hydrochloride (HCl) Prototype Capsule Formulations in Healthy Subjects [NCT03468543]	Early Phase 1	3 participants (Actual)	Interventional	2017-07-26	Terminated(stopped due to Per protocol stopping rules)
A Single Center, Open-label, Fixed Sequence, Two-period Study to Investigate the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of RO5313534 After Single Dose Administration in Healthy Volunteers and the Effect of RO5313534 on Safety and [NCT01196065]	Phase 1	16 participants (Actual)	Interventional	2010-09-30	Completed
An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia [NCT00594737]	Phase 3	17 participants (Actual)	Interventional	2007-10-31	Completed
Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression [NCT00988663]		0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to PI deceased; study did not start.)
MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers [NCT02570581]	Phase 1	16 participants (Actual)	Interventional	2014-06-30	Completed
Effects of Memantine on the Magnetic Resonance Spectroscopy (MRS) Measures of Neuronal Integrity in Subjects at Risk for Alzheimer's Disease [NCT00933608]	Phase 4	17 participants (Actual)	Interventional	2009-07-31	Completed
Open Label, Single-Arm, Multi-Centre, Study to Validate a New Alzheimer's Disease Scale in Patients With DAT, Treated With Memantine [NCT00804271]	Phase 3	487 participants (Actual)	Interventional	2008-12-31	Completed
Pilot Study of Memantine for Enhanced Stroke Recovery [NCT02144584]	Early Phase 1	20 participants (Anticipated)	Interventional	2014-01-31	Active, not recruiting
[NCT02001584]	Phase 1	0 participants	Interventional		Completed
Impact of Persistent Conductances on Motor Unit Firing in SCI [NCT02136823]		50 participants (Anticipated)	Interventional	2009-06-30	Active, not recruiting
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of D797 on Pharmacokinetics of D324 in Healthy Volunteers [NCT03569579]	Phase 1	20 participants (Actual)	Interventional	2018-04-16	Completed
The Use of Memantine for Prevention of Alzheimer's Disease [NCT05063851]	Phase 2	32 participants (Anticipated)	Interventional	2021-10-11	Recruiting
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders [NCT01333865]	Phase 4	25 participants (Actual)	Interventional	2010-01-31	Completed
Combination of Dextromethorphan and Memantine in Treating Bipolar Disorder [NCT03039842]	Phase 3	300 participants (Anticipated)	Interventional	2013-01-01	Enrolling by invitation
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study [NCT03194906]	Phase 2	34 participants (Actual)	Interventional	2017-11-07	Completed
Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis [NCT01074619]	Phase 3	90 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD) [NCT00469456]	Phase 4	265 participants (Actual)	Interventional	2007-04-30	Completed
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy [NCT00566852]	Phase 3	554 participants (Actual)	Interventional	2008-03-31	Completed
The NMDA Receptor Co-agonist D-cycloserine Accelerates Associative Learning in the Human Hippocampal CA Region [NCT00980408]		120 participants (Actual)	Interventional	2008-06-30	Completed
Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine, and Placebo in Fragile X Syndrome [NCT05418049]	Phase 2	45 participants (Anticipated)	Interventional	2022-09-08	Recruiting
Treatment of Orthostatic Intolerance [NCT00262470]	Phase 1/Phase 2	150 participants (Anticipated)	Interventional	1997-04-30	Active, not recruiting
A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease [NCT01025466]	Phase 4	206 participants (Actual)	Interventional	2008-12-31	Completed
A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients After Radiation Therapy for Central Nervous System Tumors [NCT04217694]	Early Phase 1	18 participants (Actual)	Interventional	2020-02-17	Active, not recruiting
A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease [NCT00862940]	Phase 4	277 participants (Actual)	Interventional	2005-09-30	Completed
Treatment Resistant Geriatric Depression in Primary Care: Is NAAG (N-Acetylaspartylglutamate), Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) at 3 Tesla, a Predictor of Treatment Response? [NCT01392287]	Phase 1	12 participants (Actual)	Interventional	2010-05-31	Completed
Memantine Treatment of Kleptomania: An Open-Label Study [NCT00880685]	Phase 2	12 participants (Actual)	Interventional	2009-03-31	Completed
Efficacy of Memantine Compared With Sodium Valproate in the Prophylactic Treatment of Episodic Migraine. [NCT04698525]	Phase 3	33 participants (Actual)	Interventional	2019-02-15	Completed
Phase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALS [NCT01020331]	Phase 2	20 participants (Actual)	Interventional	2005-06-30	Completed
Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study [NCT00757978]	Phase 4	22 participants (Actual)	Interventional	2006-01-31	Completed
The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study [NCT00703430]		50 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study [NCT00800709]	Phase 4	26 participants (Anticipated)	Interventional	2008-07-31	Completed
Memantine for Post-Operative Pain Control [NCT01041313]	Phase 4	120 participants (Anticipated)	Interventional	2010-01-31	Recruiting
An Open-label Extension Study Examining the Safety and Tolerability of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type Having Completed Study 10158 [NCT00857233]	Phase 3	297 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to Please see explanation in the Detailed Description field.)
Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré [NCT01409694]	Phase 3	90 participants (Actual)	Interventional	2011-09-30	Completed
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms [NCT00097942]	Phase 2	138 participants (Actual)	Interventional	2004-08-31	Completed
A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies [NCT00855686]	Phase 4	199 participants (Actual)	Interventional	2007-01-31	Completed
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease [NCT00866060]	Phase 4	800 participants (Anticipated)	Interventional	2008-02-29	Recruiting
A Pilot Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder [NCT00106405]	Phase 2	35 participants (Actual)	Interventional	2005-02-28	Completed
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults [NCT01052662]	Phase 2/Phase 3	87 participants (Actual)	Interventional	2009-10-31	Completed
Antiglutamatergic Treatment of Bulimia Nervosa and Body Dysmorphic Disorder: An Open-Label Trial of Memantine [NCT01038128]		5 participants (Actual)	Interventional	2009-12-31	Completed
Predicting Treatment Response to Memantine in Autism Spectrum Disorder Using MR Spectroscopy [NCT02811627]	Early Phase 1	10 participants (Actual)	Interventional	2016-06-30	Completed
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type [NCT00322153]	Phase 3	677 participants (Actual)	Interventional	2005-06-30	Completed
A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling [NCT00585169]	Phase 2	29 participants (Actual)	Interventional	2007-12-31	Completed
"Competence Network - Dementia (BMBF) Pharmacological and Psychosocial Treatment (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease" [NCT01921972]	Phase 4	232 participants (Actual)	Interventional	2004-11-30	Completed
An Observational Study Efficacy and Safety of Memantine XR (Extended Release) and Pregabalin Combination Therapy in Chemotherapy-Induced Peripheral Neuropathy (CIPN) [NCT03709888]		20 participants (Actual)	Observational	2016-07-09	Completed
A Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Memantine for AIDS Dementia Complex (ADC) as Concurrent Treatment With Antiretroviral Therapy [NCT00000867]	Phase 2	120 participants	Interventional	1996-12-31	Completed
Attenuation of Corticosteroid Induced Hippocampal Changes [NCT01656187]	Phase 4	46 participants (Actual)	Interventional	2012-01-31	Completed
Randomized Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) Versus Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT) in Patients With Brain Metastases [NCT05013892]		100 participants (Anticipated)	Interventional	2022-02-08	Recruiting
Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study [NCT00148616]	Phase 3	13 participants (Actual)	Interventional	2004-04-30	Terminated
Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy [NCT00986115]		0 participants (Actual)	Interventional	2010-07-31	Withdrawn(stopped due to our site was unable to enroll any qualified subjects)
The Potential Therapeutic Effects of add-on Low Dose Memantine to Improve Cognitive Deficits in Middle-to-old Aged Bipolar II Disorder Patients [NCT04035798]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial [NCT00120874]	Phase 4	20 participants (Actual)	Interventional	2006-08-31	Completed
Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia [NCT00294554]		20 participants (Actual)	Interventional	2006-04-30	Completed
CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD) [NCT00235716]	Phase 3	613 participants (Actual)	Interventional	2007-08-31	Completed
A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS [NCT00409721]	Phase 2	42 participants (Anticipated)	Interventional	2007-03-31	Completed
Memantine for Postoperative Analgesia [NCT01032759]	Phase 4	77 participants (Actual)	Interventional	2009-12-31	Terminated
Namenda as Prevention for Post-Operative Delirium [NCT00303433]	Phase 4	30 participants	Interventional	2006-03-31	Terminated
A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. [NCT00196703]	Phase 4	30 participants	Interventional	2005-03-31	Recruiting
Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) [NCT04966546]	Early Phase 1	20 participants (Anticipated)	Interventional	2022-06-01	Active, not recruiting
Memantine add-on for Improving Cognitive Impairments and Negative Symptoms in Patients With Schizophrenia [NCT02001103]	Phase 3	120 participants (Anticipated)	Interventional	2014-01-31	Recruiting
A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma [NCT06007846]	Phase 2/Phase 3	12 participants (Anticipated)	Interventional	2023-07-31	Recruiting
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer [NCT04804644]	Phase 3	200 participants (Anticipated)	Interventional	2021-03-24	Recruiting
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year [NCT04588246]	Phase 3	350 participants (Anticipated)	Interventional	2020-12-15	Recruiting
Antagonists NMDA in Relay to Ketamine in Neuropathic Pain [NCT01602185]	Phase 2	7 participants (Actual)	Interventional	2012-05-31	Completed
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism [NCT00872898]	Phase 2	124 participants (Actual)	Interventional	2009-04-30	Completed
A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type [NCT00857649]	Phase 3	369 participants (Actual)	Interventional	2003-12-31	Terminated
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia [NCT03860597]	Phase 4	42 participants (Actual)	Interventional	2018-04-01	Completed
Efficacy of the Combination of Memantine in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Young Patients to Previous Combination Therapy of Quetiapine Plus Lithium or Quetiapine Plus Aripiprazole [NCT02630888]	Phase 2	44 participants (Anticipated)	Interventional	2014-08-31	Recruiting
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis [NCT02118727]	Phase 2	89 participants (Actual)	Interventional	2018-11-07	Completed
Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis [NCT00638833]	Phase 2	20 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Unexpected side-effects: reversible and mild to moderate neurological impairment)
A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. [NCT00640198]	Phase 4	28 participants (Actual)	Interventional	2005-03-31	Completed
Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial [NCT01054599]		29 participants (Actual)	Interventional	2009-01-31	Completed
Hypofractionated Stereotactic Radiotherapy Versus Hippocampus-sparing Whole-brain Radiotherapy in Treating Cancer Patients With Brain Oligometastases: A Phase II Parallel Non-randomized and Prospective Observational Study [NCT05807165]		115 participants (Anticipated)	Observational	2023-08-01	Not yet recruiting
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors [NCT04939597]	Phase 3	192 participants (Anticipated)	Interventional	2021-11-15	Recruiting
Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients [NCT00200538]	Phase 2	52 participants (Actual)	Interventional	2005-09-30	Completed
Memantine in Systemic Lupus Erythematosus [NCT00181298]		61 participants (Actual)	Interventional	2006-03-31	Completed
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease [NCT00476008]	Phase 4	60 participants (Actual)	Interventional	2007-07-31	Completed
Monitoring Drug Efficacy Through Multi-omics Research Initiative in Alzheimer's Disease [NCT05801380]		60 participants (Anticipated)	Observational	2022-02-14	Recruiting
Multi-center Open Comparative Randomized Study of Efficacy and Safety of Akatinol Memantine 20 mg (Single-doses) vs. Akatinol Memantine 10 mg (Double-doses) in Patients With Moderate and Moderately Severe Vascular Dementia [NCT03986424]	Phase 3	130 participants (Actual)	Interventional	2018-01-23	Completed
Corticolimbic Degeneration and Treatment of Dementia [NCT00768261]	Phase 4	39 participants (Actual)	Interventional	2004-11-30	Completed
Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration [NCT01536314]	Phase 3	43 participants (Actual)	Interventional	2012-02-29	Completed
Treatment Efficacy in Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder [NCT04687566]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2020-08-11	Recruiting
Double-blind Cross-over Study of the Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury, Protocol NAM-MD-44 [NCT00462228]	Phase 4	11 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to The study was stopped due to a lack of additional subjects.)
Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion [NCT00956085]	Phase 2	12 participants (Actual)	Interventional	2009-08-31	Completed
Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism [NCT00368862]	Phase 4	80 participants	Interventional	2005-12-31	Completed
Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) [NCT04117178]	Phase 4	132 participants (Actual)	Interventional	2020-02-04	Completed
An Open-label Study to Evaluate the Efficacy and Safety of add-on Memantine [5-10 mg b.i.d (10-20 mg/Day)] to Rivastigmine [1.5-6 mg b.i.d. (3-12 mg/Day)] Treatment in Patients With Alzheimer's Disease Who Continued With Rivastigmine Treatment After a Pre [NCT00234637]	Phase 4	204 participants (Actual)	Interventional	2003-11-30	Completed
Efficacy and Safety of Memantine Hydrochloride, a Low Affinity Antagonist to N-Methyl-D-Aspartate (NMDA) Type Receptors, in the Prevention of Cognitive Decline and Disease Progression in Down's Syndrome [NCT00240760]		180 participants	Interventional	2005-10-31	Recruiting
Medications Development for Alcohol Abuse: NMDA Agents -- A Placebo-Controlled Trial of Memantine for Alcohol Dependence [NCT00246415]	Phase 2	90 participants	Interventional	2002-11-30	Completed
Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes: A Pilot Study [NCT00280774]	Phase 4	20 participants	Interventional	2006-03-31	Completed
[NCT00283309]	Phase 4	20 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to Study finished enrollment but data was never sent for publishing.)
An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity [NCT00330655]	Phase 4	15 participants (Actual)	Interventional	2006-05-31	Completed
An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type [NCT00334906]	Phase 4	75 participants	Interventional	2005-07-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's Disease [NCT00097916]	Phase 3	34 participants (Actual)	Interventional	2004-09-30	Completed
A Pilot Clinical Trial of Memantine for Essential Tremor [NCT00439699]	Phase 4	16 participants (Actual)	Interventional	2007-02-28	Completed
Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis [NCT00353665]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2005-07-31	Completed
A Sixteen-Week, Randomized, Double Blind, Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Young Adults With Down Syndrome [NCT01112683]	Phase 4	42 participants (Actual)	Interventional	2008-07-31	Completed
[NCT00141882]	Phase 3	1,119 participants (Actual)	Interventional	1999-03-31	Completed
Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study [NCT00148590]	Phase 3	24 participants (Actual)	Interventional	2005-11-30	Terminated
Memantine for Prevention of Cognitive Decline During Adjuvant or Neoadjuvant Chemotherapy in Patients With Breast Cancer [NCT04033419]	Phase 2	55 participants (Actual)	Interventional	2019-09-25	Completed
Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia [NCT00371059]	Phase 4	153 participants (Actual)	Interventional	2007-09-30	Completed
[NCT00168350]	Phase 3	1,179 participants (Actual)	Interventional	2000-03-31	Completed
Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment [NCT00624026]	Phase 3	107 participants (Actual)	Interventional	2007-11-30	Completed
A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma [NCT01260467]	Phase 2	4 participants (Actual)	Interventional	2010-11-30	Terminated
Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy. [NCT00505167]	Phase 4	64 participants (Actual)	Interventional	2007-07-31	Completed
Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury [NCT05531383]		70 participants (Anticipated)	Interventional	2021-11-26	Active, not recruiting
Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia [NCT00401167]	Phase 4	32 participants (Anticipated)	Interventional	2006-11-30	Completed
An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression [NCT00040261]	Phase 3	112 participants	Interventional	2002-06-30	Completed
The Effect of Deep Brain Stimulation on Memory Network and Neurological Function of Alzheimer's Disease [NCT03959124]		30 participants (Anticipated)	Interventional	2020-04-06	Recruiting
Developing Medication For Tobacco Addiction: NMDA Agents [NCT00136747]	Phase 1	45 participants (Actual)	Interventional	2004-01-31	Completed
Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals [NCT00136786]	Phase 1	25 participants (Actual)	Interventional	2006-12-31	Completed
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study [NCT01458470]	Phase 2	19 participants (Actual)	Interventional	2011-09-30	Completed
"A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Memantinol® (JSC GEROPHARM, Russia) 20 mg Tablets Versus Akatinol Memantine® (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg Tablets in Normal Healthy Subjects" [NCT03121820]	Phase 1	18 participants (Actual)	Interventional	2016-10-11	Completed
[NCT00187525]	Phase 4	0 participants	Interventional	2004-05-31	Completed
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease [NCT03703856]	Phase 4	32 participants (Anticipated)	Interventional	2019-01-31	Recruiting
Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial [NCT05015595]	Phase 3	20 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
NMDA Antagonist Efficacy in Reducing Human Alcohol Consumption: Impact of Family History [NCT00630955]	Phase 2	111 participants (Actual)	Interventional	2006-06-30	Completed
An Open-Label Pilot Study of Namenda (Memantine Hydrochloride) in Adult Subjects With Attention Deficit Hyperactivity Disorder (ADHD) and ADHD NOS [NCT00586573]	Phase 4	34 participants (Actual)	Interventional	2007-03-31	Completed
Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial [NCT00674219]	Phase 3	17 participants (Actual)	Interventional	2005-05-31	Completed
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride [NCT02580305]	Phase 2	564 participants (Actual)	Interventional	2015-09-30	Completed
Cognitive Effects of Memantine in Postmenopausal Women at Risk of Dementia: a Pilot Study [NCT00242632]		22 participants (Actual)	Interventional	2004-06-30	Completed
Prophylactic Effect of Memantine in Chronic Tension-Type Headache [NCT00315666]	Phase 3	40 participants	Interventional	2006-05-31	Completed
Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis [NCT00300716]	Phase 2/Phase 3	82 participants (Actual)	Interventional	2004-04-30	Completed
A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20) [NCT00305903]	Phase 4	150 participants (Anticipated)	Interventional	2006-03-31	Completed
AMEND - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis [NCT04789915]	Phase 1	46 participants (Anticipated)	Interventional	2021-05-26	Recruiting
Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial [NCT01653457]	Phase 3	60 participants (Anticipated)	Interventional	2012-09-30	Not yet recruiting
Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine [NCT00584948]		94 participants (Actual)	Interventional	2007-09-30	Completed
[NCT01744444]	Phase 2	10 participants (Actual)	Interventional	2012-11-30	Completed
An Open-Label Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) [NCT01592786]	Phase 2	906 participants (Actual)	Interventional	2012-06-30	Completed
"Efficacy of Chinese Traditional Medicine Smart Soup in Cognition and Behavior Regulation in Alzheimer's Disease" [NCT05538507]	Phase 2	180 participants (Anticipated)	Interventional	2022-06-01	Recruiting
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With M [NCT01592747]	Phase 2	479 participants (Actual)	Interventional	2012-09-30	Completed
Memantine Monotherapy for Executive Dysfunction and ADHD: A Pilot Study [NCT01844427]		0 participants (Actual)	Interventional	2013-07-31	Withdrawn
Single-Group Crossover Trial Comparing Behavioral Treatment to Memantine in Body Focused Repetitive Behaviors [NCT05796752]	Phase 2/Phase 3	28 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease [NCT05430867]	Phase 4	150 participants (Anticipated)	Interventional	2022-07-01	Not yet recruiting
Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study [NCT03168997]	Phase 4	222 participants (Anticipated)	Interventional	2017-07-15	Not yet recruiting
Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors [NCT01535040]	Phase 2	130 participants (Actual)	Interventional	2012-08-01	Completed
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases [NCT05045950]	Phase 2	53 participants (Anticipated)	Interventional	2021-11-17	Recruiting
Effects of 15-day Donepezil and Memantine on Cognitive Functions After a 24 Hours Sleep Deprivation Challenge in Healthy Volunteers: a Double-blind, Placebo-controlled, Randomised, Cross-over Study, With Modafinil as Positive Control [NCT01461174]	Phase 1	36 participants (Actual)	Interventional	2011-11-30	Completed
Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine [NCT00375778]		12 participants	Interventional	2005-04-30	Completed
The Effects of Repetitive Transcranial Magnetic Stimulation and Aerobic Exercise on Cognition, Balance and Functional Brain Networks in Patients With Alzheimer's Disease [NCT05102045]		27 participants (Actual)	Interventional	2016-09-01	Completed
A Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD [NCT04539951]	Phase 2	1,600 participants (Anticipated)	Interventional	2020-09-22	Recruiting
Memantine for Spasticity in MS Patients [NCT00638027]	Phase 4	21 participants (Actual)	Interventional	2006-07-31	Completed
Evaluation of NMDA Antagonist for Opiate Dependence [NCT00125515]	Phase 2	81 participants (Actual)	Interventional	2005-06-30	Completed
Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury [NCT02240589]		11 participants (Actual)	Interventional	2014-12-31	Completed
Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode [NCT00186498]		11 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders [NCT00344682]	Phase 4	31 participants (Actual)	Interventional	2006-06-30	Completed
"A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease" [NCT00652457]	Phase 4	50 participants (Actual)	Interventional	2004-11-23	Completed
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective? [NCT02234752]	Phase 2	3 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Funding no longer available and PI no longer working at the institution)
[NCT02535611]	Phase 3	47 participants (Actual)	Interventional	2015-10-31	Completed
An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease [NCT00551161]	Phase 4	12 participants (Actual)	Interventional	2007-08-31	Completed
A Double-Blind, Placebo-Controlled Study of Memantine in Body Focused Repetitive Behaviors [NCT04792645]	Phase 2	100 participants (Actual)	Interventional	2021-06-15	Completed
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases [NCT02360215]	Phase 3	518 participants (Actual)	Interventional	2015-07-31	Completed
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy [NCT04737967]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2021-02-15	Recruiting
Memantine in Adult Autism Spectrum Disorder [NCT01078844]		4 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Sponsor withdrew funds)
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study [NCT01533493]		33 participants (Actual)	Interventional	2012-05-31	Completed
Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study [NCT02466191]	Phase 4	7 participants (Actual)	Interventional	2015-06-30	Completed
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme [NCT01430351]	Phase 1	144 participants (Anticipated)	Interventional	2011-09-14	Active, not recruiting
An Open-label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism [NCT01999894]	Phase 2	102 participants (Actual)	Interventional	2009-11-30	Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia [NCT01555697]	Phase 1/Phase 2	80 participants (Actual)	Interventional	2014-07-31	Completed
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease [NCT01677754]	Phase 2	542 participants (Actual)	Interventional	2012-10-24	Completed
Memantine Augmentation of Lamotrigine Incomplete Response in Bipolar Depression: A Randomized Placebo Controlled Clinical Trial [NCT00305578]	Phase 4	29 participants (Actual)	Interventional	2005-08-31	Completed
Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence [NCT00476242]	Phase 2/Phase 3	82 participants (Actual)	Interventional	2008-06-30	Completed
A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia [NCT00545974]	Phase 4	81 participants (Actual)	Interventional	2007-10-31	Completed
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects [NCT03802162]	Phase 1	60 participants (Actual)	Interventional	2019-02-15	Completed
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) [NCT01592773]	Phase 2	747 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to Terminated because primary efficacy parameter failed to demonstrate statistically significant difference between memantine and placebo in controlled trials)
Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus [NCT00928954]		10 participants (Actual)	Interventional	2005-02-28	Completed
Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment [NCT01876823]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2006-04-30	Completed
Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease Receiving Donepezil, Memantine or Donepezil/Memantine Combination Therapy: Open-Labeled, Randomized, Phase IV, Superiority Study [NCT03954613]	Phase 4	198 participants (Anticipated)	Interventional	2020-10-15	Recruiting
Using Memantine in Treating Bipolar Disorder Comorbid With Alcoholism [NCT03043001]	Phase 3	60 participants (Anticipated)	Interventional	2014-01-01	Enrolling by invitation
Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder [NCT01972074]	Phase 3	84 participants (Actual)	Interventional	2015-02-17	Completed
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Sero [NCT00411398]	Phase 3	15 participants (Actual)	Interventional	2006-12-31	Completed
Glutamate-opioid Interactions in Alcohol Drinking Behaviors [NCT01519063]	Phase 2	75 participants (Actual)	Interventional	2012-01-31	Completed
Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age [NCT01902004]	Phase 4	115 participants (Actual)	Interventional	2013-10-31	Completed
A 16 Week, Investigator-initiated, Single-center, Double Blind, Randomized, Placebo-controlled Trial of Namenda® (Memantine Hcl) for Non-motor Symptoms in Parkinson's Disease [NCT00646204]	Phase 4	40 participants (Actual)	Interventional	2006-04-30	Completed
Effect of Memantine on Cognitive Impairment in Patients With Epilepsy [NCT04417543]	Phase 1	100 participants (Actual)	Interventional	2018-10-01	Completed
Effect of Memantine on Radiotherapy-related Cognitive Impairment [NCT03342443]	Phase 2/Phase 3	240 participants (Anticipated)	Interventional	2017-12-06	Recruiting
A Phase - IIa - IIb, Open Label, Single Center Trial to Study the Safety, Tolerability and Efficacy of Memantine Teva® as Supportive Long-term Treatment in Symptomatic Sickle Cell Disease [NCT03247218]	Phase 2	40 participants (Anticipated)	Interventional	2018-02-02	Recruiting
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome [NCT02304302]	Phase 2	160 participants (Actual)	Interventional	2014-10-31	Completed
Memantine for Enhancement of Rehabilitation Efficacy and Prevention of Major Depressive Disorder in Older Adults [NCT00183729]	Phase 4	35 participants (Actual)	Interventional	2005-08-31	Completed
Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity and Pavlovian-to-Instrumental Transfer (PIT) [NCT01585168]	Phase 2	71 participants (Actual)	Interventional	2011-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00120874 (16) [back to overview]	Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency
NCT00120874 (16) [back to overview]	Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)
NCT00120874 (16) [back to overview]	Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)
NCT00120874 (16) [back to overview]	Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)
NCT00120874 (16) [back to overview]	Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction
NCT00120874 (16) [back to overview]	Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)
NCT00120874 (16) [back to overview]	Change From Baseline of the Severe Impairment Battery (SIB)
NCT00120874 (16) [back to overview]	Change From Baseline of the Severe Impairment Battery (SIB)
NCT00120874 (16) [back to overview]	Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency
NCT00120874 (16) [back to overview]	Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction
NCT00120874 (16) [back to overview]	Change From Baseline of the Mini-Mental State Examination (MMSE)
NCT00120874 (16) [back to overview]	Change From Baseline of the Mini-Mental State Examination (MMSE)
NCT00120874 (16) [back to overview]	Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)
NCT00120874 (16) [back to overview]	Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)
NCT00120874 (16) [back to overview]	Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)
NCT00120874 (16) [back to overview]	Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)
NCT00125515 (1) [back to overview]	Retention in Treatment
NCT00134901 (2) [back to overview]	Weekly Cocaine Use
NCT00134901 (2) [back to overview]	Cocaine Abstinence Based on Daily Self Reported Cocaine Use
NCT00183729 (3) [back to overview]	Depressive Symptoms
NCT00183729 (3) [back to overview]	Functional Recovery
NCT00183729 (3) [back to overview]	Incidence of Major Depressive Disorder
NCT00186498 (1) [back to overview]	Memantine Effect on CVLT Long Term Recall After Right Unilateral ECT Treatment.
NCT00235716 (7) [back to overview]	All-cause Mortality
NCT00235716 (7) [back to overview]	Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline
NCT00235716 (7) [back to overview]	Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level)
NCT00235716 (7) [back to overview]	Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline
NCT00235716 (7) [back to overview]	Caregiver Activity Survey Change From Baseline
NCT00235716 (7) [back to overview]	Mini-Mental State Examination Change From Baseline
NCT00235716 (7) [back to overview]	Neuropsychiatric Inventory Change From Baseline
NCT00242632 (2) [back to overview]	Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2
NCT00242632 (2) [back to overview]	Change in Delis-Kaplan Executive Function System (DKEFS) Verbal Fluency Category Switching Between Time 1 and Time 2
NCT00255086 (2) [back to overview]	NAA/Cr Ratio
NCT00255086 (2) [back to overview]	Mean Change on the ADAS-Cog Score After 1 Year
NCT00264238 (2) [back to overview]	Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks)
NCT00264238 (2) [back to overview]	Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to End of Treatment (12 Weeks)
NCT00294554 (1) [back to overview]	Change in Dementia Rating Scale (DRS) Memory Subscore
NCT00305578 (1) [back to overview]	Change in 17-item Hamilton Depression Rating Scale From Baseline to 8 Weeks (Baseline - 8 Wks)
NCT00322153 (3) [back to overview]	Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)
NCT00322153 (3) [back to overview]	Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)
NCT00322153 (3) [back to overview]	Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)
NCT00344682 (4) [back to overview]	Hamilton Anxiety Rating Scale (HARS)
NCT00344682 (4) [back to overview]	Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)
NCT00344682 (4) [back to overview]	Montgomery-Asberg Depression Rating Score (MADRS)
NCT00344682 (4) [back to overview]	Montgomery-Asberg Depression Rating Score (MADRS)
NCT00411398 (1) [back to overview]	Hamilton Anxiety Scale
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Trail Making Test Part B.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Trail Making Test Part A.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Brief VisuoSpatial Memory Test Revised (BVMT-R) Delayed Recall Score.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Brief VisuoSpatial Memory Test Revised (BVMT-R) Total Recall Score.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Hopkins Verbal Learning Test Revised (HVLT-R) Delayed Recall Scores.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Hopkins Verbal Learning Test Revised (HVLT-R) Total Recall Learning Scores.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Symbol Digit Modality Test (SDMT) Oral Score.
NCT00462228 (8) [back to overview]	Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Symbol Digit Modality Test (SDMT)Written Score.
NCT00469456 (2) [back to overview]	Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12
NCT00469456 (2) [back to overview]	Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12
NCT00476008 (10) [back to overview]	Fuld Object Memory Evaluation
NCT00476008 (10) [back to overview]	Mini Mental Status Exam
NCT00476008 (10) [back to overview]	Motor Free Visual Perception Test - Visual Closure Subtest
NCT00476008 (10) [back to overview]	Useful Field of View
NCT00476008 (10) [back to overview]	Trail Making Test - Part B
NCT00476008 (10) [back to overview]	Trail Making Test - Part A
NCT00476008 (10) [back to overview]	The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint).
NCT00476008 (10) [back to overview]	Rey Complex Figure Test
NCT00476008 (10) [back to overview]	Cognitive Dementia Rating Scale
NCT00476008 (10) [back to overview]	Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
NCT00476242 (3) [back to overview]	Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).
NCT00476242 (3) [back to overview]	Opiate Craving Based on Heroin Craving Scale
NCT00476242 (3) [back to overview]	Opiate Use Measured by Urine Toxicology Results
NCT00545974 (5) [back to overview]	Longitudinal Changes From Baseline to 26 Weeks for Test Battery: CDR-SB, FAQ, TFLS, MMSE, EXIT25, UPDRS, Boston Naming Test
NCT00545974 (5) [back to overview]	Change in Neuropsychiatric Inventory (NPI)
NCT00545974 (5) [back to overview]	Number of Participants Starting Antipsychotic Therapy
NCT00545974 (5) [back to overview]	Longitudinal Changes From Baseline to 26 Weeks for Test Battery: Letter Fluency, Category Fluency, Digit Symbol, Digits Backwards
NCT00545974 (5) [back to overview]	Clinical Global Impression of Change (CGIC)
NCT00551161 (1) [back to overview]	Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase Monotherapy vs Combination of Memantine and Cholinesterase Inhibitor
NCT00566852 (6) [back to overview]	Median Time to Neurocognitive Failure
NCT00566852 (6) [back to overview]	Overall Survival
NCT00566852 (6) [back to overview]	Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 8, 16, and 52 Weeks
NCT00566852 (6) [back to overview]	Change in Functional Assessment of Cancer Therapy With Brain Subscale (FACT-Br) at 24 Weeks
NCT00566852 (6) [back to overview]	Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 24 Weeks
NCT00566852 (6) [back to overview]	Median Progression-free Survival Time
NCT00584948 (2) [back to overview]	Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale
NCT00584948 (2) [back to overview]	Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)
NCT00585169 (1) [back to overview]	Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS)
NCT00586066 (3) [back to overview]	Rapid Visual Information Processing Task (RVP)
NCT00586066 (3) [back to overview]	California Verbal Learning Test (CVLT) at Week 6
NCT00586066 (3) [back to overview]	California Verbal Learning Test (CVLT) at Week 12
NCT00586573 (1) [back to overview]	DSM-IV ADHD Rating Scale (AISRS) Score Change
NCT00630955 (4) [back to overview]	Sedation Responses to Alcohol
NCT00630955 (4) [back to overview]	Number of Drinks Consumed on Day 7
NCT00630955 (4) [back to overview]	Baseline-adjusted Craving (YCS)
NCT00630955 (4) [back to overview]	Stimulation Responses to Alcohol
NCT00638027 (3) [back to overview]	Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks
NCT00638027 (3) [back to overview]	Change in Multiple Sclerosis Functional Composite (MSFC) Score Between Baseline and Week 12
NCT00638027 (3) [back to overview]	Difference in the Multiple Sclerosis Spacticy Scale (MSSS-88) Between Baseline and 12 Weeks
NCT00646204 (2) [back to overview]	Unified Parkinson Disease Rating Scale (UPDRS).
NCT00646204 (2) [back to overview]	Analyses Will be Computed for the Categorical Dependent Variable (DV): Global Tremor Assessment by Examiner
NCT00649220 (8) [back to overview]	Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.
NCT00649220 (8) [back to overview]	Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.
NCT00649220 (8) [back to overview]	Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.
NCT00649220 (8) [back to overview]	"Change of Test for the Early Detection of Dementia With Discrimination From Depression [TE4D] Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia"
NCT00649220 (8) [back to overview]	"Change of Test for the Early Detection of Dementia With Discrimination From Depression [TE4D] Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression"
NCT00649220 (8) [back to overview]	Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.
NCT00649220 (8) [back to overview]	Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.
NCT00649220 (8) [back to overview]	Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20
NCT00674219 (1) [back to overview]	Psychometric Scores
NCT00768261 (2) [back to overview]	Comparison of Combined DAT Patients' Mean (SD) Hippocampal Volume Slope (mm^3/Year) Rate of Change
NCT00768261 (2) [back to overview]	Rate of Change of Hippocampal Volume Slope
NCT00830375 (1) [back to overview]	Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)
NCT00857233 (6) [back to overview]	Long-term Efficacy of Memantine on Behavioural Symptoms Using the Neuropsychiatric Inventory (NPI) - 12 Items Version Total Score.
NCT00857233 (6) [back to overview]	Number of Patients With Adverse Events (AEs)
NCT00857233 (6) [back to overview]	Percentage of Patients Who Withdrew Due to Intolerance to Treatment
NCT00857233 (6) [back to overview]	Long-term Efficacy of Memantine on Global Condition Using the Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus).
NCT00857233 (6) [back to overview]	Long-term Efficacy of Memantine on Functioning Using the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item Version Total Score
NCT00857233 (6) [back to overview]	Long-term Efficacy of Memantine on Cognition Using the Severe Impairment Battery (SIB) Total Score.
NCT00857649 (5) [back to overview]	Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.
NCT00857649 (5) [back to overview]	Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.
NCT00857649 (5) [back to overview]	Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.
NCT00857649 (5) [back to overview]	Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.
NCT00857649 (5) [back to overview]	Efficacy of Memantine on Global Condition Using CIBIC-plus.
NCT00862940 (4) [back to overview]	Changes in Total Hippocampal Volume (HCV)
NCT00862940 (4) [back to overview]	Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score
NCT00862940 (4) [back to overview]	Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score
NCT00862940 (4) [back to overview]	Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Context Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Speech Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale
NCT00872898 (15) [back to overview]	Change in Children's Communication Checklist-2 (CCC-2) - Interests Subscale
NCT00872898 (15) [back to overview]	Core Autism Treatment Scale-Improvement: Communication
NCT00872898 (15) [back to overview]	Change in Total Raw Score of Social Responsiveness Scale
NCT00872898 (15) [back to overview]	Core Autism Treatment Scale-Improvement: Social Interaction
NCT00872898 (15) [back to overview]	Core Autism Treatment Scale-Improvement: Total Score
NCT00872898 (15) [back to overview]	Extent of Absorption of Memantine (Part One)
NCT00880685 (3) [back to overview]	Clinical Global Impression Severity Scales (CGI)
NCT00880685 (3) [back to overview]	Kleptomania Symptom Assessment Scale (K-SAS)
NCT00880685 (3) [back to overview]	Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (KM-YBOCS)
NCT00928954 (2) [back to overview]	Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing
NCT00928954 (2) [back to overview]	Percent Change in Median Eye Speed
NCT00933608 (1) [back to overview]	N-acetylaspartate
NCT00956085 (1) [back to overview]	Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.
NCT01032759 (6) [back to overview]	Patient Satisfaction
NCT01032759 (6) [back to overview]	24 hr Opioid Consumption
NCT01032759 (6) [back to overview]	Pain Scores
NCT01032759 (6) [back to overview]	Opioid Related Side Effects: Pruritus
NCT01032759 (6) [back to overview]	Opioid Related Side Effects
NCT01032759 (6) [back to overview]	Hyperalgesia
NCT01038128 (4) [back to overview]	Ratings of Eating Pathology
NCT01038128 (4) [back to overview]	Body Dysmorphic Disorder Version of the Yale Brown Obsessive Compulsive Scale
NCT01038128 (4) [back to overview]	Clinical Global Impression Scale
NCT01038128 (4) [back to overview]	Number of Binge Eating and Self-induced Vomiting Episodes
NCT01052662 (3) [back to overview]	Change of Opioid Use From Week 1 to 13
NCT01052662 (3) [back to overview]	Number of Participants Who Were Estimated to Have Survived as Assessed by Survival Curve of Relapse Rate After Achieving Complete Abstinence on Week 8
NCT01052662 (3) [back to overview]	Treatment Retention
NCT01054599 (2) [back to overview]	The Change Scores in Memory Measures From Baseline to Post-treatment/Placebo Will be Compared Between the Memantine Treatment and Placebo Groups.
NCT01054599 (2) [back to overview]	A Secondary Analysis Will Examine the Possible Sustained Benefit of Continued Memantine Use.
NCT01112683 (3) [back to overview]	Changes in Benchmark Neuropsychological Measures From Baseline to End of Study
NCT01112683 (3) [back to overview]	Changes in Neuropsychological Measures From Baseline to End of Study
NCT01112683 (3) [back to overview]	Changes of Safety and Tolerability Assessments at Baseline and End of Study
NCT01260467 (1) [back to overview]	Number of Participants With Adverse Events
NCT01333865 (2) [back to overview]	Number of Participants With Reduction in ASD Symptom Severity as Defined by the NIMH Clinical Global Impression for Pervasive Developmental Disorders (CGI-PDD) Improvement Score
NCT01333865 (2) [back to overview]	Number of Participants With Reduction in ASD Symptom Severity as Defined by the Social Responsiveness Scale (SRS)
NCT01519063 (7) [back to overview]	Stimulation Response to Alcohol: Priming Dose Phase
NCT01519063 (7) [back to overview]	Stimulation Response to Alcohol at Lab Session
NCT01519063 (7) [back to overview]	Sedation Response to Alcohol: Priming Dose Phase
NCT01519063 (7) [back to overview]	Sedation Response to Alcohol at Lab Session
NCT01519063 (7) [back to overview]	Number of Drinks Consumed at Lab Session (Day 7)
NCT01519063 (7) [back to overview]	Craving AUC: Priming Dose Phase
NCT01519063 (7) [back to overview]	Craving AUC: Adlib Drinking Phase
NCT01533493 (1) [back to overview]	Percent Change in Global Executive Composite T-Score on the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)
NCT01535040 (4) [back to overview]	Smoking Withdrawal
NCT01535040 (4) [back to overview]	Retention
NCT01535040 (4) [back to overview]	Nicotine Dependence
NCT01535040 (4) [back to overview]	Adherence
NCT01555697 (2) [back to overview]	MATRICS
NCT01555697 (2) [back to overview]	Prepulse Inhibition
NCT01585168 (4) [back to overview]	Change in Impulsive Behavior as Measured on the Balloon Analog Risk Task (BART) Computerized Task Between Placebo and Study Medication
NCT01585168 (4) [back to overview]	"Change in Blood Oxygenation Level Dependent (BOLD) Activation in Anterior Cingulate Cortex During Loss Condition of Monetary Incentive Delay (MID) Task Between Placebo and Study Medication"
NCT01585168 (4) [back to overview]	"Change in Blood Oxygenation Level Dependent (BOLD) Activation in the Amygdala During Win Monetary Incentive Delay (MID) Task Between Placebo and Study Medication"
NCT01585168 (4) [back to overview]	Change in Impulsive Behavior as Measured on the Experimental Discounting Delay (EDT) Computerized Task Between Placebo and Study Medication
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12
NCT01592747 (12) [back to overview]	Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)
NCT01592747 (12) [back to overview]	Time to First Loss of Therapeutic (LTR) Response
NCT01592747 (12) [back to overview]	Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12
NCT01592773 (1) [back to overview]	Patients With Any Treatment-emergent Adverse Event
NCT01592786 (1) [back to overview]	Number of Confirmed Social Responsiveness Scale (SRS) Responders
NCT01656187 (1) [back to overview]	Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score
NCT01876823 (10) [back to overview]	Change in 24-item HAMD
NCT01876823 (10) [back to overview]	Change in Treatment Emergent Side Effects (TESS)
NCT01876823 (10) [back to overview]	Conversion to Dementia Using Clinical Dementia Rating (CDR)
NCT01876823 (10) [back to overview]	Change in Wechsler Memory Scale-III (WMS-III)
NCT01876823 (10) [back to overview]	Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)
NCT01876823 (10) [back to overview]	Change in Clinical Global Impression - Depression Change
NCT01876823 (10) [back to overview]	Change in Trails A
NCT01876823 (10) [back to overview]	Change in Clinical Global Impression - Cognitive Change
NCT01876823 (10) [back to overview]	Change in Selective Reminding Test - Delayed Recall (SRT-DR)
NCT01876823 (10) [back to overview]	Change in Trails B
NCT01902004 (4) [back to overview]	Change in Cognitive Domain Scores
NCT01902004 (4) [back to overview]	Change in Hamilton Depression Rating Scale
NCT01902004 (4) [back to overview]	Change in Montgomery Asberg Depression Rating Scale
NCT01902004 (4) [back to overview]	Number of Participants With Adverse Events
NCT01972074 (1) [back to overview]	Treatment Responder
NCT01999894 (1) [back to overview]	Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)
NCT02118727 (1) [back to overview]	The Primary Comparison for Efficacy Will be Based on a Linear Mixed Effects (LME) Model Fit to the ALSFRS-R Data for the Patients Followed Over 36 Weeks.
NCT02234752 (8) [back to overview]	Kynurenine (KYN)
NCT02234752 (8) [back to overview]	PIC/KYN
NCT02234752 (8) [back to overview]	Picolinic Acid (PIC)
NCT02234752 (8) [back to overview]	Kynurenic Acid (KYNA)
NCT02234752 (8) [back to overview]	Change in Level of Cognition
NCT02234752 (8) [back to overview]	Free Tryptophan (TRP)
NCT02234752 (8) [back to overview]	KYN/TRP
NCT02234752 (8) [back to overview]	KYNA/KYN
NCT02240589 (8) [back to overview]	Behavior Rating Inventory of Executive Function (BRIEF) Inhibit
NCT02240589 (8) [back to overview]	BVMT-R Learning
NCT02240589 (8) [back to overview]	California Verbal Learning Test - Second Edition (CVLT-II) - Long Delay Free Recall
NCT02240589 (8) [back to overview]	CVLT-II Trials 1-5 Free Recall Total
NCT02240589 (8) [back to overview]	Stroop Interference
NCT02240589 (8) [back to overview]	Brief Visuospatial Memory Test - Revised (BVMT-R) Delayed Recall
NCT02240589 (8) [back to overview]	Trail Making Part B
NCT02240589 (8) [back to overview]	Traumatic Brain Injury Quality of Life Anger (TBI QOL Anger)
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the Recall of Digits Forward (From the Differential Ability Scales; DAS-II)
NCT02304302 (12) [back to overview]	Adaptive/Behavioral Functioning of the Participants as Assessed by Change in Score on the Scales of Independent Behavior-Revised (SIB-R)
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Span (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Working Memory (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the The Go - No Go Task
NCT02304302 (12) [back to overview]	Intellectual Functioning of the Participants as Assessed by Change in Score on the Matrices Subtest of the Differential Ability Scales-II (DAS-II)
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall
NCT02304302 (12) [back to overview]	Linguistic Functioning of the Participants as Assessed by Change in Score on the Test for Reception of Grammar 2nd Edition (TROG-II)
NCT02304302 (12) [back to overview]	Safety and Tolerability of the Drug Memantine as Assessed by Change in QTc Interval
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the Paired Associates Learning (PAL) From the Cambridge Neuropsychological Test Automated Battery (CANTAB)
NCT02304302 (12) [back to overview]	Efficacy of the Drug Memantine as Assessed by Change in Score on the Pattern Recognition Memory (PRM; Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)
NCT02304302 (12) [back to overview]	Linguistic Functioning of the Participants as Assessed by Change in Score on the Peabody Picture Vocabulary Test-IV (PPVT-IV)
NCT02360215 (23) [back to overview]	Time to Neurocognitive Failure
NCT02360215 (23) [back to overview]	Change From Baseline in the Clinical Trial Battery Composite (CTB COMP) Score [Neurocognitive Decline]
NCT02360215 (23) [back to overview]	Change From Baseline in the Controlled Oral Word Association (COWA) Test (Neurocognitive Decline)
NCT02360215 (23) [back to overview]	Change From Baseline in the Hopkins Verbal Learning Test -Revised (HVLT-R) Delayed Recall Score (Neurocognitive Decline)
NCT02360215 (23) [back to overview]	Change From Baseline in the Hopkins Verbal Learning Test -Revised (HVLT-R) Delayed Recognition (Neurocognitive Decline)
NCT02360215 (23) [back to overview]	Change From Baseline in the Hopkins Verbal Learning Test -Revised (HVLT-R) Total Recall Score (Neurocognitive Decline)
NCT02360215 (23) [back to overview]	Change From Baseline in the Trail Making Test (TMT) Part A (Neurocognitive Decline)
NCT02360215 (23) [back to overview]	Change From Baseline in the Trail Making Test (TMT) Part B (Neurocognitive Decline)
NCT02360215 (23) [back to overview]	Change in M. D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Factor Score
NCT02360215 (23) [back to overview]	Change in M. D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score
NCT02360215 (23) [back to overview]	Change in M. D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Neurologic Factor Score
NCT02360215 (23) [back to overview]	Change in M. D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L VAS Score at 2 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L Index Score at 12 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L Index Score at 2 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L Index Score at 4 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L Index Score at 6 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L VAS Score at 12 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L VAS Score at 4 Months
NCT02360215 (23) [back to overview]	Change in EQ-5D-5L VAS Score at 6 Months
NCT02360215 (23) [back to overview]	Intracranial Progression-Free Survival
NCT02360215 (23) [back to overview]	Number of Patients With a Grade 3+ Adverse Event (AE) Regardless of Relationship to Treatment
NCT02360215 (23) [back to overview]	Overall Survival
NCT02535611 (4) [back to overview]	Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)
NCT02535611 (4) [back to overview]	Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)
NCT02535611 (4) [back to overview]	Investigation of Disability by Modified Rankin Scale (mRS)
NCT02535611 (4) [back to overview]	Investigation of Disability by Modified Rankin Scale (mRS)
NCT02553928 (2) [back to overview]	Adverse Events
NCT02553928 (2) [back to overview]	ADCS - CGIC Score at Week 12
NCT02580305 (5) [back to overview]	Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11)
NCT02580305 (5) [back to overview]	Change From Baseline to Week-26 in Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL)
NCT02580305 (5) [back to overview]	Change From Baseline to Week-26 in Neuropsychiatric Inventory (NPI)
NCT02580305 (5) [back to overview]	Change From Baseline to Week-26 in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
NCT02580305 (5) [back to overview]	Change From Baseline to Week-26 in Change in Mini Mental State Examination (MMSE)
NCT03121820 (2) [back to overview]	Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)
NCT03121820 (2) [back to overview]	Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))
NCT03468543 (1) [back to overview]	Gastric Retention by Magnetic Resonance Imaging (MRI)
NCT03860597 (3) [back to overview]	Mismatch Negativity (MMN); Unit of Measure of MMN is Microvolts.
NCT03860597 (3) [back to overview]	Prepulse Inhibition (PPI)
NCT03860597 (3) [back to overview]	"Gamma Auditory Steady-state Response (ASSR). The Primary Unit of Measure of Auditory Steady State Response (ASSR) is Gamma Evoked Power (γEP), Expressed as Microvolts-squared."
NCT03988803 (4) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (BI 425809 + Memantine : Memantine)
NCT03988803 (4) [back to overview]	Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (BI 425809 + Memantine : BI 425809)
NCT03988803 (4) [back to overview]	Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (BI 425809 + Memantine : Memantine)
NCT03988803 (4) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (BI 425809 + Memantine : BI 425809)
NCT04033419 (17) [back to overview]	Change in Executive Function - One Touch Stockings (OTS) of Cambridge
NCT04033419 (17) [back to overview]	Change in Processing Speed - Rapid Visual Processing (RVP)
NCT04033419 (17) [back to overview]	Change in Quality of Life - Functional Assessment of Cancer Therapy-General
NCT04033419 (17) [back to overview]	Change in Attention and Working Memory - Digit Span
NCT04033419 (17) [back to overview]	Change in Self-reported Cognitive Function - PROMIS Cognitive Function
NCT04033419 (17) [back to overview]	Change in Semantic Fluency - Animal Naming Test
NCT04033419 (17) [back to overview]	Change in Verbal Fluency - Controlled Oral Word Association Test
NCT04033419 (17) [back to overview]	Change in Karnofsky Performance Status
NCT04033419 (17) [back to overview]	Change in Verbal Memory - Hopkins Verbal Learning Test-Revised
NCT04033419 (17) [back to overview]	Change in Visual Working Memory - Delayed Matching to Sample Test
NCT04033419 (17) [back to overview]	Number of Adverse Events - Safety
NCT04033419 (17) [back to overview]	Change in Anxiety Symptoms - PROMIS Emotional Distress-Anxiety
NCT04033419 (17) [back to overview]	Change in Depressive Symptoms - PROMIS Depression
NCT04033419 (17) [back to overview]	Proportion of Enrolled Participants Who do Not Meet the Primary Outcome Measure - Attrition
NCT04033419 (17) [back to overview]	Change in Processing Speed and Executive Function - Trail Making Test
NCT04033419 (17) [back to overview]	Proportion of Invited Participants Who Enroll - Recruitment
NCT04033419 (17) [back to overview]	Proportion of Scheduled Drug Doses Taken - Adherence
NCT04698525 (4) [back to overview]	The Migraine Disability Assessment MIDAS Scale Will Measure Before and After the Treatment to Improve the Quality of Life in Both Groups After Three Months of Treatment.
NCT04698525 (4) [back to overview]	The Change in the Intensity of the Pain in a Migraine Attack Will be Measured by a Visual Analogue Scale (VAS).
NCT04698525 (4) [back to overview]	Reduction in Days of Headache Pain With Treatment of Memantine or Valproate in the Preventive Management of Episodic Migraine.
NCT04698525 (4) [back to overview]	Measure Changes in Weight With the Administration of Active Drugs.
NCT04792645 (7) [back to overview]	Hamilton Anxiety Rating Scale
NCT04792645 (7) [back to overview]	Massachusetts General Hospital Hairpulling (Skin Picking) Scale
NCT04792645 (7) [back to overview]	Skin Picking Symptom Assessment Scale
NCT04792645 (7) [back to overview]	Clinical Global Impressions-Improvement Scale (CGI-I)
NCT04792645 (7) [back to overview]	NIMH Symptom Severity Scale (for TTM or Skin Picking)
NCT04792645 (7) [back to overview]	Hamilton Depression Rating Scale
NCT04792645 (7) [back to overview]	Sheehan Disability Scale

Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency

"The RMBPC is a 24 item rating scale of the frequency of memory and behavioral problems in the AD subject and of how upset or bothered their caregivers react. Frequency is rated from 0 (least frequent) to 4 (most frequent) and caregiver reaction is rated from 0 (not at all) to 4 (extremely bothered or upset). Higher scores indicate more frequent memory and behavioral problems in the subject with AD as well as a more upset or bothered caregiver. Possible scores range from 0 to 96." (NCT00120874)
Timeframe: Baseline to 52 weeks

Intervention	units on a scale (Mean)
Memantine + CIPCM Program	24.4
Memantine Alone	32.4

Intervention	units on a scale (Least Squares Mean)
	6 months minus baseline	12 months minus baseline	18 months minus baseline	24 months minus baseline	30 months minus baseline	36 months minus baseline	42 months minus baseline	48 months minus baseline	Average change from baseline
Memantine	1.11	3.32	5.69	6.73	7.64	8.31	8.24	11.74	6.38
Placebo	3.04	4.26	6.04	6.71	8.90	10.77	10.61	10.85	7.78
Vitamin E	1.38	2.40	4.34	4.32	7.87	9.00	10.35	10.73	5.97
Vitamin E + Memantine	1.53	2.48	3.46	5.76	5.85	8.26	7.97	9.70	6.13

Intervention	units on a scale (Mean)
	At baseline	At end of treatment
Non-Responders: Memantine Open Label	30	28.8
Responders: Memantine Open Label	23.8	13.0

Intervention	units on a scale (Mean)
	Mean at baseline	Mean at end of treatment
Non-Responders: Memantine Open Label	14.9	14.6
Responders: Memantine Open Label	11.8	5.0

Intervention	seconds (Mean)
	baseline score	6 week score	12 week score
Memantine	104.6	128.7	86.6
Placebo	113.3	100.8	105.5

Intervention	units on a scale (Mean)
	Baseline Sum of Retrieval Score	12 month Sum of Retrieval Score
Memantine	18.38	17.94
Placebo	18.87	19.08

Intervention	participants (Number)
	DriveABLE passed	DriveABLE same or improved
Memantine	13	13
Placebo	10	9

Intervention	units on a scale (Mean)
	1) Word Recall - Baseline	1) Word Recall - 12 Months	2) Commands - Baseline	2) Commands - 12 Months	3) Constructional Praxis - Baseline	3) Constructional Praxis - 12 Months	4) Ideational Praxis - Baseline	4) Ideational Praxis - 12 months	5) Naming - Baseline	5) Naming - 12 months	6) Orientation - Baseline	6) Orientation - 12 Months	7) Word Recognition - Baseline	7) Word Recognition - 12 Months	8) Remember Test Instructions - Baseline	8) Remember Test Instructions - 12 Months	9) Spoken Language - Baseline	9) Spoken Language - 12 Months	10) Word Finding - Baseline	10) Word Finding - 12 Months	11) Comprehension - Baseline	11) Comprehension - 12 Months
Memantine	4.00	4.13	0	.85	3.44	3.46	5.00	5.00	2.38	1.77	.44	.46	7.27	9.31	0.00	0.00	0.00	0	0.00	.08	.06	.15
Placebo	4.33	4.56	.40	.23	3.40	3.54	5.00	4.92	1.80	1.31	.80	.85	9.60	8.10	0.00	0.00	.20	.23	.13	.15	.07	.31

Intervention	units on a scale (Mean)
	CDR-SB	FAQ	TFLS	MMSE	EXIT25	UPDRS	Boston naming test
Memantine	1.5	4.3	-3.7	-1.2	1.9	1.7	-1.4
Placebo	1.5	2.9	-2.8	-0.9	0.7	1.4	0.7

Intervention	number of items recalled (Mean)
	Letter fluency	Category fluency	Digit symbol	Digits backwards
Memantine	-0.1	-0.5	-3.9	0.1
Placebo	-0.3	-0.7	4.2	-0.2

Intervention	ratio (normalized to T2-corrected water (Mean)
	Change in NAA [(t2-t1) - (t1-t0)]	Change in Cr [(t2-t1) - (t1-t0)]	Change in Cho [(t2-t1) - (t1-t0)]	Change in mI [(t2-t1) - (t1-t0)]	Change in NAA/Cr [(t2-t1) - (t1-t0)]	Change in Cho/Cr [(t2-t1) - (t1-t0)]	Change in mI/Cr [(t2-t1) - (t1-t0)]	Change in NAA/Cho [(t2-t1) - (t1-t0)]	Change in NAA/mI [(t2-t1) - (t1-t0)]
Memantine	-54	-2	9	16	-0.09	0.02	0.04	-0.26	-0.35

Intervention	units on a scale (Median)
	8-weeks	16-weeks	52-weeks
WBRT+Memantine	-0.36	0	0
WBRT+Placebo	-0.72	0	0

Intervention	z-score (Mean)
	RVPA, Week 6	RVPA, Week 12	RVPB, Week 6	RVPB, Week 12
Memantine	-1.3997	-0.1508	-2.4440	-1.4833
Placebo	-0.6859	-0.6017	-0.2353	-0.2108

Intervention	correct items (Mean)
	CVLT Trial 1	CVLT Trial 5	CVLT Short Delay Free Recall	CVLT Long Delay Free Recall
Memantine	11.55	9.15	11.31	14.03
Placebo	10.65	9.05	10.24	13.53

Intervention	Units on a scale (Mean)
	Total Symptoms	Inattentive Symptoms	Hyperactive Symptoms
Memantine	-17.5	-10.6	-6.9

Intervention	units on a scale (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 20
Memantine	-2.3	-0.3	-1.3	0.7	1.4

Intervention	(mm^3/year) (Mean)
	left hippocampal volume slope	right hippocampal volume slope
Improved	-70	-77
Stable	-100	-105
Worsening	-106	-141

Intervention	mm^3/year (Mean)
	left hippocampal volume slope	right hippocampal volume slope
1 Very Mild to Mild DAT Untreated	-70.2418748	-99.9437062
2 Very Mild to Mild DAT Treated With Donepezil	-88.4738591	-94.3258652
3 Very Mild to Mild DAT Treated With the Combination	-94.0768115	-125.0687876
4 Nondemented Comparison Subjects.	-46.9484805	-80.0840066

Intervention	participants (Number)
	Patients with AEs	Patients with serious AEs (SAEs)	Patients with AEs Leading to Withdrawal	Patients with Baseline Events
Memantine	191	27	24	1

Intervention	mm^3/year (Mean)
Memantine 10 mg Tablets Twice Daily	-218
Placebo Tablets Twice Daily	-220

Intervention	Scale scores (Least Squares Mean)
Memantine 10 mg Tablets Twice Daily	-0.50
Placebo Tablets Twice Daily	-0.74

memantine

Cross-References

Synonyms (123)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (2)

Protein Targets (34)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (137)

Molecular Functions (59)

Ceullar Components (47)

Bioassays (269)

Research

Studies (2,541)

Market Indicators

Research Demand Index: 105.04

Study Types

Clinical Trials (215)

Trial Overview

Trial Outcomes

Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency

Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)

Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)

Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)

Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction

Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)

Change From Baseline of the Severe Impairment Battery (SIB)

Change From Baseline of the Severe Impairment Battery (SIB)

Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency

Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction

Change From Baseline of the Mini-Mental State Examination (MMSE)

Change From Baseline of the Mini-Mental State Examination (MMSE)

Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)

Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)

Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)

Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)

Retention in Treatment

Weekly Cocaine Use

Cocaine Abstinence Based on Daily Self Reported Cocaine Use

Depressive Symptoms

Functional Recovery

Incidence of Major Depressive Disorder

Memantine Effect on CVLT Long Term Recall After Right Unilateral ECT Treatment.

All-cause Mortality

Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline

Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level)

Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline

Caregiver Activity Survey Change From Baseline

Mini-Mental State Examination Change From Baseline

Neuropsychiatric Inventory Change From Baseline

Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2

Change in Delis-Kaplan Executive Function System (DKEFS) Verbal Fluency Category Switching Between Time 1 and Time 2

NAA/Cr Ratio

Mean Change on the ADAS-Cog Score After 1 Year

Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks)

Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to End of Treatment (12 Weeks)

Change in Dementia Rating Scale (DRS) Memory Subscore

Change in 17-item Hamilton Depression Rating Scale From Baseline to 8 Weeks (Baseline - 8 Wks)

Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)

Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)

Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)

Hamilton Anxiety Rating Scale (HARS)

Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)

Montgomery-Asberg Depression Rating Score (MADRS)

Montgomery-Asberg Depression Rating Score (MADRS)

Hamilton Anxiety Scale

Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Trail Making Test Part B.

Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Trail Making Test Part A.

Improvements From Baseline Scores After 6 and 12 Weeks of Memantine Compared to Placebo on the Brief VisuoSpatial Memory Test Revised (BVMT-R) Delayed Recall Score.

Intervention	mL/year (Mean)
Memantine 10 mg Tablets Twice Daily	15.24
Placebo Tablets Twice Daily	15.32

Intervention	logMAR (Number)
	Participant 1, Right Eye	Participant 1, Left Eye	Participant 2, Right Eye	Participant 2, Left Eye	Participant 3, RIght Eye	Participant 3, Left Eye	Patricipant 4, RIght Eye	Participant 4, Left Eye	Participant 5, Right Eye	Particpant 5, Left Eye	Particpant 6, RIght Eye	Particpant 6, Left Eye	Particpant 7, Right Eye	Particpant 7, Left Eye	Participant 8, Right Eye	Participant 8, Left Eye	Particpant 9, Right Eye	Participant 9, Left Eye	Participant 10, Right Eye	Participant 10. Left Eye
Gabapentin	0	0.2	0.1	0.2	-0.1	NA	0.3	0.1	0.1	0	0.4	0.2	-0.1	0.1	0.1	0	0	0	-0.1	0.1
Memantine	0.1	0.2	0.2	0	-0.2	NA	-0.1	0.1	0.2	0.1	0	0.2	0.1	0.1	0	0.1	0	0	0.3	0.2

Intervention	number of episodes (Mean)
	Binge Eating Baseline	Binge Eating Endpoint	Purging Baseline	Purging Endpoint
Memantine	20.67	31.33	21.67	36.67

Intervention	Mean Proportion of Opioid Use in Week 13 (Mean)
Memantine 30mg/Day + Buprenorphine	0.00
Memantine 15mg/Day + Buprenorphine	0.27
Memantine 0mg/Day + Buprenorphine	0.39

Intervention	scores on a scale (Mean)
	7-24 Spatial Recall Tests Learning Change Score	SRT Continuous Long-Term Retrieval Change Score
Memantine	1.00	4.38
Sugar Pill	1.78	8.11

Intervention	scores on a scale (Mean)
	SRT CLTR Baseline	SRT CLTR Post-Open Label	7-24 Total Learning Baseline	7-24 Total Learning Post-Open Label
Memantine	32.67	40.33	30.33	31.67
Sugar Pill	22.71	40.29	28.14	32.43

Intervention	scores on a scale (Mean)
	Peabody Picture Vocabulary Test-III	Test for the Reception of Grammar	Verbal Fluency (from the NEPSY)	Recall of Digits (DAS)	Spatial working memory (strategy)	Scales of Independent Behavior Revised (SIB-R)
Memantine	0.72	2.33	0.78	5.39	-0.06	5.94
Placebo	-1.42	-0.42	0.21	-7.47	-1.47	4.88

Intervention	units on a scale (Mean)
	Pattern recognition memory pre/post diff scores	Paired associates task stages pre/post diff scores	Paired associates task 1st trial pre/post diff	CVLT Free Recall Total	Rivermead Behavioral Memory Test
Memantine	-0.22	0.56	0.39	5.84	1.3
Placebo	-0.84	0	0.68	2.53	0.79

Intervention	participants (Number)
	Increased anxiety	Transient dizziness	Echolalia	Androgenic alopecia
Memantine	2	1	1	0
Placebo	0	0	0	1

Intervention	standardized T-score (Mean)
	Placebo	Memantine
Healthy Subjects: 10 mg Memantine 1st, Then Placebo	56.3	56.6
Healthy Subjects: 20 mg Memantine 1st, Then Placebo	66.6	57.6
Healthy Subjects: Placebo 1st, Then 10 mg Memantine	53.4	60.2
Healthy Subjects: Placebo 1st, Then 20 mg Memantine	48.6	53.7
Subjects With Schizophrenia: 10 mg Memantine 1st, Then Placebo	41.1	34.3
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo	37.7	31.0
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine	40.4	44.6
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine	34.2	35.8